{
  "files": {
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/data%20integrity%20references/pics%20good%20practices%20for%20data%20management%20and%20integrity%202021%207.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/data%20integrity%20references/pics%20good%20practices%20for%20data%20management%20and%20integrity%202021%207.pdf",
      "sha256": "13952b56d329c3806b79e4903bc1e8b53854f0e330c7ec31237d00f8409302e8",
      "size": 975750,
      "pages": 63,
      "regulator": "PICS",
      "filename": "pics%20good%20practices%20for%20data%20management%20and%20integrity%202021%207.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/data%20integrity%20references/uk%20mhra%20data%20integrity%20definitions%20%20and%20guidance%20for%20industry%20withdrawn.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/data%20integrity%20references/uk%20mhra%20data%20integrity%20definitions%20%20and%20guidance%20for%20industry%20withdrawn.pdf",
      "sha256": "b39415e3fe6c68ddb307486e8e190b3173d79eacedb93fa0781227103b96e442",
      "size": 698599,
      "pages": 16,
      "regulator": "OTHER",
      "filename": "uk%20mhra%20data%20integrity%20definitions%20%20and%20guidance%20for%20industry%20withdrawn.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/data%20integrity%20references/uk%20mhra%20gxp%20data%20integrity%20guidance%20and%20definitions%202018%203.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/data%20integrity%20references/uk%20mhra%20gxp%20data%20integrity%20guidance%20and%20definitions%202018%203.pdf",
      "sha256": "e05dda11a93324c47f3f96aa106933d0073d8eb450f09d736ea53b19cf7ebd0d",
      "size": 456031,
      "pages": 21,
      "regulator": "OTHER",
      "filename": "uk%20mhra%20gxp%20data%20integrity%20guidance%20and%20definitions%202018%203.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/data%20integrity%20references/who%20guideline%20on%20data%20integrity%20trs%201033%202021.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/data%20integrity%20references/who%20guideline%20on%20data%20integrity%20trs%201033%202021.pdf",
      "sha256": "9689a674a039babc0a9c17e2c517ec2efcfcdafc943d5b99b48aeb5ee785920a",
      "size": 174329,
      "pages": 25,
      "regulator": "OTHER",
      "filename": "who%20guideline%20on%20data%20integrity%20trs%201033%202021.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/annex%201%20manufacture%20of%20sterile%20medicinal%20products%202022%2008%2022%20final%20revision.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/annex%201%20manufacture%20of%20sterile%20medicinal%20products%202022%2008%2022%20final%20revision.pdf",
      "sha256": "91cc7b7196ad906d6f992d566dab163360877dc234b153436bdccf107b830806",
      "size": 241382,
      "pages": null,
      "regulator": "OTHER",
      "filename": "annex%201%20manufacture%20of%20sterile%20medicinal%20products%202022%2008%2022%20final%20revision.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/annex%2010%20manufacture%20of%20pressurised%20metered%20dose%20aerosol.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/annex%2010%20manufacture%20of%20pressurised%20metered%20dose%20aerosol.pdf",
      "sha256": "d9536d2d679594842eb1226a4b924a06c47d19ae73b9087a00dd201e6c4606d2",
      "size": 174451,
      "pages": null,
      "regulator": "OTHER",
      "filename": "annex%2010%20manufacture%20of%20pressurised%20metered%20dose%20aerosol.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/annex%2011%20computerised%20systems%202011.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/annex%2011%20computerised%20systems%202011.pdf",
      "sha256": "06dfddce466ce12763a68a094e9eef97e523537da35a40e6aa5a8bd6bc44749b",
      "size": 301975,
      "pages": null,
      "regulator": "OTHER",
      "filename": "annex%2011%20computerised%20systems%202011.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/annex%2012%20use%20of%20inonising%20radiation%20in%20the%20manufacture%20of%20medicinal%20products.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/annex%2012%20use%20of%20inonising%20radiation%20in%20the%20manufacture%20of%20medicinal%20products.pdf",
      "sha256": "cdf6f34fcfc34d01b8923e7a9e1b93772a2efbfd71d2e9357b07349fd81a104e",
      "size": 267519,
      "pages": null,
      "regulator": "OTHER",
      "filename": "annex%2012%20use%20of%20inonising%20radiation%20in%20the%20manufacture%20of%20medicinal%20products.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/annex%2013%20manufacture%20of%20investigational%20medicinal%20products%202010%202%203.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/annex%2013%20manufacture%20of%20investigational%20medicinal%20products%202010%202%203.pdf",
      "sha256": "fc14cae997b646b1d8e571be0d9629c2bd5c002d2b124baf8970489917cd146e",
      "size": 601586,
      "pages": null,
      "regulator": "OTHER",
      "filename": "annex%2013%20manufacture%20of%20investigational%20medicinal%20products%202010%202%203.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/annex%2014%20manufacture%20of%20products%20derived%20from%20human%20blood%20or%20human%20plasma2011%2011.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/annex%2014%20manufacture%20of%20products%20derived%20from%20human%20blood%20or%20human%20plasma2011%2011.pdf",
      "sha256": "c33c1f19a93aa91a66c084a563354cfe729ca7f59f2ca06aee14ab7875855cfb",
      "size": 423232,
      "pages": null,
      "regulator": "OTHER",
      "filename": "annex%2014%20manufacture%20of%20products%20derived%20from%20human%20blood%20or%20human%20plasma2011%2011.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/annex%2015%20qualification%20and%20validation%202015%20final.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/annex%2015%20qualification%20and%20validation%202015%20final.pdf",
      "sha256": "1202f6c91927b3cf5cf87fb70b892f07540bda4b14321c7289a934578d8ca1e0",
      "size": 590024,
      "pages": null,
      "regulator": "OTHER",
      "filename": "annex%2015%20qualification%20and%20validation%202015%20final.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/annex%2016%20certification%20by%20a%20qualified%20person%20and%20batch%20release%202015%2010%2012.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/annex%2016%20certification%20by%20a%20qualified%20person%20and%20batch%20release%202015%2010%2012.pdf",
      "sha256": "77a1a808289eccfd3a023c27738e2e484c3393a048ed9cb37269adcf6f188537",
      "size": 389755,
      "pages": null,
      "regulator": "OTHER",
      "filename": "annex%2016%20certification%20by%20a%20qualified%20person%20and%20batch%20release%202015%2010%2012.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/annex%2017%20real%20time%20release%20testing%20and%20parametric%20release%202018%2012%2026.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/annex%2017%20real%20time%20release%20testing%20and%20parametric%20release%202018%2012%2026.pdf",
      "sha256": "abea6367e7a4c5dca8dadb0cc82d3d0d30463bfb22df29385f670941aa94cedc",
      "size": 347275,
      "pages": null,
      "regulator": "OTHER",
      "filename": "annex%2017%20real%20time%20release%20testing%20and%20parametric%20release%202018%2012%2026.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/annex%2019%20reference%20and%20retention%20samples.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/annex%2019%20reference%20and%20retention%20samples.pdf",
      "sha256": "208fdaa18857063ce9e40438f487146b391cc752e6e1101089e53e358b2d19fa",
      "size": 282212,
      "pages": null,
      "regulator": "OTHER",
      "filename": "annex%2019%20reference%20and%20retention%20samples.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/annex%202%20manufacture%20of%20biological%20active%20substances%20and%20medicinal%20products%20for%20human%20use%202018%206%2026.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/annex%202%20manufacture%20of%20biological%20active%20substances%20and%20medicinal%20products%20for%20human%20use%202018%206%2026.pdf",
      "sha256": "f3bb7e78b30c2b0346f0c669899d48dd3c94d601a58594019f0b43b8ca858255",
      "size": 121969,
      "pages": null,
      "regulator": "OTHER",
      "filename": "annex%202%20manufacture%20of%20biological%20active%20substances%20and%20medicinal%20products%20for%20human%20use%202018%206%2026.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/annex%2021%20importation%20of%20medicinal%20products%202022%2002%2016.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/annex%2021%20importation%20of%20medicinal%20products%202022%2002%2016.pdf",
      "sha256": "473962032a0013d906082a4b67ff1ce83c11aa229927b6d77b68931559a93da8",
      "size": 212529,
      "pages": null,
      "regulator": "OTHER",
      "filename": "annex%2021%20importation%20of%20medicinal%20products%202022%2002%2016.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/annex%2022%20artificial%20intelligence%202025%207.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/annex%2022%20artificial%20intelligence%202025%207.pdf",
      "sha256": "8bf6faa5bebacc6ff6e9b24e941b5ba551448ffc1c7053778c4f36a6f5f284b3",
      "size": 357521,
      "pages": null,
      "regulator": "OTHER",
      "filename": "annex%2022%20artificial%20intelligence%202025%207.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/annex%203%20manufacture%20of%20radiopharmaceuticals.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/annex%203%20manufacture%20of%20radiopharmaceuticals.pdf",
      "sha256": "b793f95344e78cb50b2507e2a4becba946169833119e57d1239160f34c43dd0e",
      "size": 287757,
      "pages": null,
      "regulator": "OTHER",
      "filename": "annex%203%20manufacture%20of%20radiopharmaceuticals.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/annex%204%20manufacture%20of%20veterinary%20medicinal%20products%20other%20than%20immunological%20ones.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/annex%204%20manufacture%20of%20veterinary%20medicinal%20products%20other%20than%20immunological%20ones.pdf",
      "sha256": "34333ec22b3925565bab46fb9d8adcbe4209bcc879ae8cea7b0e89bb3144d4c8",
      "size": 135379,
      "pages": null,
      "regulator": "OTHER",
      "filename": "annex%204%20manufacture%20of%20veterinary%20medicinal%20products%20other%20than%20immunological%20ones.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/annex%205%20manufacture%20of%20immunological%20veterinary%20medicinal%20products.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/annex%205%20manufacture%20of%20immunological%20veterinary%20medicinal%20products.pdf",
      "sha256": "08b8c4289b073dbf4c251f3715a7351eda3de4ff5495733a8cb219a0a30ef0db",
      "size": 377208,
      "pages": null,
      "regulator": "OTHER",
      "filename": "annex%205%20manufacture%20of%20immunological%20veterinary%20medicinal%20products.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/annex%206%20manufacture%20of%20medicinal%20gases.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/annex%206%20manufacture%20of%20medicinal%20gases.pdf",
      "sha256": "cdbb8971c689b15c39a63389ee80e77bc20b8eed5c4da425fb47900a4932c9af",
      "size": 386529,
      "pages": null,
      "regulator": "OTHER",
      "filename": "annex%206%20manufacture%20of%20medicinal%20gases.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/annex%207%20manufacture%20of%20herbal%20medicinal%20products%202009%209%2001.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/annex%207%20manufacture%20of%20herbal%20medicinal%20products%202009%209%2001.pdf",
      "sha256": "b1dccf912b73e69b799b843c465c03b496467517fa8250464043d963f659208a",
      "size": 220277,
      "pages": null,
      "regulator": "OTHER",
      "filename": "annex%207%20manufacture%20of%20herbal%20medicinal%20products%202009%209%2001.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/annex%208%20sampling%20of%20starting%20and%20packaging%20materials.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/annex%208%20sampling%20of%20starting%20and%20packaging%20materials.pdf",
      "sha256": "32e015d3f42a46199a52311388db11f067262ea5474e87f2019bb6764ff15fff",
      "size": 178919,
      "pages": null,
      "regulator": "OTHER",
      "filename": "annex%208%20sampling%20of%20starting%20and%20packaging%20materials.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/annex%209%20manufacture%20of%20liquids%20creams%20and%20ointments.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/annex%209%20manufacture%20of%20liquids%20creams%20and%20ointments.pdf",
      "sha256": "f0cdce570155f9b1b935cf5082813bbe02eb112d1e28ac734bb7dfcdd6cb7460",
      "size": 160961,
      "pages": null,
      "regulator": "OTHER",
      "filename": "annex%209%20manufacture%20of%20liquids%20creams%20and%20ointments.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/eu%20formalized%20ra%20for%20ascertaining%20appropriate%20gmp%20for%20excipients%20of%20medicinal%20products%20for%20human%20use%202015%203%2019.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/eu%20formalized%20ra%20for%20ascertaining%20appropriate%20gmp%20for%20excipients%20of%20medicinal%20products%20for%20human%20use%202015%203%2019.pdf",
      "sha256": "807d9b0ff877314d51dd8ee0ffcf98f5f26ac14b12d47ea685012f286613db08",
      "size": 265470,
      "pages": null,
      "regulator": "OTHER",
      "filename": "eu%20formalized%20ra%20for%20ascertaining%20appropriate%20gmp%20for%20excipients%20of%20medicinal%20products%20for%20human%20use%202015%203%2019.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/eu%20gmp%20part%203%20site%20master%20file.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/eu%20gmp%20part%203%20site%20master%20file.pdf",
      "sha256": "148b9d0f73de4327a0583898261c99d6be42f999f033cdb291e4e71ea5838da8",
      "size": 265312,
      "pages": null,
      "regulator": "OTHER",
      "filename": "eu%20gmp%20part%203%20site%20master%20file.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/eu%20gmp%20part%204%20gmp%20for%20advanced%20therapy%20medicinal%20products.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/eu%20gmp%20part%204%20gmp%20for%20advanced%20therapy%20medicinal%20products.pdf",
      "sha256": "a20c2bbf9eca11db36ba7d51ee0ffe8aa25a41413df78f9c231fca8ad93fe716",
      "size": 304685,
      "pages": null,
      "regulator": "OTHER",
      "filename": "eu%20gmp%20part%204%20gmp%20for%20advanced%20therapy%20medicinal%20products.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/eu%20good%20distribution%20practice%20of%20active%20substances%20for%20medicinal%20products%20for%20human%20use%202015%203%2019.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/eu%20good%20distribution%20practice%20of%20active%20substances%20for%20medicinal%20products%20for%20human%20use%202015%203%2019.pdf",
      "sha256": "66a3ba8a80de751e95ceef5dad8eb22363d34db4184a71475be43dd33274f96d",
      "size": 93831,
      "pages": null,
      "regulator": "OTHER",
      "filename": "eu%20good%20distribution%20practice%20of%20active%20substances%20for%20medicinal%20products%20for%20human%20use%202015%203%2019.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/eu%20good%20distribution%20practice%20of%20medicinal%20products%20for%20human%20use%202013%2011%205.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/eu%20good%20distribution%20practice%20of%20medicinal%20products%20for%20human%20use%202013%2011%205.pdf",
      "sha256": "c2d2e03955d9c7f92a3cba6eb7be1e8ea51c52619d284892ff52952d61845d4e",
      "size": 114063,
      "pages": null,
      "regulator": "OTHER",
      "filename": "eu%20good%20distribution%20practice%20of%20medicinal%20products%20for%20human%20use%202013%2011%205.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/eugmp/Glossary.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/eugmp/Glossary.pdf",
      "sha256": "2247de17acd3836c536abef8a5f3b80e973ecd30c5de195f371a461c2ee14e90",
      "size": 305043,
      "pages": null,
      "regulator": "OTHER",
      "filename": "Glossary.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/eugmp/eu%20gmp%20guide%20chapter%201%20pharmaceutical%20quality%20system.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/eugmp/eu%20gmp%20guide%20chapter%201%20pharmaceutical%20quality%20system.pdf",
      "sha256": "a621bbc975e6634065c15e5e3755a22a780ad9ea49d9704b7f0a0fd9020d2994",
      "size": 362385,
      "pages": null,
      "regulator": "OTHER",
      "filename": "eu%20gmp%20guide%20chapter%201%20pharmaceutical%20quality%20system.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/eugmp/eu%20gmp%20guide%20chapter%202%20personnel%20effective%20from%202014%202%2016.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/eugmp/eu%20gmp%20guide%20chapter%202%20personnel%20effective%20from%202014%202%2016.pdf",
      "sha256": "33842ef9a587eb0fc1a75e4d21b7213aaf790251112757e1d92e17344cd84435",
      "size": 303665,
      "pages": null,
      "regulator": "OTHER",
      "filename": "eu%20gmp%20guide%20chapter%202%20personnel%20effective%20from%202014%202%2016.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/eugmp/eu%20gmp%20guide%20chapter%203%20premises%20and%20equipment%202015%203%201.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/eugmp/eu%20gmp%20guide%20chapter%203%20premises%20and%20equipment%202015%203%201.pdf",
      "sha256": "045597b20090ba39e81984ae7fed202a8264cfe39f1a9902d4ef3cfe09bdbaa8",
      "size": 296025,
      "pages": null,
      "regulator": "OTHER",
      "filename": "eu%20gmp%20guide%20chapter%203%20premises%20and%20equipment%202015%203%201.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/eugmp/eu%20gmp%20guide%20chapter%204%20documentation%202011.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/eugmp/eu%20gmp%20guide%20chapter%204%20documentation%202011.pdf",
      "sha256": "8aa137d914de5903a2fe4db875f39e78cc5674a7d68c6a33b210f23b337536c4",
      "size": 402376,
      "pages": null,
      "regulator": "OTHER",
      "filename": "eu%20gmp%20guide%20chapter%204%20documentation%202011.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/eugmp/eu%20gmp%20guide%20chapter%205%20production%202015%203%201.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/eugmp/eu%20gmp%20guide%20chapter%205%20production%202015%203%201.pdf",
      "sha256": "6e017afa7ae54c66c82c24747a66f8c0277567b625669090ee9be7396bfe5b7f",
      "size": 482149,
      "pages": null,
      "regulator": "OTHER",
      "filename": "eu%20gmp%20guide%20chapter%205%20production%202015%203%201.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/eugmp/eu%20gmp%20guide%20chapter%206%20quality%20control%202014.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/eugmp/eu%20gmp%20guide%20chapter%206%20quality%20control%202014.pdf",
      "sha256": "2aad1bdcb75fe065c23fbb6d29b294d880ea6877094f6cb8300ed571b5bb7a0b",
      "size": 352481,
      "pages": null,
      "regulator": "OTHER",
      "filename": "eu%20gmp%20guide%20chapter%206%20quality%20control%202014.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/eugmp/eu%20gmp%20guide%20chapter%207%20outsourced%20activities.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/eugmp/eu%20gmp%20guide%20chapter%207%20outsourced%20activities.pdf",
      "sha256": "943acf8b1c53544fb8b8f22669edf03c42f71422a2159b3c4675273121e86472",
      "size": 248887,
      "pages": null,
      "regulator": "OTHER",
      "filename": "eu%20gmp%20guide%20chapter%207%20outsourced%20activities.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/eugmp/eu%20gmp%20guide%20chapter%208%20complaints%20quality%20defects%20and%20product%20recalls%202015%203%201.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/eugmp/eu%20gmp%20guide%20chapter%208%20complaints%20quality%20defects%20and%20product%20recalls%202015%203%201.pdf",
      "sha256": "c1e5fabac1d523aae7d4a265522428983e1050cff44f8784a447b3bd4d559881",
      "size": 314742,
      "pages": null,
      "regulator": "OTHER",
      "filename": "eu%20gmp%20guide%20chapter%208%20complaints%20quality%20defects%20and%20product%20recalls%202015%203%201.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/eugmp/eu%20gmp%20guide%20chapter%209.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/eugmp/eu%20gmp%20guide%20chapter%209.pdf",
      "sha256": "b04f6619c4f4e8562418c8cc2477166de362ec7df4b9587adc21adc211b79008",
      "size": 124415,
      "pages": null,
      "regulator": "OTHER",
      "filename": "eu%20gmp%20guide%20chapter%209.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/eugmp/eu%20gmp%20guide%20introduction%202011.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/eugmp/eu%20gmp%20guide%20introduction%202011.pdf",
      "sha256": "88d1c3fd8d6a3a97eee97afa1be0c7050c10c6978ae8859d9ddcf60f308996f4",
      "size": 192313,
      "pages": null,
      "regulator": "OTHER",
      "filename": "eu%20gmp%20guide%20introduction%202011.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/eugmp/eu%20gmp%20guide%20part%202%202014%208%2013.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/eugmp/eu%20gmp%20guide%20part%202%202014%208%2013.pdf",
      "sha256": "8129d9237ea978bfc63121066f506f557928d526f3c320e2c678b15c4550d77d",
      "size": 273613,
      "pages": null,
      "regulator": "OTHER",
      "filename": "eu%20gmp%20guide%20part%202%202014%208%2013.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/eugmp/template%20for%20the%20written%20confirmation%20for%20active%20substances%20exported%20to%20the%20EU%202013.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/eugmp/template%20for%20the%20written%20confirmation%20for%20active%20substances%20exported%20to%20the%20EU%202013.pdf",
      "sha256": "72f72881d56bd788cfcf87f0ce67e3cd266fcb6b12c93756a6796339e188a0c0",
      "size": 146362,
      "pages": null,
      "regulator": "OTHER",
      "filename": "template%20for%20the%20written%20confirmation%20for%20active%20substances%20exported%20to%20the%20EU%202013.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/gmp%20requirements%20applicable%20to%20the%20early%20manufacturing%20stpes%20for%20comminuted%20plants%20and%20herbal%20extracts.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/gmp%20requirements%20applicable%20to%20the%20early%20manufacturing%20stpes%20for%20comminuted%20plants%20and%20herbal%20extracts.pdf",
      "sha256": "354524f1dc0c997acb7e918f27e1ee76714d1e2d6363515a49841e4bdf2d41eb",
      "size": 117362,
      "pages": null,
      "regulator": "OTHER",
      "filename": "gmp%20requirements%20applicable%20to%20the%20early%20manufacturing%20stpes%20for%20comminuted%20plants%20and%20herbal%20extracts.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/guidance%20related%20to%20GMP%20GDP%20and%20PMF%20distant%20assessments.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/guidance%20related%20to%20GMP%20GDP%20and%20PMF%20distant%20assessments.pdf",
      "sha256": "8336efdbe80e3773f995e8bbee0f35a63458be8fbec63c2d601e6228bcfab4f7",
      "size": 409974,
      "pages": null,
      "regulator": "OTHER",
      "filename": "guidance%20related%20to%20GMP%20GDP%20and%20PMF%20distant%20assessments.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/guideline%20on%20the%20responsibilities%20of%20the%20sponsor.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/guideline%20on%20the%20responsibilities%20of%20the%20sponsor.pdf",
      "sha256": "929270dd052c649458dabbced508d74f5796cd1009825227081b198717f73716",
      "size": 322403,
      "pages": null,
      "regulator": "OTHER",
      "filename": "guideline%20on%20the%20responsibilities%20of%20the%20sponsor.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/guidelines%20on%20gmp%20for%20investigational%20medicinal%20products%20for%20human%20use.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/guidelines%20on%20gmp%20for%20investigational%20medicinal%20products%20for%20human%20use.pdf",
      "sha256": "5eb039f5912083176f654430350009b8fae424356dccdb616c2a222843869ba6",
      "size": 519198,
      "pages": null,
      "regulator": "OTHER",
      "filename": "guidelines%20on%20gmp%20for%20investigational%20medicinal%20products%20for%20human%20use.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/health%20based%20exposure%20limits%20for%20use%20in%20risk%20identification%20in%20the%20manufacture%20of%20different%20medicinal%20products%20in%20shared%20facilities.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/health%20based%20exposure%20limits%20for%20use%20in%20risk%20identification%20in%20the%20manufacture%20of%20different%20medicinal%20products%20in%20shared%20facilities.pdf",
      "sha256": "14980671952b6274bce8e06a31d54ad4a862c6085b5012398a24145d76de12da",
      "size": 399006,
      "pages": null,
      "regulator": "OTHER",
      "filename": "health%20based%20exposure%20limits%20for%20use%20in%20risk%20identification%20in%20the%20manufacture%20of%20different%20medicinal%20products%20in%20shared%20fac"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/reflection%20paper%20on%20GMP%20and%20MAH%202022%20ver%202.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/reflection%20paper%20on%20GMP%20and%20MAH%202022%20ver%202.pdf",
      "sha256": "f2bd589f6aecca02ddb752fa53b81194136aff75542bbeec7871bf79a51ada5a",
      "size": 1307339,
      "pages": null,
      "regulator": "OTHER",
      "filename": "reflection%20paper%20on%20GMP%20and%20MAH%202022%20ver%202.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/EC%20guidelines%20on%20the%20details%20of%20the%20various%20categories%20of%20variations%20kr%20annex.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/EC%20guidelines%20on%20the%20details%20of%20the%20various%20categories%20of%20variations%20kr%20annex.pdf",
      "sha256": "2b04f5c25977e71fbb0eaa87cd07d9706a2dd1f40dc4b279f5ed778494cefe32",
      "size": 274349,
      "pages": null,
      "regulator": "OTHER",
      "filename": "EC%20guidelines%20on%20the%20details%20of%20the%20various%20categories%20of%20variations%20kr%20annex.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/EC%20guidelines%20on%20the%20details%20of%20the%20various%20categories%20of%20variations.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/EC%20guidelines%20on%20the%20details%20of%20the%20various%20categories%20of%20variations.pdf",
      "sha256": "384ebd810d5f6b0b1f6e5e23d14c0352a0e47438e1f8e9f6c7e7737fcdc25300",
      "size": 1930106,
      "pages": 84,
      "regulator": "OTHER",
      "filename": "EC%20guidelines%20on%20the%20details%20of%20the%20various%20categories%20of%20variations.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/Excipients%20in%20the%20Dossier%20for%20Application.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/Excipients%20in%20the%20Dossier%20for%20Application.pdf",
      "sha256": "f88c619dc5c795be9abcde72e23a473fc76a5797d0fbc7d76cba7599f368c989",
      "size": 406643,
      "pages": null,
      "regulator": "OTHER",
      "filename": "Excipients%20in%20the%20Dossier%20for%20Application.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/In%20Use%20Stability%20Testing.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/In%20Use%20Stability%20Testing.pdf",
      "sha256": "3be879af3788aaef7a4eb8c55319d9910469872c2aed7b3c1b13cb9354dfa6ce",
      "size": 156316,
      "pages": null,
      "regulator": "OTHER",
      "filename": "In%20Use%20Stability%20Testing.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/Maximum%20ShelfLife%20After%20Opening.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/Maximum%20ShelfLife%20After%20Opening.pdf",
      "sha256": "1b7a12cbccf937293260c4cf5f178933aaef2fa0659908fdf1acfa7088272429",
      "size": 185395,
      "pages": null,
      "regulator": "OTHER",
      "filename": "Maximum%20ShelfLife%20After%20Opening.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/Start%20Of%20Shelf%20Life%20Of%20the%20Finished%20Dosage%20Form.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/Start%20Of%20Shelf%20Life%20Of%20the%20Finished%20Dosage%20Form.pdf",
      "sha256": "5d3c20d500ae799c01fe936a35cd4e1e3f64c609c1d72be44f0433f97cfc0380",
      "size": 92842,
      "pages": null,
      "regulator": "OTHER",
      "filename": "Start%20Of%20Shelf%20Life%20Of%20the%20Finished%20Dosage%20Form.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/Summary%20of%20Requirements%20for%20Active%20Substances.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/Summary%20of%20Requirements%20for%20Active%20Substances.pdf",
      "sha256": "c5f5e5a74cb581c17af9688dcb3b4ef12b609e602b2686f0f595b92ad4eb4871",
      "size": 344502,
      "pages": null,
      "regulator": "OTHER",
      "filename": "Summary%20of%20Requirements%20for%20Active%20Substances.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/addendum%20to%20nirs%20guideline%20defining%20the%20scope%20of%20an%20nirs%20procedure.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/addendum%20to%20nirs%20guideline%20defining%20the%20scope%20of%20an%20nirs%20procedure.pdf",
      "sha256": "38efe5df0595095f285c3c06eb7960e4ffba0e8a75474c82b3ac666ab64ec990",
      "size": 348983,
      "pages": null,
      "regulator": "OTHER",
      "filename": "addendum%20to%20nirs%20guideline%20defining%20the%20scope%20of%20an%20nirs%20procedure.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/ema%20fda%20pilot%20program%20for%20parallel%20assessment%20of%20quality%20by%20design%20applications.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/ema%20fda%20pilot%20program%20for%20parallel%20assessment%20of%20quality%20by%20design%20applications.pdf",
      "sha256": "7920f02c94c8b196357b7bee4477b450382484054695b50bc647d19c462bd591",
      "size": 205680,
      "pages": null,
      "regulator": "OTHER",
      "filename": "ema%20fda%20pilot%20program%20for%20parallel%20assessment%20of%20quality%20by%20design%20applications.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/guideline%20on%20development%20production%20characterisation%20and%20specification%20for%20monoclonal%20antibodies%20and%20related%20products.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/guideline%20on%20development%20production%20characterisation%20and%20specification%20for%20monoclonal%20antibodies%20and%20related%20products.pdf",
      "sha256": "980f93e3be2771c8159956f9f3c01ec1b8e6609f575dcbd77179acd07688d5f4",
      "size": 437655,
      "pages": null,
      "regulator": "OTHER",
      "filename": "guideline%20on%20development%20production%20characterisation%20and%20specification%20for%20monoclonal%20antibodies%20and%20related%20products.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/guideline%20on%20manufacture%20of%20the%20finished%20dosage%20form.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/guideline%20on%20manufacture%20of%20the%20finished%20dosage%20form.pdf",
      "sha256": "7eec8d2666ec054b19d60f2c5a1b4beec7fe7b244be0062c0f0228ba251e75aa",
      "size": 426273,
      "pages": null,
      "regulator": "OTHER",
      "filename": "guideline%20on%20manufacture%20of%20the%20finished%20dosage%20form.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/guideline%20on%20process%20%20validation%20for%20finished%20products%20final.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/guideline%20on%20process%20%20validation%20for%20finished%20products%20final.pdf",
      "sha256": "255ca5892822ab089eddafe1ed800c2d0a31283b867cbee76cde309404ea1282",
      "size": 565555,
      "pages": null,
      "regulator": "OTHER",
      "filename": "guideline%20on%20process%20%20validation%20for%20finished%20products%20final.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/guideline%20on%20process%20%20validation%20for%20the%20manufacture%20of%20biotechnology%20derived%20active%20substances.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/guideline%20on%20process%20%20validation%20for%20the%20manufacture%20of%20biotechnology%20derived%20active%20substances.pdf",
      "sha256": "5128c5773635996cda1bdada400595353a87dac0cff90addc6009f5dac8471df",
      "size": 480764,
      "pages": null,
      "regulator": "OTHER",
      "filename": "guideline%20on%20process%20%20validation%20for%20the%20manufacture%20of%20biotechnology%20derived%20active%20substances.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/guideline%20on%20quality%20documentation%20for%20medicinal%20products%20when%20used%20with%20a%20medical%20device.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/guideline%20on%20quality%20documentation%20for%20medicinal%20products%20when%20used%20with%20a%20medical%20device.pdf",
      "sha256": "c041334cad514fd7b2317a69498d4cf15d830d84868bf1e5f4665779335b8d10",
      "size": 862686,
      "pages": null,
      "regulator": "OTHER",
      "filename": "guideline%20on%20quality%20documentation%20for%20medicinal%20products%20when%20used%20with%20a%20medical%20device.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/guideline%20on%20the%20chemistry%20of%20active%20substances.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/guideline%20on%20the%20chemistry%20of%20active%20substances.pdf",
      "sha256": "c350fa4ddb95ae30f642c7eb8a96f10dcc9bf909c9b0000105172639f7c25f2e",
      "size": 478883,
      "pages": null,
      "regulator": "OTHER",
      "filename": "guideline%20on%20the%20chemistry%20of%20active%20substances.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/guideline%20on%20the%20quality%20of%20water%20for%20pharmaceutical%20use.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/guideline%20on%20the%20quality%20of%20water%20for%20pharmaceutical%20use.pdf",
      "sha256": "7e5436ce48e42ffdbff5e78776d1a724a1b190898e2c10b75285ac0fcdcae8bc",
      "size": 420470,
      "pages": null,
      "regulator": "OTHER",
      "filename": "guideline%20on%20the%20quality%20of%20water%20for%20pharmaceutical%20use.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/guideline%20on%20the%20sterilization%20of%20the%20medicinal%20product%20active%20substance%20excipient%20and%20primary%20container.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/guideline%20on%20the%20sterilization%20of%20the%20medicinal%20product%20active%20substance%20excipient%20and%20primary%20container.pdf",
      "sha256": "4d9f47199e930a488505c33d51889b20390b811aa0bf0a41e8962a21f95f80aa",
      "size": 932638,
      "pages": null,
      "regulator": "OTHER",
      "filename": "guideline%20on%20the%20sterilization%20of%20the%20medicinal%20product%20active%20substance%20excipient%20and%20primary%20container.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/nir%20spectroscopy%20data%20requirements%20for%20new%20submissions%20and%20variations%202014%201%2027.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/nir%20spectroscopy%20data%20requirements%20for%20new%20submissions%20and%20variations%202014%201%2027.pdf",
      "sha256": "e002d0e967c1c4424205a374347ddb803ca89bf097429b23d3288abecb2ad9ef",
      "size": 132062,
      "pages": null,
      "regulator": "OTHER",
      "filename": "nir%20spectroscopy%20data%20requirements%20for%20new%20submissions%20and%20variations%202014%201%2027.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/plastic%20immediate%20packaging%20materials.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/plastic%20immediate%20packaging%20materials.pdf",
      "sha256": "796c700d1dcf41b3a842a33ad8314647e1e894ad6daa099902c6964f12cd299d",
      "size": 419870,
      "pages": null,
      "regulator": "OTHER",
      "filename": "plastic%20immediate%20packaging%20materials.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/q%20and%20a%20design%20space%20verification.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/q%20and%20a%20design%20space%20verification.pdf",
      "sha256": "fbd0a559906976ac341e1b17bb1882b295345b0ee4ad81b67e52fd8f0db71b04",
      "size": 202254,
      "pages": null,
      "regulator": "OTHER",
      "filename": "q%20and%20a%20design%20space%20verification.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/q%20and%20a%20on%20api%20mix.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/q%20and%20a%20on%20api%20mix.pdf",
      "sha256": "2290933b83855ed8e51816016339493f53a7aeb25cc29509a52323e669f0931f",
      "size": 183749,
      "pages": null,
      "regulator": "OTHER",
      "filename": "q%20and%20a%20on%20api%20mix.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/q%20and%20a%20on%20comparability%20considerations%20for%20ATMP.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/q%20and%20a%20on%20comparability%20considerations%20for%20ATMP.pdf",
      "sha256": "31cab291afe74f1dc7950d55cee5efe240358ee19d3460b168cf33e5217d2407",
      "size": 417767,
      "pages": null,
      "regulator": "OTHER",
      "filename": "q%20and%20a%20on%20comparability%20considerations%20for%20ATMP.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/q%20and%20a%20production%20of%20wfi%20by%20non%20distillation%20methods.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/q%20and%20a%20production%20of%20wfi%20by%20non%20distillation%20methods.pdf",
      "sha256": "8c856bf17debd3026d5e6deea18c28b97a4feb020b5ba499869b0fba0693a5db",
      "size": 586204,
      "pages": null,
      "regulator": "OTHER",
      "filename": "q%20and%20a%20production%20of%20wfi%20by%20non%20distillation%20methods.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/real%20time%20release%20testing%20final.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/real%20time%20release%20testing%20final.pdf",
      "sha256": "e6e373a0e6bab9ca6371a1aaa61f01f1884f5d0ff56d51ba24308467c7262de1",
      "size": 455758,
      "pages": null,
      "regulator": "OTHER",
      "filename": "real%20time%20release%20testing%20final.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/reflection%20paper%20on%20selection%20of%20starting%20materials%20for%20manufacture%20of%20chemical%20active%20substances.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/reflection%20paper%20on%20selection%20of%20starting%20materials%20for%20manufacture%20of%20chemical%20active%20substances.pdf",
      "sha256": "b1ad371b2df9400fefda0f37255da594d6e9155a1ad3f3b93dc8975435abde3a",
      "size": 410803,
      "pages": null,
      "regulator": "OTHER",
      "filename": "reflection%20paper%20on%20selection%20of%20starting%20materials%20for%20manufacture%20of%20chemical%20active%20substances.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/stability%20testing%20for%20applications%20for%20variations%20to%20a%20marketing%20authorization%202014.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/stability%20testing%20for%20applications%20for%20variations%20to%20a%20marketing%20authorization%202014.pdf",
      "sha256": "399549d4e0edf989fc8b9491e7d39ef92ab7dc42686785b8fcb8f6ab07c2d9d4",
      "size": 450030,
      "pages": null,
      "regulator": "OTHER",
      "filename": "stability%20testing%20for%20applications%20for%20variations%20to%20a%20marketing%20authorization%202014.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/gmp/ICH%20Q7%20API%20GMP%20Guide%20Chapter%201.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/gmp/ICH%20Q7%20API%20GMP%20Guide%20Chapter%201.pdf",
      "sha256": "e793eaef25c0a4377946c92fc94bcc319934e9ca3b9aaffc24e98590ab3c2acb",
      "size": 368259,
      "pages": null,
      "regulator": "ICH",
      "filename": "ICH%20Q7%20API%20GMP%20Guide%20Chapter%201.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/gmp/ICH%20Q7%20API%20GMP%20Guide%20Chapter%2010.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/gmp/ICH%20Q7%20API%20GMP%20Guide%20Chapter%2010.pdf",
      "sha256": "0fc8947418cc9a4e90f910e102c7b2b6aedc71aa49e08b73ff559c4d7bb54d90",
      "size": 271229,
      "pages": null,
      "regulator": "ICH",
      "filename": "ICH%20Q7%20API%20GMP%20Guide%20Chapter%2010.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/gmp/ICH%20Q7%20API%20GMP%20Guide%20Chapter%2011.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/gmp/ICH%20Q7%20API%20GMP%20Guide%20Chapter%2011.pdf",
      "sha256": "14306e1e0bc33d492bc6e32b668c56619209bf81655a2179f2ad9438f929f264",
      "size": 341952,
      "pages": null,
      "regulator": "ICH",
      "filename": "ICH%20Q7%20API%20GMP%20Guide%20Chapter%2011.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/gmp/ICH%20Q7%20API%20GMP%20Guide%20Chapter%2012.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/gmp/ICH%20Q7%20API%20GMP%20Guide%20Chapter%2012.pdf",
      "sha256": "2dcd68aae8c83300fe6b19971d035e0e8658d54ed2f746e8e6166b4d6a2bc2ba",
      "size": 351591,
      "pages": null,
      "regulator": "ICH",
      "filename": "ICH%20Q7%20API%20GMP%20Guide%20Chapter%2012.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/gmp/ICH%20Q7%20API%20GMP%20Guide%20Chapter%2013.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/gmp/ICH%20Q7%20API%20GMP%20Guide%20Chapter%2013.pdf",
      "sha256": "3a4c96e83e9fa802bab29382af22fddd35dd30999bf0d0c2e4d91e8b9f879426",
      "size": 271062,
      "pages": null,
      "regulator": "ICH",
      "filename": "ICH%20Q7%20API%20GMP%20Guide%20Chapter%2013.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/gmp/ICH%20Q7%20API%20GMP%20Guide%20Chapter%2014.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/gmp/ICH%20Q7%20API%20GMP%20Guide%20Chapter%2014.pdf",
      "sha256": "6e2f6f13f24879469c3fa86dc643497defb9fc8ed5bdf6726b66f31507adb5fc",
      "size": 292119,
      "pages": null,
      "regulator": "ICH",
      "filename": "ICH%20Q7%20API%20GMP%20Guide%20Chapter%2014.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/gmp/ICH%20Q7%20API%20GMP%20Guide%20Chapter%2015.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/gmp/ICH%20Q7%20API%20GMP%20Guide%20Chapter%2015.pdf",
      "sha256": "580d8451d4f356900f251f7bfc3cc8b6551a695309019f6dfe039e76fcc08633",
      "size": 257912,
      "pages": null,
      "regulator": "ICH",
      "filename": "ICH%20Q7%20API%20GMP%20Guide%20Chapter%2015.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/gmp/ICH%20Q7%20API%20GMP%20Guide%20Chapter%2016.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/gmp/ICH%20Q7%20API%20GMP%20Guide%20Chapter%2016.pdf",
      "sha256": "4baad3046c9ee3db85f9610309f21e495597a172d2be181140b0452551a82dc0",
      "size": 269982,
      "pages": null,
      "regulator": "ICH",
      "filename": "ICH%20Q7%20API%20GMP%20Guide%20Chapter%2016.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/gmp/ICH%20Q7%20API%20GMP%20Guide%20Chapter%2017.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/gmp/ICH%20Q7%20API%20GMP%20Guide%20Chapter%2017.pdf",
      "sha256": "5bef2e53f0ff2cf3d9a305805ac80e1b64ff302b6cb353d7c6a211e4135bbaab",
      "size": 291221,
      "pages": null,
      "regulator": "ICH",
      "filename": "ICH%20Q7%20API%20GMP%20Guide%20Chapter%2017.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/gmp/ICH%20Q7%20API%20GMP%20Guide%20Chapter%2018.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/gmp/ICH%20Q7%20API%20GMP%20Guide%20Chapter%2018.pdf",
      "sha256": "298d3f4d89a41aede1aacf1b58ddd6cfaec47fa4de942b955bc03abc2fc446cd",
      "size": 339863,
      "pages": null,
      "regulator": "ICH",
      "filename": "ICH%20Q7%20API%20GMP%20Guide%20Chapter%2018.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/gmp/ICH%20Q7%20API%20GMP%20Guide%20Chapter%2019.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/gmp/ICH%20Q7%20API%20GMP%20Guide%20Chapter%2019.pdf",
      "sha256": "69a2f93a22c203ad5221d0b313babb4ddeccc44f27b223c43bc7947f91a2d7ad",
      "size": 304733,
      "pages": null,
      "regulator": "ICH",
      "filename": "ICH%20Q7%20API%20GMP%20Guide%20Chapter%2019.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/gmp/ICH%20Q7%20API%20GMP%20Guide%20Chapter%202.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/gmp/ICH%20Q7%20API%20GMP%20Guide%20Chapter%202.pdf",
      "sha256": "4ce42ea3d3bfdd664b45c0f564b73bb09d419d9cd26d8926d51e16effd44ec9b",
      "size": 312301,
      "pages": null,
      "regulator": "ICH",
      "filename": "ICH%20Q7%20API%20GMP%20Guide%20Chapter%202.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/gmp/ICH%20Q7%20API%20GMP%20Guide%20Chapter%2020.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/gmp/ICH%20Q7%20API%20GMP%20Guide%20Chapter%2020.pdf",
      "sha256": "68ddb9774b95f4e3db33daee605d6c25b281e8a0c6bcd5ccb2f38bf2e5336ad2",
      "size": 364568,
      "pages": null,
      "regulator": "ICH",
      "filename": "ICH%20Q7%20API%20GMP%20Guide%20Chapter%2020.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/gmp/ICH%20Q7%20API%20GMP%20Guide%20Chapter%203.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/gmp/ICH%20Q7%20API%20GMP%20Guide%20Chapter%203.pdf",
      "sha256": "1084b11f98faa7265288474a28e8ac3469f4b9868f0f12a7c10893a5c58838c2",
      "size": 270825,
      "pages": null,
      "regulator": "ICH",
      "filename": "ICH%20Q7%20API%20GMP%20Guide%20Chapter%203.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/gmp/ICH%20Q7%20API%20GMP%20Guide%20Chapter%204.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/gmp/ICH%20Q7%20API%20GMP%20Guide%20Chapter%204.pdf",
      "sha256": "fe135c5c638fe6454219b4d6e254af1d9a148e14acb7117f4ebcd3968569be91",
      "size": 315508,
      "pages": null,
      "regulator": "ICH",
      "filename": "ICH%20Q7%20API%20GMP%20Guide%20Chapter%204.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/gmp/ICH%20Q7%20API%20GMP%20Guide%20Chapter%205.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/gmp/ICH%20Q7%20API%20GMP%20Guide%20Chapter%205.pdf",
      "sha256": "8bebcf969efe1461a3a1da0a04b5ad9c485a0c4992406249266f3d038cc89ef7",
      "size": 326639,
      "pages": null,
      "regulator": "ICH",
      "filename": "ICH%20Q7%20API%20GMP%20Guide%20Chapter%205.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/gmp/ICH%20Q7%20API%20GMP%20Guide%20Chapter%206.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/gmp/ICH%20Q7%20API%20GMP%20Guide%20Chapter%206.pdf",
      "sha256": "f602f42c00fa77a5f44f2f59fe2bd76edb2e45d8308fb38491401e4fde10375e",
      "size": 358478,
      "pages": null,
      "regulator": "ICH",
      "filename": "ICH%20Q7%20API%20GMP%20Guide%20Chapter%206.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/gmp/ICH%20Q7%20API%20GMP%20Guide%20Chapter%207.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/gmp/ICH%20Q7%20API%20GMP%20Guide%20Chapter%207.pdf",
      "sha256": "8cfe101cd5bd124c9a546ef0c95d24714d61363c7569dd63570be0d240ea0e65",
      "size": 304862,
      "pages": null,
      "regulator": "ICH",
      "filename": "ICH%20Q7%20API%20GMP%20Guide%20Chapter%207.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/gmp/ICH%20Q7%20API%20GMP%20Guide%20Chapter%208.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/gmp/ICH%20Q7%20API%20GMP%20Guide%20Chapter%208.pdf",
      "sha256": "b1c5f6dcfcc534abad4685906fd826e027bf2f4d6688348257fad3b896ebef35",
      "size": 316454,
      "pages": null,
      "regulator": "ICH",
      "filename": "ICH%20Q7%20API%20GMP%20Guide%20Chapter%208.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/gmp/ICH%20Q7%20API%20GMP%20Guide%20Chapter%209.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/gmp/ICH%20Q7%20API%20GMP%20Guide%20Chapter%209.pdf",
      "sha256": "5357d98db5b88fcf0d8d7da06025c3361323e30bb868f76b09df5876dc41c2f9",
      "size": 282549,
      "pages": null,
      "regulator": "ICH",
      "filename": "ICH%20Q7%20API%20GMP%20Guide%20Chapter%209.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/gmp/Q7%20iwg%20q%20and%20a%2010%20june%202015.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/gmp/Q7%20iwg%20q%20and%20a%2010%20june%202015.pdf",
      "sha256": "e17a218ec20c3781ffb041dc2ea63866ffca4a2d9c3619cd72f067368c4be8d6",
      "size": 873757,
      "pages": null,
      "regulator": "ICH",
      "filename": "Q7%20iwg%20q%20and%20a%2010%20june%202015.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/M4%20Implementation%20Working%20Group%20Questions%20and%20Answers%20R3.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/M4%20Implementation%20Working%20Group%20Questions%20and%20Answers%20R3.pdf",
      "sha256": "5af50034510081a7c28cb748c17e5ecd5286a34dfa6314f47069300a6b9d4e8d",
      "size": 304688,
      "pages": null,
      "regulator": "ICH",
      "filename": "M4%20Implementation%20Working%20Group%20Questions%20and%20Answers%20R3.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/M4%20Organization%20of%20The%20Common%20Technical%20Document.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/M4%20Organization%20of%20The%20Common%20Technical%20Document.pdf",
      "sha256": "5af3e3925cee12bd56bb5b3a7d824bfcd48abd551ba5281e138eb19d5bbe543f",
      "size": 449263,
      "pages": null,
      "regulator": "ICH",
      "filename": "M4%20Organization%20of%20The%20Common%20Technical%20Document.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/M4Q%20Implementation%20Working%20Group%20Questions%20and%20Answers%20R1.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/M4Q%20Implementation%20Working%20Group%20Questions%20and%20Answers%20R1.pdf",
      "sha256": "d427394281e7f4a65db17e5757ea7b8d8f3281e3d16f5f03bf096818a7033d84",
      "size": 689119,
      "pages": null,
      "regulator": "ICH",
      "filename": "M4Q%20Implementation%20Working%20Group%20Questions%20and%20Answers%20R1.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/M4QR1%20The%20Common%20Technical%20Document%20Quality%20Part%20Module%202%20Module%203.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/M4QR1%20The%20Common%20Technical%20Document%20Quality%20Part%20Module%202%20Module%203.pdf",
      "sha256": "44f52cb22494367538a3158f4c3779227f8f056557a5e17a8cb902dab49baa0e",
      "size": 665290,
      "pages": null,
      "regulator": "ICH",
      "filename": "M4QR1%20The%20Common%20Technical%20Document%20Quality%20Part%20Module%202%20Module%203.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/M4QR2%20The%20Common%20Technical%20Document%20Quality%20Part%20Draft%202025%205%2014.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/M4QR2%20The%20Common%20Technical%20Document%20Quality%20Part%20Draft%202025%205%2014.pdf",
      "sha256": "2d28cc6489303b32130f1eac48b3d6b92f45addaf464941ad180d6620ded5f2d",
      "size": 290022,
      "pages": null,
      "regulator": "ICH",
      "filename": "M4QR2%20The%20Common%20Technical%20Document%20Quality%20Part%20Draft%202025%205%2014.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q1%20stability%20testing%20of%20new%20drug%20substances%20and%20drug%20products.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q1%20stability%20testing%20of%20new%20drug%20substances%20and%20drug%20products.pdf",
      "sha256": "7d4d78d9bf3b4a6ce9522cebab0912fd0617479d5b92124ea64dc6748e1b4566",
      "size": 290262,
      "pages": null,
      "regulator": "ICH",
      "filename": "Q1%20stability%20testing%20of%20new%20drug%20substances%20and%20drug%20products.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q10%20pharmaceutical%20quality%20system.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q10%20pharmaceutical%20quality%20system.pdf",
      "sha256": "b7b8d1fe140dd0c603243432b83f272b16d791318a81dd97e4667dbaf90e8299",
      "size": 819536,
      "pages": null,
      "regulator": "ICH",
      "filename": "Q10%20pharmaceutical%20quality%20system.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q11%20development%20and%20manufacture%20of%20drug%20substances%20step%204.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q11%20development%20and%20manufacture%20of%20drug%20substances%20step%204.pdf",
      "sha256": "1ff7f5a910877fc7ff04d94777400f19651d77dc782b6fa9f385f9053b396c08",
      "size": 1080825,
      "pages": null,
      "regulator": "ICH",
      "filename": "Q11%20development%20and%20manufacture%20of%20drug%20substances%20step%204.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q11%20iwg%20q%20and%20a%2023%20august%202017.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q11%20iwg%20q%20and%20a%2023%20august%202017.pdf",
      "sha256": "df7675886f86a88e5c41e059feb26538322f170c2c2ed9f4bea15f9458e75f1c",
      "size": 1094089,
      "pages": null,
      "regulator": "ICH",
      "filename": "Q11%20iwg%20q%20and%20a%2023%20august%202017.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q12%20pharmaceutical%20product%20lifecycle%20management%202019%2011%2020%20final.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q12%20pharmaceutical%20product%20lifecycle%20management%202019%2011%2020%20final.pdf",
      "sha256": "afbd3b807d534f15a854db54520c804bdac2a3cd823b2a05d28f90d88226193e",
      "size": 187603,
      "pages": null,
      "regulator": "ICH",
      "filename": "Q12%20pharmaceutical%20product%20lifecycle%20management%202019%2011%2020%20final.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q12%20pharmaceutical%20product%20lifecycle%20management%20annex%202019%2011%2020.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q12%20pharmaceutical%20product%20lifecycle%20management%20annex%202019%2011%2020.pdf",
      "sha256": "cb00b73a34c34e35b4800da5ab2943a60cf09b1d65bb233728e0fbbb676ab7af",
      "size": 217914,
      "pages": null,
      "regulator": "ICH",
      "filename": "Q12%20pharmaceutical%20product%20lifecycle%20management%20annex%202019%2011%2020.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q13%20continuous%20manufacturing%20of%20drug%20substances%20and%20drug%20products%20final%20version%202022%2011%2016.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q13%20continuous%20manufacturing%20of%20drug%20substances%20and%20drug%20products%20final%20version%202022%2011%2016.pdf",
      "sha256": "72660d589d14b5fefc23d50759b5ffc9883c9abd052f9b7e7263dfc577d27721",
      "size": 263092,
      "pages": null,
      "regulator": "ICH",
      "filename": "Q13%20continuous%20manufacturing%20of%20drug%20substances%20and%20drug%20products%20final%20version%202022%2011%2016.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q14%20analytical%20procedure%20development%20final%202023%2011%201.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q14%20analytical%20procedure%20development%20final%202023%2011%201.pdf",
      "sha256": "d4e6eb4deef5e3e506a47d026d0011ce3bc23a7dd8ce326b55b2400a47825968",
      "size": 241949,
      "pages": null,
      "regulator": "ICH",
      "filename": "Q14%20analytical%20procedure%20development%20final%202023%2011%201.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q1AR2%20stability%20testing%20of%20new%20drug%20substances%20and%20dproducts.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q1AR2%20stability%20testing%20of%20new%20drug%20substances%20and%20dproducts.pdf",
      "sha256": "cdf8a13d0845477e0093fdad01a2d6ba598cde70b270882b9689ac78af7db565",
      "size": 636693,
      "pages": null,
      "regulator": "ICH",
      "filename": "Q1AR2%20stability%20testing%20of%20new%20drug%20substances%20and%20dproducts.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q1B%20photostability%20testing%20of%20new%20drug%20substances%20and%20products.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q1B%20photostability%20testing%20of%20new%20drug%20substances%20and%20products.pdf",
      "sha256": "e2512d06c8ef8fc7db8a50738f3f1fdc79b5b66a055827b4e5cc203395a01809",
      "size": 368427,
      "pages": null,
      "regulator": "ICH",
      "filename": "Q1B%20photostability%20testing%20of%20new%20drug%20substances%20and%20products.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q1C%20stability%20testing%20for%20new%20dosage%20forms.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q1C%20stability%20testing%20for%20new%20dosage%20forms.pdf",
      "sha256": "985568a1e9b4c99fa3a66ee9653abaef2e6cbdee2d3317c559756d2f89414367",
      "size": 119278,
      "pages": null,
      "regulator": "ICH",
      "filename": "Q1C%20stability%20testing%20for%20new%20dosage%20forms.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q1D%20bracketing%20and%20matrixing%20designs%20for%20stability%20testing.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q1D%20bracketing%20and%20matrixing%20designs%20for%20stability%20testing.pdf",
      "sha256": "3351c4fb2ed637e341dee7bbb323c2e39357c475fcd2cbc8e2eac76e2ff0382b",
      "size": 300383,
      "pages": null,
      "regulator": "ICH",
      "filename": "Q1D%20bracketing%20and%20matrixing%20designs%20for%20stability%20testing.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q1E%20evaluation%20for%20stability%20data.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q1E%20evaluation%20for%20stability%20data.pdf",
      "sha256": "ca7e0771600d4bb19c088433ff6962734405d51c0b40d37f90ae9fd61f200f60",
      "size": 577430,
      "pages": null,
      "regulator": "ICH",
      "filename": "Q1E%20evaluation%20for%20stability%20data.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q2R2%20validation%20of%20analytical%20procedures%202023%2011%201.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q2R2%20validation%20of%20analytical%20procedures%202023%2011%201.pdf",
      "sha256": "0fe7355f678354f36f57c0dafe5b4fb685a0e0cab3523a7a6ef11577a2a3210d",
      "size": 245605,
      "pages": null,
      "regulator": "ICH",
      "filename": "Q2R2%20validation%20of%20analytical%20procedures%202023%2011%201.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q5AR2%20viral%20safety%20evaluation%20of%20biotechnology%20products%20derived%20from%20cell%20lines%20of%20human%20or%20animal%20origin%202023%2011%201.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q5AR2%20viral%20safety%20evaluation%20of%20biotechnology%20products%20derived%20from%20cell%20lines%20of%20human%20or%20animal%20origin%202023%2011%201.pdf",
      "sha256": "87085a6bf521133eab895a093678d784b2c21dad18ad721f56285fc05c53d2c6",
      "size": 334688,
      "pages": null,
      "regulator": "ICH",
      "filename": "Q5AR2%20viral%20safety%20evaluation%20of%20biotechnology%20products%20derived%20from%20cell%20lines%20of%20human%20or%20animal%20origin%202023%2011%201.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q5B%20analysis%20of%20expression%20construct%20in%20cells%20used%20for%20production.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q5B%20analysis%20of%20expression%20construct%20in%20cells%20used%20for%20production.pdf",
      "sha256": "fb825403deff2eff94a6cfd73edc80783f5962605f9f0c52bb44a3b705b8f2e1",
      "size": 293378,
      "pages": null,
      "regulator": "ICH",
      "filename": "Q5B%20analysis%20of%20expression%20construct%20in%20cells%20used%20for%20production.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q5C%20stability%20testing%20of%20biotechnological%20biological%20products.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q5C%20stability%20testing%20of%20biotechnological%20biological%20products.pdf",
      "sha256": "5b434268f7ed3b291b7f87345592f9da55df41e937f15973e510836a94e88c2d",
      "size": 435628,
      "pages": null,
      "regulator": "ICH",
      "filename": "Q5C%20stability%20testing%20of%20biotechnological%20biological%20products.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q5D%20derivation%20and%20characterisation%20of%20cell%20substrates.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q5D%20derivation%20and%20characterisation%20of%20cell%20substrates.pdf",
      "sha256": "134aa0f5fac27ec2e04818d982b604b39450dde3fb264adc32cc26e3c7325dd9",
      "size": 568889,
      "pages": null,
      "regulator": "ICH",
      "filename": "Q5D%20derivation%20and%20characterisation%20of%20cell%20substrates.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q5E%20comparability%20biotech%20bio%20products%20subject%20to%20changes%20in%20manufacturing%20process.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q5E%20comparability%20biotech%20bio%20products%20subject%20to%20changes%20in%20manufacturing%20process.pdf",
      "sha256": "4afbbf873e6784c5e4d3fa2f826f4fda29c43c747e04c17e4ff18f236bb6b086",
      "size": 555943,
      "pages": null,
      "regulator": "ICH",
      "filename": "Q5E%20comparability%20biotech%20bio%20products%20subject%20to%20changes%20in%20manufacturing%20process.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q6A%20specifications%20for%20chemical%20drug%20substances%20and%20drug%20products.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q6A%20specifications%20for%20chemical%20drug%20substances%20and%20drug%20products.pdf",
      "sha256": "7f470fedb98f4e09739f9b1b03ec84ba3738ef95d613cfe626f3063897b383e8",
      "size": 1164385,
      "pages": null,
      "regulator": "ICH",
      "filename": "Q6A%20specifications%20for%20chemical%20drug%20substances%20and%20drug%20products.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q6B%20specifications%20for%20biotechnological%20biological%20products.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q6B%20specifications%20for%20biotechnological%20biological%20products.pdf",
      "sha256": "bfe064d83fb17ae68e9cd993835960a950c04f6383e9f7c5c136ee9bbef717b1",
      "size": 739341,
      "pages": null,
      "regulator": "ICH",
      "filename": "Q6B%20specifications%20for%20biotechnological%20biological%20products.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q8%20Q9%20Q10%20QNA%20R4%20Step%204%202010%20November.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q8%20Q9%20Q10%20QNA%20R4%20Step%204%202010%20November.pdf",
      "sha256": "2bec22b52c1f960623ad7b308b37c495b497e6dae04ffdb9721b4cb1d391930e",
      "size": 472490,
      "pages": null,
      "regulator": "ICH",
      "filename": "Q8%20Q9%20Q10%20QNA%20R4%20Step%204%202010%20November.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q8%20R2%20Pharmaceutical%20Development%20Annex.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q8%20R2%20Pharmaceutical%20Development%20Annex.pdf",
      "sha256": "833fa38f05002f94a4e8d79c69b9fe2cc1f8336b82905156f55f39bf61c62b40",
      "size": 935979,
      "pages": null,
      "regulator": "ICH",
      "filename": "Q8%20R2%20Pharmaceutical%20Development%20Annex.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q9(R1)%20Quality%20Risk%20Management%202023%201%2018%20final.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q9(R1)%20Quality%20Risk%20Management%202023%201%2018%20final.pdf",
      "sha256": "5364581b6c59e8da7ca72b3d19aba02ef0f3b9e64b1cc8cfe19e2e09bbc66735",
      "size": 1018522,
      "pages": null,
      "regulator": "ICH",
      "filename": "Q9(R1)%20Quality%20Risk%20Management%202023%201%2018%20final.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/quality%20iwg%20ptc%20r2%20dec%206%202011.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/quality%20iwg%20ptc%20r2%20dec%206%202011.pdf",
      "sha256": "0246d3ce8ba4524c6d58d1f0e7faac7352bff2c8acd151bd8f6be5d207f5e017",
      "size": 602023,
      "pages": null,
      "regulator": "ICH",
      "filename": "quality%20iwg%20ptc%20r2%20dec%206%202011.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/kgmp/annex%201%20Korean%20good%20manufacturing%20practices%20for%20medicinal%20products%20in%20Kor%20Eng%202022%2012%2029%20effective%20from%202023%201%201.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/kgmp/annex%201%20Korean%20good%20manufacturing%20practices%20for%20medicinal%20products%20in%20Kor%20Eng%202022%2012%2029%20effective%20from%202023%201%201.pdf",
      "sha256": "11eb10b9d4a53b61ac2ac135d3f2ce51c15bb5109a26cd62fcb083673e652f37",
      "size": 147067,
      "pages": null,
      "regulator": "OTHER",
      "filename": "annex%201%20Korean%20good%20manufacturing%20practices%20for%20medicinal%20products%20in%20Kor%20Eng%202022%2012%2029%20effective%20from%202023%201%201.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/kgmp/annex%201%20Korean%20good%20manufacturing%20practices%20for%20medicinal%20products%20in%20Kor%20Eng%202022%2012%2029%20effective%20from%202023%2012%208.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/kgmp/annex%201%20Korean%20good%20manufacturing%20practices%20for%20medicinal%20products%20in%20Kor%20Eng%202022%2012%2029%20effective%20from%202023%2012%208.pdf",
      "sha256": "5c685347565d1a622a17ebc921ebf610ae786181cc10355866e654f483c5bb2e",
      "size": 147272,
      "pages": null,
      "regulator": "OTHER",
      "filename": "annex%201%20Korean%20good%20manufacturing%20practices%20for%20medicinal%20products%20in%20Kor%20Eng%202022%2012%2029%20effective%20from%202023%2012%208.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/kgmp/annex%201-2%20Korean%20good%20manufacturing%20practices%20for%20active%20pharmaceutical%20ingredients%20in%20Kor%20Eng%202022%2012%2029.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/kgmp/annex%201-2%20Korean%20good%20manufacturing%20practices%20for%20active%20pharmaceutical%20ingredients%20in%20Kor%20Eng%202022%2012%2029.pdf",
      "sha256": "f707c942f2efc36fbf21d57b301287a1444c478915329641fc2845c7a0136f13",
      "size": 139309,
      "pages": null,
      "regulator": "OTHER",
      "filename": "annex%201-2%20Korean%20good%20manufacturing%20practices%20for%20active%20pharmaceutical%20ingredients%20in%20Kor%20Eng%202022%2012%2029.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/kgmp/annex%203%20Korean%20good%20manufacturing%20practices%20for%20biological%20products%20in%20Kor%20Eng%202021%209%2010.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/kgmp/annex%203%20Korean%20good%20manufacturing%20practices%20for%20biological%20products%20in%20Kor%20Eng%202021%209%2010.pdf",
      "sha256": "fc5f065c42c244155b6388773d1fdfa96884c5f32e64787ef6590c4613a8c6bb",
      "size": 148410,
      "pages": null,
      "regulator": "OTHER",
      "filename": "annex%203%20Korean%20good%20manufacturing%20practices%20for%20biological%20products%20in%20Kor%20Eng%202021%209%2010.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/kgmp/annex%203-2%20Korean%20good%20manufacturing%20practices%20for%20radiopharmaceuticals%20in%20Kor%20Eng%202021%209%2010.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/kgmp/annex%203-2%20Korean%20good%20manufacturing%20practices%20for%20radiopharmaceuticals%20in%20Kor%20Eng%202021%209%2010.pdf",
      "sha256": "6228f88087603a88a2657adbe1e3c44d531864c85f22e3c1d757544e2ac0c431",
      "size": 174244,
      "pages": null,
      "regulator": "OTHER",
      "filename": "annex%203-2%20Korean%20good%20manufacturing%20practices%20for%20radiopharmaceuticals%20in%20Kor%20Eng%202021%209%2010.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/kgmp/annex%203-3%20Korean%20good%20manufacturing%20practices%20for%20medicinal%20gases%20in%20Kor%20Eng%202014%208%2021.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/kgmp/annex%203-3%20Korean%20good%20manufacturing%20practices%20for%20medicinal%20gases%20in%20Kor%20Eng%202014%208%2021.pdf",
      "sha256": "9426aa0c9b8d009338deeabc3a5bf0e23486036e2f3b829392f240516e3aea5b",
      "size": 245683,
      "pages": null,
      "regulator": "OTHER",
      "filename": "annex%203-3%20Korean%20good%20manufacturing%20practices%20for%20medicinal%20gases%20in%20Kor%20Eng%202014%208%2021.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/kgmp/annex%204-2%20Korean%20good%20manufacturing%20practices%20for%20investigational%20products%20in%20Kor%20Eng%202016%2010%2028.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/kgmp/annex%204-2%20Korean%20good%20manufacturing%20practices%20for%20investigational%20products%20in%20Kor%20Eng%202016%2010%2028.pdf",
      "sha256": "b0c9352cce16754ad389494d889149f25f1bae50ab1350e2595c1cd87a1b9296",
      "size": 140078,
      "pages": null,
      "regulator": "OTHER",
      "filename": "annex%204-2%20Korean%20good%20manufacturing%20practices%20for%20investigational%20products%20in%20Kor%20Eng%202016%2010%2028.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/kgmp/pharmaceutical%20facilities%20standard%20decree%20enforcement%20regulation%20in%20Kor%20Eng%202021%2011%2019.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/kgmp/pharmaceutical%20facilities%20standard%20decree%20enforcement%20regulation%20in%20Kor%20Eng%202021%2011%2019.pdf",
      "sha256": "f94eeffe24382a45ac2560380abc7de3c6a2d8f7b07693ca61e9d4c92f746479",
      "size": 151209,
      "pages": null,
      "regulator": "OTHER",
      "filename": "pharmaceutical%20facilities%20standard%20decree%20enforcement%20regulation%20in%20Kor%20Eng%202021%2011%2019.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/kgmp/pharmaceutical%20facilities%20standard%20decree%20in%20Kor%20Eng%202021%2010%2019.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/kgmp/pharmaceutical%20facilities%20standard%20decree%20in%20Kor%20Eng%202021%2010%2019.pdf",
      "sha256": "4cb297c97b1c4ca04b0ca3b469fa5db4bf67b870f871f9241f8de0319cf6468a",
      "size": 167847,
      "pages": null,
      "regulator": "OTHER",
      "filename": "pharmaceutical%20facilities%20standard%20decree%20in%20Kor%20Eng%202021%2010%2019.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/quality%20by%20design/Example%20QbD%20for%20IR%20Tablet%202012%20kr.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/quality%20by%20design/Example%20QbD%20for%20IR%20Tablet%202012%20kr.pdf",
      "sha256": "967172ef13bd63d15d9585fccfaaf11cc3123608d26df80d9af56539baf8189e",
      "size": 149717,
      "pages": null,
      "regulator": "OTHER",
      "filename": "Example%20QbD%20for%20IR%20Tablet%202012%20kr.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/quality%20by%20design/Example%20QbD%20for%20IR%20Tablet%202012.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/quality%20by%20design/Example%20QbD%20for%20IR%20Tablet%202012.pdf",
      "sha256": "cf9b7071889ed7388812ff3d399e7fec09f516de5f55e6f0cc34867503e6f6b6",
      "size": 1552241,
      "pages": 107,
      "regulator": "OTHER",
      "filename": "Example%20QbD%20for%20IR%20Tablet%202012.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/quality%20by%20design/MockP2discussionpaper-20070904-002-EN-v1.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/quality%20by%20design/MockP2discussionpaper-20070904-002-EN-v1.pdf",
      "sha256": "ea4eb5f3e84e3f2e5d707060c6a39ddde14ab3f935c162f2f7214698adb63d3c",
      "size": 710847,
      "pages": 69,
      "regulator": "OTHER",
      "filename": "MockP2discussionpaper-20070904-002-EN-v1.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/quality%20by%20design/MockP2presentation-20070904-001-EN-v1.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/quality%20by%20design/MockP2presentation-20070904-001-EN-v1.pdf",
      "sha256": "79a7fdba51c2954057d45f370ec87f2a7e7e31922c5ea6ea992f2d91a2fa84b3",
      "size": 396358,
      "pages": 80,
      "regulator": "OTHER",
      "filename": "MockP2presentation-20070904-001-EN-v1.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/quality%20by%20design/PQLI%20A%20Mab%20Case%20Study%20kr.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/quality%20by%20design/PQLI%20A%20Mab%20Case%20Study%20kr.pdf",
      "sha256": "6e8df5c123aa555f9779443dc09abebd3a92819e39f0ca042e819db7c1c9522a",
      "size": 208347,
      "pages": null,
      "regulator": "OTHER",
      "filename": "PQLI%20A%20Mab%20Case%20Study%20kr.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/quality%20by%20design/PQLI_A_Mab_Case_Study_Version_2_1[1].pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/quality%20by%20design/PQLI_A_Mab_Case_Study_Version_2_1[1].pdf",
      "sha256": "16a45c7451e957bf6a4410d47868f4e10840f00c932c9b672aba03690c7281f3",
      "size": 4760212,
      "pages": 278,
      "regulator": "OTHER",
      "filename": "PQLI_A_Mab_Case_Study_Version_2_1[1].pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/quality%20by%20design/QBD_ACE_Case_History%20kr.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/quality%20by%20design/QBD_ACE_Case_History%20kr.pdf",
      "sha256": "285379ac985adfd4d6a72b1266c382c8a8e4d13add3f0313ef0e9c5b2c9a1d53",
      "size": 171205,
      "pages": null,
      "regulator": "OTHER",
      "filename": "QBD_ACE_Case_History%20kr.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/quality%20by%20design/QBD_ACE_Case_History.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/quality%20by%20design/QBD_ACE_Case_History.pdf",
      "sha256": "075bdd66257b81c409889a64fccda03bafa273c916f5104d37e961df52223d66",
      "size": 1429794,
      "pages": 92,
      "regulator": "OTHER",
      "filename": "QBD_ACE_Case_History.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/quality%20by%20design/a%20vax%20applying%20quality%20by%20design%20to%20vaccines%202012%20kr.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/quality%20by%20design/a%20vax%20applying%20quality%20by%20design%20to%20vaccines%202012%20kr.pdf",
      "sha256": "16d168272fdf84d72d5e5c49cce2b8c45835107a98462223f467667e118cc6f6",
      "size": 191304,
      "pages": null,
      "regulator": "OTHER",
      "filename": "a%20vax%20applying%20quality%20by%20design%20to%20vaccines%202012%20kr.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/quality%20by%20design/efpia%20mock%20p2%20discussion%20paper%20kr.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/quality%20by%20design/efpia%20mock%20p2%20discussion%20paper%20kr.pdf",
      "sha256": "82a6eda85f668473f8efd0a6185f01c4cf2b420248e0e4d55ce16c4ac1f8ca60",
      "size": 183842,
      "pages": null,
      "regulator": "OTHER",
      "filename": "efpia%20mock%20p2%20discussion%20paper%20kr.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/quality%20by%20design/mhlw%20quality%20overall%20summary%20mock%20p2%20kr.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/quality%20by%20design/mhlw%20quality%20overall%20summary%20mock%20p2%20kr.pdf",
      "sha256": "0d0f6fa203541dbacfe49d817a5d93278ba0abab18b8a1c53d39fabd7c605b89",
      "size": 143336,
      "pages": null,
      "regulator": "OTHER",
      "filename": "mhlw%20quality%20overall%20summary%20mock%20p2%20kr.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/quality%20by%20design/q%20and%20a%20level%20of%20detail%20in%20the%20regulatory%20submissions.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/quality%20by%20design/q%20and%20a%20level%20of%20detail%20in%20the%20regulatory%20submissions.pdf",
      "sha256": "2c4bf52ec2b8ce2506a8e65ec7e620204828b757346f2a4f0b3878c4c0be4a7d",
      "size": 230619,
      "pages": null,
      "regulator": "OTHER",
      "filename": "q%20and%20a%20level%20of%20detail%20in%20the%20regulatory%20submissions.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/quality%20by%20design/q%20and%20a%20nor%20par%20dsp%20normal%20variability.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/quality%20by%20design/q%20and%20a%20nor%20par%20dsp%20normal%20variability.pdf",
      "sha256": "1afbeb07839e742a12bdc91c4adfba013f12112e2b5dd087a531fef30238cccc",
      "size": 285723,
      "pages": null,
      "regulator": "OTHER",
      "filename": "q%20and%20a%20nor%20par%20dsp%20normal%20variability.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/quality%20by%20design/qbd%20modified%20release%20tablet%202011%20final%20kr.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/quality%20by%20design/qbd%20modified%20release%20tablet%202011%20final%20kr.pdf",
      "sha256": "e3b61d91f827409533879f0b19ea9e4b7f47589f2862ace2c6cfe0abd9924b29",
      "size": 212559,
      "pages": 10,
      "regulator": "OTHER",
      "filename": "qbd%20modified%20release%20tablet%202011%20final%20kr.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/quality%20by%20design/qbd%20modified%20release%20tablet%202011%20final.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/quality%20by%20design/qbd%20modified%20release%20tablet%202011%20final.pdf",
      "sha256": "20ff76c6e0355c39939ec04b52f8fc15b1f0415b585bc4d11f58b3421c6d900e",
      "size": 2302867,
      "pages": 161,
      "regulator": "OTHER",
      "filename": "qbd%20modified%20release%20tablet%202011%20final.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/quality%20by%20design/qos%20mock%20p2%20sakura%20tablet.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/quality%20by%20design/qos%20mock%20p2%20sakura%20tablet.pdf",
      "sha256": "5c4c3cbaa05a6968aa91442377bfdd6ee6089d417f0280be2ae49ab373eecb2c",
      "size": 528860,
      "pages": 59,
      "regulator": "OTHER",
      "filename": "qos%20mock%20p2%20sakura%20tablet.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/buildings%20and%20facilities%201%20what%20is%20penicillin.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/buildings%20and%20facilities%201%20what%20is%20penicillin.pdf",
      "sha256": "fe12246408dfb11633c4da6f33d0099eecda5ad0e8b8d176ac909deb29390126",
      "size": 117443,
      "pages": null,
      "regulator": "FDA",
      "filename": "buildings%20and%20facilities%201%20what%20is%20penicillin.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/buildings%20and%20facilities%2010%20can%20contamination%20of%20drug%20products%20be%20detected.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/buildings%20and%20facilities%2010%20can%20contamination%20of%20drug%20products%20be%20detected.pdf",
      "sha256": "107af27d2678047c9c29ed60417663fdb2895bf43a29293523bf1537f2749747",
      "size": 133723,
      "pages": null,
      "regulator": "FDA",
      "filename": "buildings%20and%20facilities%2010%20can%20contamination%20of%20drug%20products%20be%20detected.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/buildings%20and%20facilities%202%20what%20are%20the%20penicillin%20drugs.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/buildings%20and%20facilities%202%20what%20are%20the%20penicillin%20drugs.pdf",
      "sha256": "bf90903efa7480e44bc1fdc9fa40ff862c4184a89a38232f5ec5b862c3006b97",
      "size": 139071,
      "pages": null,
      "regulator": "FDA",
      "filename": "buildings%20and%20facilities%202%20what%20are%20the%20penicillin%20drugs.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/buildings%20and%20facilities%203%20is%20cross%20contamination%20a%20concern%20with%20penicillin%20drugs.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/buildings%20and%20facilities%203%20is%20cross%20contamination%20a%20concern%20with%20penicillin%20drugs.pdf",
      "sha256": "a55700652fe140487419603101c45d68040c319822b38bbde7a2256931f7c07a",
      "size": 121523,
      "pages": null,
      "regulator": "FDA",
      "filename": "buildings%20and%20facilities%203%20is%20cross%20contamination%20a%20concern%20with%20penicillin%20drugs.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/buildings%20and%20facilities%204%20are%20there%20special%20manufacturing%20requirements%20for%20penicillin%20drugs.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/buildings%20and%20facilities%204%20are%20there%20special%20manufacturing%20requirements%20for%20penicillin%20drugs.pdf",
      "sha256": "b2dec9100229dab6697d1146ef61aba9422b5738a302c222fdd80d27a7bf6f5c",
      "size": 143416,
      "pages": null,
      "regulator": "FDA",
      "filename": "buildings%20and%20facilities%204%20are%20there%20special%20manufacturing%20requirements%20for%20penicillin%20drugs.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/buildings%20and%20facilities%205%20why%20is%20fda%20concerned%20about%20drug%20contamination%20with%20alogenated%20anisole%20compounds.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/buildings%20and%20facilities%205%20why%20is%20fda%20concerned%20about%20drug%20contamination%20with%20alogenated%20anisole%20compounds.pdf",
      "sha256": "d3fb7e516e4b8374fed0f61f031de5001df77e563b752c8a902c6e99072b2479",
      "size": 133919,
      "pages": null,
      "regulator": "FDA",
      "filename": "buildings%20and%20facilities%205%20why%20is%20fda%20concerned%20about%20drug%20contamination%20with%20alogenated%20anisole%20compounds.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/buildings%20and%20facilities%206%20are%20there%20any%20health%20effects.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/buildings%20and%20facilities%206%20are%20there%20any%20health%20effects.pdf",
      "sha256": "bfbd13c4adeea07b52ca638a8814b4acede13b9a8f88e9ef97f70c1b76cf2580",
      "size": 126211,
      "pages": null,
      "regulator": "FDA",
      "filename": "buildings%20and%20facilities%206%20are%20there%20any%20health%20effects.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/buildings%20and%20facilities%207%20has%20fda%20identified%20the%20source.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/buildings%20and%20facilities%207%20has%20fda%20identified%20the%20source.pdf",
      "sha256": "73bfd0975392de21b99d843cddbf69e36cef0010f4f08a930b1e4b85d6831263",
      "size": 128992,
      "pages": null,
      "regulator": "FDA",
      "filename": "buildings%20and%20facilities%207%20has%20fda%20identified%20the%20source.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/buildings%20and%20facilities%208%20what%20is%20fda%20expectation.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/buildings%20and%20facilities%208%20what%20is%20fda%20expectation.pdf",
      "sha256": "ab9c9ed4aa5283d945469fbaa3617d0b9eda450e72cc5429245c47fbe7ca5025",
      "size": 129025,
      "pages": null,
      "regulator": "FDA",
      "filename": "buildings%20and%20facilities%208%20what%20is%20fda%20expectation.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/buildings%20and%20facilities%209%20are%20there%20any%20standards%20applicable%20to%20preventing%20contamination.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/buildings%20and%20facilities%209%20are%20there%20any%20standards%20applicable%20to%20preventing%20contamination.pdf",
      "sha256": "a10a452f36e9baa874c586874d16b5bfbcfede74c91e3468f2764964862669f8",
      "size": 126728,
      "pages": null,
      "regulator": "FDA",
      "filename": "buildings%20and%20facilities%209%20are%20there%20any%20standards%20applicable%20to%20preventing%20contamination.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/control%20of%20components%201%20record%20control%202%20audit%20report.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/control%20of%20components%201%20record%20control%202%20audit%20report.pdf",
      "sha256": "3a53023e173659417c36ce0e1a6cd0467b4863dbe82c7580cdcb65ef61d81a81",
      "size": 150407,
      "pages": null,
      "regulator": "FDA",
      "filename": "control%20of%20components%201%20record%20control%202%20audit%20report.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/control%20of%20components%2010%20control%20measures%20for%20minimizing%20pathogenic%20agent.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/control%20of%20components%2010%20control%20measures%20for%20minimizing%20pathogenic%20agent.pdf",
      "sha256": "82b51825276275bad280c1ea1be4d4ee30a9a5580d8bc65e7789bacd6147e179",
      "size": 174032,
      "pages": null,
      "regulator": "FDA",
      "filename": "control%20of%20components%2010%20control%20measures%20for%20minimizing%20pathogenic%20agent.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/control%20of%20components%2011%20formation%20of%20glass%20lamellae.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/control%20of%20components%2011%20formation%20of%20glass%20lamellae.pdf",
      "sha256": "45901f3b83c725f67f4bdf92ea59d2445ad1580cd0357586416cbcdd37d250de",
      "size": 195658,
      "pages": null,
      "regulator": "FDA",
      "filename": "control%20of%20components%2011%20formation%20of%20glass%20lamellae.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/control%20of%20components%2012%20flexible%20intravenous%20solution%20bags.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/control%20of%20components%2012%20flexible%20intravenous%20solution%20bags.pdf",
      "sha256": "451acba2fb42e168483c4dc873f691205b8e92d9fb9c2053ac47f9de3ba1f8da",
      "size": 148521,
      "pages": null,
      "regulator": "FDA",
      "filename": "control%20of%20components%2012%20flexible%20intravenous%20solution%20bags.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/control%20of%20components%2013%20compromised%20IV%20solution%20bag%20integrity.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/control%20of%20components%2013%20compromised%20IV%20solution%20bag%20integrity.pdf",
      "sha256": "88f1bed245a0559c9af44c57309c76ca6b51d7a7f6e4a4548ea1872d103621a2",
      "size": 152336,
      "pages": null,
      "regulator": "FDA",
      "filename": "control%20of%20components%2013%20compromised%20IV%20solution%20bag%20integrity.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/control%20of%20components%2014%20must%20each%20batch%20of%20a%20USP%20grade%20API%20be%20tested.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/control%20of%20components%2014%20must%20each%20batch%20of%20a%20USP%20grade%20API%20be%20tested.pdf",
      "sha256": "982184b40efae99a8bd18c1017c50e2733ecc740ded03f738010e1102cfaa1ae",
      "size": 144128,
      "pages": null,
      "regulator": "FDA",
      "filename": "control%20of%20components%2014%20must%20each%20batch%20of%20a%20USP%20grade%20API%20be%20tested.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/control%20of%20components%2015%20who%20is%20responsible%20for%20analytically%20testing%20APIs.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/control%20of%20components%2015%20who%20is%20responsible%20for%20analytically%20testing%20APIs.pdf",
      "sha256": "a577c4a1a2d90c45f801f308e831db2f1111ae2e1c17e8865a3adaa11d6df37c",
      "size": 167293,
      "pages": null,
      "regulator": "FDA",
      "filename": "control%20of%20components%2015%20who%20is%20responsible%20for%20analytically%20testing%20APIs.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/control%20of%20components%202%20production%20control%202%20container%20closures%20ampling.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/control%20of%20components%202%20production%20control%202%20container%20closures%20ampling.pdf",
      "sha256": "ed7bd1276fc20732516c1b5187c5a9590d7251fd5d6efcff7f57b553f0ea2eb8",
      "size": 154392,
      "pages": null,
      "regulator": "FDA",
      "filename": "control%20of%20components%202%20production%20control%202%20container%20closures%20ampling.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/control%20of%20components%204%20how%20many%20containers%20of%20each%20component%20sampled.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/control%20of%20components%204%20how%20many%20containers%20of%20each%20component%20sampled.pdf",
      "sha256": "69d5e6354f69841b42ec5a2231247bc25e4767f5604fc848d8b77218d3ef2e9d",
      "size": 212368,
      "pages": null,
      "regulator": "FDA",
      "filename": "control%20of%20components%204%20how%20many%20containers%20of%20each%20component%20sampled.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/control%20of%20components%205%20melamine.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/control%20of%20components%205%20melamine.pdf",
      "sha256": "8748c7825d31e3f197664f708b65f76c0b21029202e40796f256f5d89db10774",
      "size": 135192,
      "pages": null,
      "regulator": "FDA",
      "filename": "control%20of%20components%205%20melamine.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/control%20of%20components%206%20animal%20derived%20ingredients.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/control%20of%20components%206%20animal%20derived%20ingredients.pdf",
      "sha256": "fd3ed3430be0da3bd5469b7795ccdb6aab1cab86a7671203d237dbfce42e8080",
      "size": 169534,
      "pages": null,
      "regulator": "FDA",
      "filename": "control%20of%20components%206%20animal%20derived%20ingredients.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/control%20of%20components%207%20primary%20concerns%20animal%20derived%20ingredients.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/control%20of%20components%207%20primary%20concerns%20animal%20derived%20ingredients.pdf",
      "sha256": "7811e0761d8c66eff87d630bb0710a91afe65c702291e57529714cd7534e75dc",
      "size": 152168,
      "pages": null,
      "regulator": "FDA",
      "filename": "control%20of%20components%207%20primary%20concerns%20animal%20derived%20ingredients.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/control%20of%20components%208%20manufacturing%20contamination%20risks.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/control%20of%20components%208%20manufacturing%20contamination%20risks.pdf",
      "sha256": "01037279f8d1a0bbe32b26e84a8b6c8695fcfe90524076d3e1b74229f17e8766",
      "size": 188144,
      "pages": null,
      "regulator": "FDA",
      "filename": "control%20of%20components%208%20manufacturing%20contamination%20risks.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/control%20of%20components%209%20minimizing%20pathogenic%20agent.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/control%20of%20components%209%20minimizing%20pathogenic%20agent.pdf",
      "sha256": "5086915dbe3bf2c4af54d67f1814dee9ea3527169a759392cc0c01d66005e9cd",
      "size": 188109,
      "pages": null,
      "regulator": "FDA",
      "filename": "control%20of%20components%209%20minimizing%20pathogenic%20agent.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/equipment%2001%20lab%20control%201%20auto%20calibration%20balance.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/equipment%2001%20lab%20control%201%20auto%20calibration%20balance.pdf",
      "sha256": "2a1d17847425b64ee0147f68a86bef402985bb26b50e0cb38e3545ff2b9a5e77",
      "size": 150176,
      "pages": null,
      "regulator": "FDA",
      "filename": "equipment%2001%20lab%20control%201%20auto%20calibration%20balance.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/equipment%2002%20approved%20equipment%20list.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/equipment%2002%20approved%20equipment%20list.pdf",
      "sha256": "46534700cc7544aae70c0aff0673d427cfee25f40491b1a4dd5e95ad11a5ad2f",
      "size": 145460,
      "pages": null,
      "regulator": "FDA",
      "filename": "equipment%2002%20approved%20equipment%20list.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/equipment%2003%20lab%20control%204%20toc.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/equipment%2003%20lab%20control%204%20toc.pdf",
      "sha256": "0bb1428e7f6134e918d81e67ce58b17add1cc791ae093e4e4778eac9a22c058f",
      "size": 154566,
      "pages": null,
      "regulator": "FDA",
      "filename": "equipment%2003%20lab%20control%204%20toc.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/equipment%2004%20control%20of%20components%203%20production%20control%203%20media%20fill%20failure.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/equipment%2004%20control%20of%20components%203%20production%20control%203%20media%20fill%20failure.pdf",
      "sha256": "42e25a5c1c894bdfc6a3fd92db32297e39f5705ff9c317c95bb72d2d9a4ae44a",
      "size": 184586,
      "pages": null,
      "regulator": "FDA",
      "filename": "equipment%2004%20control%20of%20components%203%20production%20control%203%20media%20fill%20failure.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/equipment%2005%20cleaning%20validation%20requirements%20for%20potent%20compounds.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/equipment%2005%20cleaning%20validation%20requirements%20for%20potent%20compounds.pdf",
      "sha256": "8019aa0bbabc359d9db2ad2a99e3a63663e336a10372bf7c07faada6f6cf8573",
      "size": 145536,
      "pages": null,
      "regulator": "FDA",
      "filename": "equipment%2005%20cleaning%20validation%20requirements%20for%20potent%20compounds.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/equipment%2006%20how%20do%20i%20perform%20cleaning%20validation.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/equipment%2006%20how%20do%20i%20perform%20cleaning%20validation.pdf",
      "sha256": "11c854709dc9a57c5871f16cbfef8b57844a7ec94bbaa28ce504d787bdf7af48",
      "size": 147478,
      "pages": null,
      "regulator": "FDA",
      "filename": "equipment%2006%20how%20do%20i%20perform%20cleaning%20validation.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/equipment%2007%20does%20equpment%20need%20to%20be%20clean%20enough.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/equipment%2007%20does%20equpment%20need%20to%20be%20clean%20enough.pdf",
      "sha256": "b52dab1ac81ccf281a83decf3b7927e6e2427e46d016c100f288ff619451bcce",
      "size": 148127,
      "pages": null,
      "regulator": "FDA",
      "filename": "equipment%2007%20does%20equpment%20need%20to%20be%20clean%20enough.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/equipment%2008%20do%20firms%20need%20to%20quantify%20total%20amount%20of%20residues.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/equipment%2008%20do%20firms%20need%20to%20quantify%20total%20amount%20of%20residues.pdf",
      "sha256": "be5d4b18e4b4a6263bbc0b3b0e3f4917abf1851c0c040a0c20d5eb8c995012e6",
      "size": 157639,
      "pages": null,
      "regulator": "FDA",
      "filename": "equipment%2008%20do%20firms%20need%20to%20quantify%20total%20amount%20of%20residues.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/equipment%2009%20should%20laboratory%20glassware%20be%20included%20in%20cleaning%20validation%20program.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/equipment%2009%20should%20laboratory%20glassware%20be%20included%20in%20cleaning%20validation%20program.pdf",
      "sha256": "d17edbde05a8541a14d18d47672510ff45aa702b160a6c3dda189b16dc49af84",
      "size": 157007,
      "pages": null,
      "regulator": "FDA",
      "filename": "equipment%2009%20should%20laboratory%20glassware%20be%20included%20in%20cleaning%20validation%20program.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/equipment%2010%20acceptable%20level%20of%20detergent%20residue.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/equipment%2010%20acceptable%20level%20of%20detergent%20residue.pdf",
      "sha256": "7fce608b8f579dfefd07983ecf23f807ce5f0bf65d6b126752d7081d1cfb4f99",
      "size": 123064,
      "pages": null,
      "regulator": "FDA",
      "filename": "equipment%2010%20acceptable%20level%20of%20detergent%20residue.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/equipment%2011%20material%20specific%20cleaning%20procedure.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/equipment%2011%20material%20specific%20cleaning%20procedure.pdf",
      "sha256": "ef15156ff5452cf5bc58089a00fdf2ff892fd34ee222f8b92542458d00a7d63d",
      "size": 133320,
      "pages": null,
      "regulator": "FDA",
      "filename": "equipment%2011%20material%20specific%20cleaning%20procedure.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/equipment%2012%20testing%20rinse%20solution.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/equipment%2012%20testing%20rinse%20solution.pdf",
      "sha256": "8b3eb164d9813790be6e0712a53ae125d9c0c2338897997230e2505cfedb7e41",
      "size": 147158,
      "pages": null,
      "regulator": "FDA",
      "filename": "equipment%2012%20testing%20rinse%20solution.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/equipment%2013%20does%20fda%20prefer%20one%20type%20of%20material%20over%20another.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/equipment%2013%20does%20fda%20prefer%20one%20type%20of%20material%20over%20another.pdf",
      "sha256": "93eb13df20798da964010a1841e450664294f3ccb8e04797064e7163201dbbcc",
      "size": 144530,
      "pages": null,
      "regulator": "FDA",
      "filename": "equipment%2013%20does%20fda%20prefer%20one%20type%20of%20material%20over%20another.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/general%201%20USP%20999.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/general%201%20USP%20999.pdf",
      "sha256": "2174099f8851aaab056542127ee2c97d55c2f8f9c72bf6a3c353a64d273a9e29",
      "size": 133607,
      "pages": null,
      "regulator": "FDA",
      "filename": "general%201%20USP%20999.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/general%202%20comment.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/general%202%20comment.pdf",
      "sha256": "9dfeff5f7982b4c2745725aa23f0485faee2a9e0d8a163a3d3a9e2e1f82436b5",
      "size": 136244,
      "pages": null,
      "regulator": "FDA",
      "filename": "general%202%20comment.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/holding%20and%20distribution%201%20what%20is%20recall.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/holding%20and%20distribution%201%20what%20is%20recall.pdf",
      "sha256": "503f3a8abf3effdb7ac0782cd0d651c548b8d4bdd9dd20d276edbd3098faa200",
      "size": 120982,
      "pages": null,
      "regulator": "FDA",
      "filename": "holding%20and%20distribution%201%20what%20is%20recall.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/holding%20and%20distribution%202%20can%20fda%20mandate%20a%20recall.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/holding%20and%20distribution%202%20can%20fda%20mandate%20a%20recall.pdf",
      "sha256": "8d7755d5d383a6a373fa77eff31458697f8fb7ef4ee3e0007e26823ecd5036f4",
      "size": 126646,
      "pages": null,
      "regulator": "FDA",
      "filename": "holding%20and%20distribution%202%20can%20fda%20mandate%20a%20recall.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/holding%20and%20distribution%203%20are%20otc%20drugs%20subject%20to%20the%20same%20recall%20provisions.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/holding%20and%20distribution%203%20are%20otc%20drugs%20subject%20to%20the%20same%20recall%20provisions.pdf",
      "sha256": "09b94f503a144ed323d2a26e893a558bd921d5478eab96c6a2835b3e91a67fde",
      "size": 116051,
      "pages": null,
      "regulator": "FDA",
      "filename": "holding%20and%20distribution%203%20are%20otc%20drugs%20subject%20to%20the%20same%20recall%20provisions.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/holding%20and%20distribution%204%20do%20manufacturers%20of%20otc%20products%20have%20to%20report%20quality%20defects.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/holding%20and%20distribution%204%20do%20manufacturers%20of%20otc%20products%20have%20to%20report%20quality%20defects.pdf",
      "sha256": "aa489704c4214ad7525c32dae2347e12793da11bf4f8b445a1b5ccaa19a1649f",
      "size": 137891,
      "pages": null,
      "regulator": "FDA",
      "filename": "holding%20and%20distribution%204%20do%20manufacturers%20of%20otc%20products%20have%20to%20report%20quality%20defects.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/holding%20and%20distribution%205%20does%20fda%20expect%20firms%20to%20investigate.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/holding%20and%20distribution%205%20does%20fda%20expect%20firms%20to%20investigate.pdf",
      "sha256": "ace9aa557dbea3b05e47b1076c1577f1666f10d306324b4600c5946d54f5ff92",
      "size": 127173,
      "pages": null,
      "regulator": "FDA",
      "filename": "holding%20and%20distribution%205%20does%20fda%20expect%20firms%20to%20investigate.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/holding%20and%20distribution%206%20what%20happens%20if%20a%20firm%20does%20not%20voluntarily%20recall.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/holding%20and%20distribution%206%20what%20happens%20if%20a%20firm%20does%20not%20voluntarily%20recall.pdf",
      "sha256": "7dd1b298800a1d9f86c4f30d01290cae6ddd877349f9562f992f375ae0835458",
      "size": 123875,
      "pages": null,
      "regulator": "FDA",
      "filename": "holding%20and%20distribution%206%20what%20happens%20if%20a%20firm%20does%20not%20voluntarily%20recall.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/lab%20control%2010%20is%20it%20acceptable%20to%20release%20non%20penicillin%20finished%20drug%20products.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/lab%20control%2010%20is%20it%20acceptable%20to%20release%20non%20penicillin%20finished%20drug%20products.pdf",
      "sha256": "4e10830efc3a09811642ee1d86383d94ac9a1ade0fb83ec12356c4070bf01050",
      "size": 152021,
      "pages": null,
      "regulator": "FDA",
      "filename": "lab%20control%2010%20is%20it%20acceptable%20to%20release%20non%20penicillin%20finished%20drug%20products.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/lab%20control%2011%20can%20a%20facility%20that%20produced%20penicillin%20dosage%20forms%20be%20decontaminated%20and%20renovated.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/lab%20control%2011%20can%20a%20facility%20that%20produced%20penicillin%20dosage%20forms%20be%20decontaminated%20and%20renovated.pdf",
      "sha256": "03272001915d5881a5165da61db371924f09ee2b60f373072922286a8b01dbdf",
      "size": 151764,
      "pages": null,
      "regulator": "FDA",
      "filename": "lab%20control%2011%20can%20a%20facility%20that%20produced%20penicillin%20dosage%20forms%20be%20decontaminated%20and%20renovated.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/lab%20control%2012%20is%20there%20an%20acceptable%20level%20of%20penicillin%20residue.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/lab%20control%2012%20is%20there%20an%20acceptable%20level%20of%20penicillin%20residue.pdf",
      "sha256": "a3e8b8e828517699a16cb50dcdf9c292a49c34b0b57ca0e9d1805b39a0100a0a",
      "size": 127546,
      "pages": null,
      "regulator": "FDA",
      "filename": "lab%20control%2012%20is%20there%20an%20acceptable%20level%20of%20penicillin%20residue.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/lab%20control%2013%20for%20injectable%20drugs%20in%20multiple%20dose%20containers.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/lab%20control%2013%20for%20injectable%20drugs%20in%20multiple%20dose%20containers.pdf",
      "sha256": "e8462103c7edbd1e2af64919f9bc07e313bc1ea8c26ae352d1ac84b9d831b7ef",
      "size": 156262,
      "pages": null,
      "regulator": "FDA",
      "filename": "lab%20control%2013%20for%20injectable%20drugs%20in%20multiple%20dose%20containers.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/lab%20control%2014%20how%20long%20may%20a%20firm%20store%20in%20process%20intermediates.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/lab%20control%2014%20how%20long%20may%20a%20firm%20store%20in%20process%20intermediates.pdf",
      "sha256": "15442eea451fc83eafddf5ab944c5ed134acb06347e4816d0a6469e64c8b536b",
      "size": 152807,
      "pages": null,
      "regulator": "FDA",
      "filename": "lab%20control%2014%20how%20long%20may%20a%20firm%20store%20in%20process%20intermediates.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/lab%20control%2015%20what%20material%20can%20be%20used%20as%20calibration%20standards%20for%20chromatographic%20systems.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/lab%20control%2015%20what%20material%20can%20be%20used%20as%20calibration%20standards%20for%20chromatographic%20systems.pdf",
      "sha256": "dd1c23c35c9483fbed85b5a70ed03afbb3e3fbd484530e801845bbdcbd452f9f",
      "size": 141856,
      "pages": null,
      "regulator": "FDA",
      "filename": "lab%20control%2015%20what%20material%20can%20be%20used%20as%20calibration%20standards%20for%20chromatographic%20systems.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/lab%20control%2016%20what%20material%20can%20be%20used%20for%20system%20suitability.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/lab%20control%2016%20what%20material%20can%20be%20used%20for%20system%20suitability.pdf",
      "sha256": "08a0f7e89282f99aa7eba66cdbe929bf851b57cb675fc51ea2aef9a6e6e6df5f",
      "size": 142915,
      "pages": null,
      "regulator": "FDA",
      "filename": "lab%20control%2016%20what%20material%20can%20be%20used%20for%20system%20suitability.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/lab%20control%2017%20is%20it%20ever%20appropriate%20to%20perform%20a%20trial%20injection%20of%20samples.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/lab%20control%2017%20is%20it%20ever%20appropriate%20to%20perform%20a%20trial%20injection%20of%20samples.pdf",
      "sha256": "dd1379b2ac39995f92839572fdcff00b033fc6095952abe261dda6d11429e5a3",
      "size": 151700,
      "pages": null,
      "regulator": "FDA",
      "filename": "lab%20control%2017%20is%20it%20ever%20appropriate%20to%20perform%20a%20trial%20injection%20of%20samples.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/lab%20control%202%20stress%20test.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/lab%20control%202%20stress%20test.pdf",
      "sha256": "e552dd3f36d96edb70d02e8ccac9066ac9a94ab5768547aedd86e6b8265f6547",
      "size": 164731,
      "pages": null,
      "regulator": "FDA",
      "filename": "lab%20control%202%20stress%20test.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/lab%20control%203%20LVP%20particulate%20matter.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/lab%20control%203%20LVP%20particulate%20matter.pdf",
      "sha256": "74e2e1807df066ed1e025791b903de0ef19f50ad6f70e771f2c1a22d5ea74df5",
      "size": 171471,
      "pages": null,
      "regulator": "FDA",
      "filename": "lab%20control%203%20LVP%20particulate%20matter.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/lab%20control%205%20laser%20oxygen%20analyzer.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/lab%20control%205%20laser%20oxygen%20analyzer.pdf",
      "sha256": "774e6c748136e0da32c8c054831bf6617ed485ddcaf37d45e33ce57f86bc4c32",
      "size": 148481,
      "pages": null,
      "regulator": "FDA",
      "filename": "lab%20control%205%20laser%20oxygen%20analyzer.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/lab%20control%206%20expiration%20dating.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/lab%20control%206%20expiration%20dating.pdf",
      "sha256": "f3fd3f1a3bd21f3163de9385b5dc75aeff2e23abe3e1f86d1088daa151bef484",
      "size": 159719,
      "pages": null,
      "regulator": "FDA",
      "filename": "lab%20control%206%20expiration%20dating.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/lab%20control%207%20unvalidated%20method.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/lab%20control%207%20unvalidated%20method.pdf",
      "sha256": "1471693ee230d14f4e9969a8ea858c1f8e48c8bb2c422a7544534ba65310278d",
      "size": 155878,
      "pages": null,
      "regulator": "FDA",
      "filename": "lab%20control%207%20unvalidated%20method.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/lab%20control%208%20lal%20method.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/lab%20control%208%20lal%20method.pdf",
      "sha256": "6f2a14b28032e17fd78776f080b5ddb86e076fec367005d7164b140495dbf58b",
      "size": 118312,
      "pages": null,
      "regulator": "FDA",
      "filename": "lab%20control%208%20lal%20method.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/lab%20control%209%20endotoxin%20testing.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/lab%20control%209%20endotoxin%20testing.pdf",
      "sha256": "cca1f141b8cfe7519820f1d34b313de747074c44b76ca89d298d2aa14b2def97",
      "size": 122390,
      "pages": null,
      "regulator": "FDA",
      "filename": "lab%20control%209%20endotoxin%20testing.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/production%20control%201%20status%20label.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/production%20control%201%20status%20label.pdf",
      "sha256": "091873daca013aa063fe04c70b65454a7f3da299585ac3c5245380c873537fdf",
      "size": 153279,
      "pages": null,
      "regulator": "FDA",
      "filename": "production%20control%201%20status%20label.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/production%20control%2010%20media%20fill%20frequency.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/production%20control%2010%20media%20fill%20frequency.pdf",
      "sha256": "54ffa436aad664575390136666568deefd72aad3ef6e44e523e0b1bda5f72d45",
      "size": 177436,
      "pages": null,
      "regulator": "FDA",
      "filename": "production%20control%2010%20media%20fill%20frequency.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/production%20control%2011%20concerns%20about%20human%20topical%20antiseptic%20drug%20products.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/production%20control%2011%20concerns%20about%20human%20topical%20antiseptic%20drug%20products.pdf",
      "sha256": "9da8b041be91edaf3504ec653016c6b2d470bb2a221e505c6f51c984974164e4",
      "size": 117389,
      "pages": null,
      "regulator": "FDA",
      "filename": "production%20control%2011%20concerns%20about%20human%20topical%20antiseptic%20drug%20products.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/production%20control%2012%20cgmp%20regulations%20human%20topical%20antiseptic%20drug%20products.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/production%20control%2012%20cgmp%20regulations%20human%20topical%20antiseptic%20drug%20products.pdf",
      "sha256": "a15a624599bb42cc0a743ce5223dc89994fe1441027a1d063a219791152abbc6",
      "size": 189947,
      "pages": null,
      "regulator": "FDA",
      "filename": "production%20control%2012%20cgmp%20regulations%20human%20topical%20antiseptic%20drug%20products.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/production%20control%2013%20microbiological%20contamination%20of%20human%20topical%20antiseptic%20drug%20products.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/production%20control%2013%20microbiological%20contamination%20of%20human%20topical%20antiseptic%20drug%20products.pdf",
      "sha256": "7e825740e212c94a95638ad9e8e0b49a7b320747794c8ff28a536b456a5f900d",
      "size": 166629,
      "pages": null,
      "regulator": "FDA",
      "filename": "production%20control%2013%20microbiological%20contamination%20of%20human%20topical%20antiseptic%20drug%20products.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/production%20control%2014%20leptospira%20species%20penetrate%20sterilizing%20grade%20filters.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/production%20control%2014%20leptospira%20species%20penetrate%20sterilizing%20grade%20filters.pdf",
      "sha256": "7588d4f3e8ff87f64c8bfb1477be19606097470c9a39e965c1d44fb62b03d922",
      "size": 226879,
      "pages": null,
      "regulator": "FDA",
      "filename": "production%20control%2014%20leptospira%20species%20penetrate%20sterilizing%20grade%20filters.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/production%20control%2015%20withdrawal%20of%20its%20draft%20guidance%20for%20industry%20on%20powder%20blends%20and%20finished%20dosage%20units.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/production%20control%2015%20withdrawal%20of%20its%20draft%20guidance%20for%20industry%20on%20powder%20blends%20and%20finished%20dosage%20units.pdf",
      "sha256": "c47559a2e81c6338d700d31efadb02f1549ccd6ff43fb0e22ff6a642eac212ac",
      "size": 159347,
      "pages": null,
      "regulator": "FDA",
      "filename": "production%20control%2015%20withdrawal%20of%20its%20draft%20guidance%20for%20industry%20on%20powder%20blends%20and%20finished%20dosage%20units.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/production%20control%2016%20proper%20sampling%20of%20powder%20blends.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/production%20control%2016%20proper%20sampling%20of%20powder%20blends.pdf",
      "sha256": "acfd47481dd9607e754f04ced69f9767837540039baca29b44a786d6e1fafbc3",
      "size": 150838,
      "pages": null,
      "regulator": "FDA",
      "filename": "production%20control%2016%20proper%20sampling%20of%20powder%20blends.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/production%20control%2017%20innovative%20approaches%20to%20adequacy%20of%20mixing%20of%20powder%20blends.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/production%20control%2017%20innovative%20approaches%20to%20adequacy%20of%20mixing%20of%20powder%20blends.pdf",
      "sha256": "f74d09a060debf82ea7b4db4ea7c148b25b9ee7dca1d04186c2f7e0991f11f4b",
      "size": 151366,
      "pages": null,
      "regulator": "FDA",
      "filename": "production%20control%2017%20innovative%20approaches%20to%20adequacy%20of%20mixing%20of%20powder%20blends.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/production%20control%2018%20in%20process%20stratified%20sampling.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/production%20control%2018%20in%20process%20stratified%20sampling.pdf",
      "sha256": "d84cdce5687ef50f90863a2ccf163c22dad23221d389b404cc7de4ad7dfd8a6a",
      "size": 130037,
      "pages": null,
      "regulator": "FDA",
      "filename": "production%20control%2018%20in%20process%20stratified%20sampling.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/production%20control%2019%20for%20a%20nonsterile%20compendial%20drug%20product%20that%20includes%20an%20antimicrobial%20preservative%20in%20its%20formulation.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/production%20control%2019%20for%20a%20nonsterile%20compendial%20drug%20product%20that%20includes%20an%20antimicrobial%20preservative%20in%20its%20formulation.pdf",
      "sha256": "514fe06caab4f35f20ba2e137dc8248d2b6cd8f51e991f39b0a392b51db3276f",
      "size": 160709,
      "pages": null,
      "regulator": "FDA",
      "filename": "production%20control%2019%20for%20a%20nonsterile%20compendial%20drug%20product%20that%20includes%20an%20antimicrobial%20preservative%20in%20its%20formulation.pd"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/production%20control%2020%20do%20pharmaceutical%20manufacturers%20need%20to%20have%20written%20procedures.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/production%20control%2020%20do%20pharmaceutical%20manufacturers%20need%20to%20have%20written%20procedures.pdf",
      "sha256": "0a3e4234e8fbff440bff6847c8afbf5d8317634c1cdda62ef35c08f7049c2701",
      "size": 173200,
      "pages": null,
      "regulator": "FDA",
      "filename": "production%20control%2020%20do%20pharmaceutical%20manufacturers%20need%20to%20have%20written%20procedures.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/production%20control%2021%20for%20drug%20products%20formulated%20with%20preservatives.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/production%20control%2021%20for%20drug%20products%20formulated%20with%20preservatives.pdf",
      "sha256": "e09754539d5adebe059ab89b89afe30372d6f2086c79e2d79980d3619128a910",
      "size": 127322,
      "pages": null,
      "regulator": "FDA",
      "filename": "production%20control%2021%20for%20drug%20products%20formulated%20with%20preservatives.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/production%20control%2022%20parametric%20release%20for%20products%20not%20terminally%20sterilized.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/production%20control%2022%20parametric%20release%20for%20products%20not%20terminally%20sterilized.pdf",
      "sha256": "ca1e00e4f4c0346a26f2641a0c085899818756e1208b2fdfbbd466293c6b3a72",
      "size": 188273,
      "pages": null,
      "regulator": "FDA",
      "filename": "production%20control%2022%20parametric%20release%20for%20products%20not%20terminally%20sterilized.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/production%20control%2023%20ophthalmic%20drug%20products.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/production%20control%2023%20ophthalmic%20drug%20products.pdf",
      "sha256": "2d1700804bad82e554e29f2dedcabfdb4182f109e32e77b6f438d16f8b72b586",
      "size": 216821,
      "pages": null,
      "regulator": "FDA",
      "filename": "production%20control%2023%20ophthalmic%20drug%20products.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/production%20control%204%20record%20control%201%20reject%20rate.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/production%20control%204%20record%20control%201%20reject%20rate.pdf",
      "sha256": "66a41fa9e457b06a55a442cddc133f7f901efb0a2c4f02e4f5af089e419dded2",
      "size": 154152,
      "pages": null,
      "regulator": "FDA",
      "filename": "production%20control%204%20record%20control%201%20reject%20rate.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/production%20control%205%20validation%20batch.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/production%20control%205%20validation%20batch.pdf",
      "sha256": "03034ae0b0e4f7a2b85f71c10de217af9f1a70827afde47300b4d0f1b4e532f6",
      "size": 177681,
      "pages": null,
      "regulator": "FDA",
      "filename": "production%20control%205%20validation%20batch.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/production%20control%206%20ISO.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/production%20control%206%20ISO.pdf",
      "sha256": "edbc0c225582a6144b29d0446530c0f127eb00ece4847f8bc7265a0c20a740d5",
      "size": 159095,
      "pages": null,
      "regulator": "FDA",
      "filename": "production%20control%206%20ISO.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/production%20control%207%20pat.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/production%20control%207%20pat.pdf",
      "sha256": "771ff7ee960f1a4bb0c2d27c35ef1ef6fb8b1f25b38dd818f31e37efee6555b2",
      "size": 163384,
      "pages": null,
      "regulator": "FDA",
      "filename": "production%20control%207%20pat.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/production%20control%208%20how%20do%20i%20contact%20cder.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/production%20control%208%20how%20do%20i%20contact%20cder.pdf",
      "sha256": "0bfa2f3741f380f4ed4af5b590fd95616cd5fb7601fb2dcf6a3a4a343ecc6816",
      "size": 109854,
      "pages": null,
      "regulator": "FDA",
      "filename": "production%20control%208%20how%20do%20i%20contact%20cder.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/production%20control%209%20how%20do%20i%20contact%20cber.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/production%20control%209%20how%20do%20i%20contact%20cber.pdf",
      "sha256": "546ca4fd783c6f34a62604c9574bdd7a10fafc13bcdd02afbf174e719322ec8a",
      "size": 109102,
      "pages": null,
      "regulator": "FDA",
      "filename": "production%20control%209%20how%20do%20i%20contact%20cber.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/record%20control%2003%20records%20not%20accessible%20to%20fda.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/record%20control%2003%20records%20not%20accessible%20to%20fda.pdf",
      "sha256": "0352a78003a3975c915a6e996d0bcc959f55827996ded85fae875dc0e4536954",
      "size": 189322,
      "pages": null,
      "regulator": "FDA",
      "filename": "record%20control%2003%20records%20not%20accessible%20to%20fda.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/record%20control%2004%20part%2011%20regulations%20and%20predicate%20rule.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/record%20control%2004%20part%2011%20regulations%20and%20predicate%20rule.pdf",
      "sha256": "2cb98e86020eed7786440f1b9fad401ab99b016eb9e6f6c5e22410f53fc5804b",
      "size": 190157,
      "pages": null,
      "regulator": "FDA",
      "filename": "record%20control%2004%20part%2011%20regulations%20and%20predicate%20rule.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/record%20control%2005%20expiry%20dating%20for%20chemicals%20reagents%20solutiosn%20solvents.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/record%20control%2005%20expiry%20dating%20for%20chemicals%20reagents%20solutiosn%20solvents.pdf",
      "sha256": "2839ac5afd7cedf8453bf9e6bae01060fc813bfe283184487dd9ee4600b405d2",
      "size": 163140,
      "pages": null,
      "regulator": "FDA",
      "filename": "record%20control%2005%20expiry%20dating%20for%20chemicals%20reagents%20solutiosn%20solvents.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/returned%20n%20salvaged%201%20natural%20disaster.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/returned%20n%20salvaged%201%20natural%20disaster.pdf",
      "sha256": "41c399080ed59b472c52fa86dcfb8c568d48c2826be2a3cd4314644289a1acc1",
      "size": 169776,
      "pages": null,
      "regulator": "FDA",
      "filename": "returned%20n%20salvaged%201%20natural%20disaster.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/returned%20n%20salvaged%202%20toxic%20fumes%20radiation.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/returned%20n%20salvaged%202%20toxic%20fumes%20radiation.pdf",
      "sha256": "51ac3eebe74d224d0f6262ce69f0eb02ce10398dcb34f709db23a6d6f52fc645",
      "size": 129769,
      "pages": null,
      "regulator": "FDA",
      "filename": "returned%20n%20salvaged%202%20toxic%20fumes%20radiation.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/returned%20n%20salvaged%203%20radioactive%20materials.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/returned%20n%20salvaged%203%20radioactive%20materials.pdf",
      "sha256": "24462d4b82931a8064e1d395f9fe943f7ea3a58e15db12a372d501a588fbc51f",
      "size": 175119,
      "pages": null,
      "regulator": "FDA",
      "filename": "returned%20n%20salvaged%203%20radioactive%20materials.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cpg/cpg%20sec%20130%20300%20fda%20access%20to%20audit%20results.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cpg/cpg%20sec%20130%20300%20fda%20access%20to%20audit%20results.pdf",
      "sha256": "68309a107045d33aca0cf7eb47bf8cd7c883e48b458a0632982f977f00902b71",
      "size": 156716,
      "pages": null,
      "regulator": "FDA",
      "filename": "cpg%20sec%20130%20300%20fda%20access%20to%20audit%20results.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cpg/cpg%20sec%20425%20100%20cgmp%20applicatibility%20to%20hardware%20and%20software.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cpg/cpg%20sec%20425%20100%20cgmp%20applicatibility%20to%20hardware%20and%20software.pdf",
      "sha256": "5b8707421d37c5411aca5b09f8fa14fed8f5b15702f206a2d02061cd287c92d0",
      "size": 138486,
      "pages": null,
      "regulator": "FDA",
      "filename": "cpg%20sec%20425%20100%20cgmp%20applicatibility%20to%20hardware%20and%20software.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cpg/cpg%20sec%20425%20200%20vendor%20responsibility.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cpg/cpg%20sec%20425%20200%20vendor%20responsibility.pdf",
      "sha256": "878631d2083e0d8588dc9c9f5581b26be9a9a3743fd0b8c1bfc4f10aa614546a",
      "size": 138137,
      "pages": null,
      "regulator": "FDA",
      "filename": "cpg%20sec%20425%20200%20vendor%20responsibility.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cpg/cpg%20sec%20425%20300%20source%20code%20for%20process%20control%20application%20program.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cpg/cpg%20sec%20425%20300%20source%20code%20for%20process%20control%20application%20program.pdf",
      "sha256": "4e3ceae961fa6626697c24145d3e9218a951afd3816a411ebe0178dc985d804c",
      "size": 162333,
      "pages": null,
      "regulator": "FDA",
      "filename": "cpg%20sec%20425%20300%20source%20code%20for%20process%20control%20application%20program.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cpg/cpg%20sec%20425%20400%20input%20output%20checking.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cpg/cpg%20sec%20425%20400%20input%20output%20checking.pdf",
      "sha256": "38fa887211453f337dd76677c20f431bb4368b04efd896476d7c2bf10526793a",
      "size": 148312,
      "pages": null,
      "regulator": "FDA",
      "filename": "cpg%20sec%20425%20400%20input%20output%20checking.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cpg/cpg%20sec%20425%20500%20identification%20of%20persons%20on%20batch%20records.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cpg/cpg%20sec%20425%20500%20identification%20of%20persons%20on%20batch%20records.pdf",
      "sha256": "1fb4e77ce035765ac3fe1eb0112f93372107ca580e45115be27bc9fd33b95fb3",
      "size": 143180,
      "pages": null,
      "regulator": "FDA",
      "filename": "cpg%20sec%20425%20500%20identification%20of%20persons%20on%20batch%20records.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cpg/cpgsec490100.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cpg/cpgsec490100.pdf",
      "sha256": "2e29297d3cec00d879d38431d2a6700a2078499531996669216892ccccb5b028",
      "size": 288836,
      "pages": null,
      "regulator": "FDA",
      "filename": "cpgsec490100.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cpgm/cp%207356%20002m%20surveillance%20inspections%20of%20protein%20DS%20manufacturers%202021%2010%201.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cpgm/cp%207356%20002m%20surveillance%20inspections%20of%20protein%20DS%20manufacturers%202021%2010%201.pdf",
      "sha256": "ebef8fb72e81a620da1c86c2760f85cd95dc34207b6eeab4ca797b4f240fd790",
      "size": 962588,
      "pages": 106,
      "regulator": "FDA",
      "filename": "cp%207356%20002m%20surveillance%20inspections%20of%20protein%20DS%20manufacturers%202021%2010%201.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cpgm/cp%207356%20002m%20surveillance%20inspections%20of%20protein%20drug%20substance%20manufacturers%202021%2010%201%20kr.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cpgm/cp%207356%20002m%20surveillance%20inspections%20of%20protein%20drug%20substance%20manufacturers%202021%2010%201%20kr.pdf",
      "sha256": "878957bf467b7dd37ad5685fc44ef51019d9082b2e490a287ef7e27aaa7b8945",
      "size": 343496,
      "pages": null,
      "regulator": "FDA",
      "filename": "cp%207356%20002m%20surveillance%20inspections%20of%20protein%20drug%20substance%20manufacturers%202021%2010%201%20kr.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cpgm/cp%207356%20843%20postapproval%20inspections%202023%203%2013%20kr.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cpgm/cp%207356%20843%20postapproval%20inspections%202023%203%2013%20kr.pdf",
      "sha256": "f05eb3e7ecafc4381d7d48ab56213c4d4a0689d51c593965abb64bbe17b50d2b",
      "size": 261808,
      "pages": null,
      "regulator": "FDA",
      "filename": "cp%207356%20843%20postapproval%20inspections%202023%203%2013%20kr.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cpgm/cp%207356%20843%20postapproval%20inspections%202023%203%2013.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cpgm/cp%207356%20843%20postapproval%20inspections%202023%203%2013.pdf",
      "sha256": "2f569933b84ed8981f9319d2d1deea4838af6d419e00aecaffe3cdfceabd5bf8",
      "size": 606271,
      "pages": 50,
      "regulator": "FDA",
      "filename": "cp%207356%20843%20postapproval%20inspections%202023%203%2013.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cpgm/cpgm%207345%20848%20inspection%20of%20biological%20drug%20products%202010%2010%201%20kr.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cpgm/cpgm%207345%20848%20inspection%20of%20biological%20drug%20products%202010%2010%201%20kr.pdf",
      "sha256": "51cb2790104cd599452c7c47802247367a737344182131125c9b3f56397d5efb",
      "size": 154462,
      "pages": null,
      "regulator": "FDA",
      "filename": "cpgm%207345%20848%20inspection%20of%20biological%20drug%20products%202010%2010%201%20kr.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cpgm/cpgm%207345%20848%20inspection%20of%20biological%20drug%20products%202010%2010%201.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cpgm/cpgm%207345%20848%20inspection%20of%20biological%20drug%20products%202010%2010%201.pdf",
      "sha256": "33252bfefd846d9c05adac0d0ba175200f141d4b4e1e560be749faa1e81dc7d5",
      "size": 458518,
      "pages": 82,
      "regulator": "FDA",
      "filename": "cpgm%207345%20848%20inspection%20of%20biological%20drug%20products%202010%2010%201.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cpgm/cpgm%207346%20832%20preapproval%20inspections%202022%2010%2017%20kr.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cpgm/cpgm%207346%20832%20preapproval%20inspections%202022%2010%2017%20kr.pdf",
      "sha256": "2ad6eca5b17bf09030e7182aa5440be549b81a322a318fbc1a0481b3da93ab4f",
      "size": 307721,
      "pages": null,
      "regulator": "FDA",
      "filename": "cpgm%207346%20832%20preapproval%20inspections%202022%2010%2017%20kr.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cpgm/cpgm%207346%20832%20preapproval%20inspections%202022%2010%2017.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cpgm/cpgm%207346%20832%20preapproval%20inspections%202022%2010%2017.pdf",
      "sha256": "a089eb24b8ea9962a0af41017742f690c844ee8e02714d4b485af31ba0e92716",
      "size": 709966,
      "pages": 58,
      "regulator": "FDA",
      "filename": "cpgm%207346%20832%20preapproval%20inspections%202022%2010%2017.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cpgm/cpgm%207356%20002%20drug%20manufacturing%20inspections%202022%2010%2017%20kr.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cpgm/cpgm%207356%20002%20drug%20manufacturing%20inspections%202022%2010%2017%20kr.pdf",
      "sha256": "28d87d518e3b053536e9144b80a8662394626cd65d9026e43beea3fe3d1ae73c",
      "size": 249586,
      "pages": null,
      "regulator": "FDA",
      "filename": "cpgm%207356%20002%20drug%20manufacturing%20inspections%202022%2010%2017%20kr.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cpgm/cpgm%207356%20002%20drug%20manufacturing%20inspections%202022%2010%2017.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cpgm/cpgm%207356%20002%20drug%20manufacturing%20inspections%202022%2010%2017.pdf",
      "sha256": "394dc1f339a6ec8d92eb229165b6cfc7329bb48880590c3520984eebc9c9f3ea",
      "size": 1119196,
      "pages": 44,
      "regulator": "FDA",
      "filename": "cpgm%207356%20002%20drug%20manufacturing%20inspections%202022%2010%2017.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cpgm/cpgm%207356%20002a%20sterile%20drug%20process%20inspections%202015%209%2011%20kr.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cpgm/cpgm%207356%20002a%20sterile%20drug%20process%20inspections%202015%209%2011%20kr.pdf",
      "sha256": "ff33ee22ea82b8652bcbad62c8d4c99ded16f1f9e610fabb187d09c8df018d8e",
      "size": 157084,
      "pages": null,
      "regulator": "FDA",
      "filename": "cpgm%207356%20002a%20sterile%20drug%20process%20inspections%202015%209%2011%20kr.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cpgm/cpgm%207356%20002a%20sterile%20drug%20processing%20inspections%202016%209%2011.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cpgm/cpgm%207356%20002a%20sterile%20drug%20processing%20inspections%202016%209%2011.pdf",
      "sha256": "d3268370495679272bf084f8f0216249ff6bd6802b023a0f8b393b2ca6b46692",
      "size": 958355,
      "pages": 54,
      "regulator": "FDA",
      "filename": "cpgm%207356%20002a%20sterile%20drug%20processing%20inspections%202016%209%2011.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cpgm/cpgm%207356%20002f%20api%20process%20inspection%202015%209%2011%20kr.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cpgm/cpgm%207356%20002f%20api%20process%20inspection%202015%209%2011%20kr.pdf",
      "sha256": "52a91e28b379334777df47f109bfc730673169a6686cda770f8f6a0aa8972c13",
      "size": 146254,
      "pages": null,
      "regulator": "FDA",
      "filename": "cpgm%207356%20002f%20api%20process%20inspection%202015%209%2011%20kr.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cpgm/cpgm%207356%20002f%20api%20process%20inspection%202015%209%2011.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cpgm/cpgm%207356%20002f%20api%20process%20inspection%202015%209%2011.pdf",
      "sha256": "fc813dc32dc8b0459f3a2c83c785b448e1c798a640cd34dfd86eac691685c9c1",
      "size": 738725,
      "pages": 31,
      "regulator": "FDA",
      "filename": "cpgm%207356%20002f%20api%20process%20inspection%202015%209%2011.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/21%20cfr%20part%2011%202024%205%2026.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/21%20cfr%20part%2011%202024%205%2026.pdf",
      "sha256": "368878ce1d27e432eb51cd5b33427a074e6c030df76aa119d3c8f1ddce74022f",
      "size": 337953,
      "pages": null,
      "regulator": "FDA",
      "filename": "21%20cfr%20part%2011%202024%205%2026.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/21%20cfr%20part%204%20combination%20products.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/21%20cfr%20part%204%20combination%20products.pdf",
      "sha256": "2b7e201bf6ce94cd8fa67c6b6c3ebaf62fe860e4aa06b1254caef475054b8c59",
      "size": 157852,
      "pages": null,
      "regulator": "FDA",
      "filename": "21%20cfr%20part%204%20combination%20products.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblecgmp/Amendments%20to%20CGMP%202008%20FR.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblecgmp/Amendments%20to%20CGMP%202008%20FR.pdf",
      "sha256": "25eb5c86516506b8581055d25beb1ede47997f340c48492a2e76b83effadf882",
      "size": 1126325,
      "pages": null,
      "regulator": "FDA",
      "filename": "Amendments%20to%20CGMP%202008%20FR.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblecgmp/Ch10Equipment.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblecgmp/Ch10Equipment.pdf",
      "sha256": "a77b6f3551f3b62cdcea44750f3cd4f38349d5e53a82292074f935ca4127b685",
      "size": 288978,
      "pages": null,
      "regulator": "FDA",
      "filename": "Ch10Equipment.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblecgmp/Ch11Components.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblecgmp/Ch11Components.pdf",
      "sha256": "0fb4a5de00468d9e7a7913deb5c07e76e3cc251f274d6285bfa6a9b414104b72",
      "size": 546384,
      "pages": null,
      "regulator": "FDA",
      "filename": "Ch11Components.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblecgmp/Ch12ProductionProcessControl.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblecgmp/Ch12ProductionProcessControl.pdf",
      "sha256": "9ccb5cebdf75f68f21652584c68d326cbdfbaf80602eb57da830cebe7e1e27ab",
      "size": 362677,
      "pages": null,
      "regulator": "FDA",
      "filename": "Ch12ProductionProcessControl.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblecgmp/Ch13PackagingLabeling.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblecgmp/Ch13PackagingLabeling.pdf",
      "sha256": "b91dacc98b0958d573e6f3a7df82a66f957917f9006204e40598ecdfa619800d",
      "size": 579293,
      "pages": null,
      "regulator": "FDA",
      "filename": "Ch13PackagingLabeling.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblecgmp/Ch14HoldingDistribution.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblecgmp/Ch14HoldingDistribution.pdf",
      "sha256": "893f77aebee5e6e9caa6b0155915a5ce82756cc814eed1bd5d1d82d6ba3dba96",
      "size": 135993,
      "pages": null,
      "regulator": "FDA",
      "filename": "Ch14HoldingDistribution.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblecgmp/Ch15LaboratoryControl.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblecgmp/Ch15LaboratoryControl.pdf",
      "sha256": "32dea82be6fc2047615d6a6fc056ae65f27aec7c4557a46584addbc1afc3f66c",
      "size": 376242,
      "pages": null,
      "regulator": "FDA",
      "filename": "Ch15LaboratoryControl.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblecgmp/Ch16RecordsReports.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblecgmp/Ch16RecordsReports.pdf",
      "sha256": "9d19fa4ca1025fc2272b60c8289c4a4fbf9633fa85c660cd90860b7f8f11094f",
      "size": 707072,
      "pages": null,
      "regulator": "FDA",
      "filename": "Ch16RecordsReports.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblecgmp/Ch17Returnedproducts.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblecgmp/Ch17Returnedproducts.pdf",
      "sha256": "c1323cd54a19c1188b36a4368912a9c09948ee0fda9539b1efbd5f3a2e35d171",
      "size": 193419,
      "pages": null,
      "regulator": "FDA",
      "filename": "Ch17Returnedproducts.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblecgmp/Ch1GeneralComments.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblecgmp/Ch1GeneralComments.pdf",
      "sha256": "6262ea7469924213268562ae7ad500e52b18db17ed9d3054c8b467718dd55152",
      "size": 262842,
      "pages": null,
      "regulator": "FDA",
      "filename": "Ch1GeneralComments.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblecgmp/Ch7Definitions.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblecgmp/Ch7Definitions.pdf",
      "sha256": "839978d8fe86799560a284a12e89a2a1b5b3da4a3bb06b9b2b269da75412a9d3",
      "size": 364564,
      "pages": null,
      "regulator": "FDA",
      "filename": "Ch7Definitions.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblecgmp/Ch8OrganizationAndPersonnel.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblecgmp/Ch8OrganizationAndPersonnel.pdf",
      "sha256": "961e369f2a7027097deef793e02c9a5661b9eba96345bb57df73aa4e9714cae8",
      "size": 380530,
      "pages": null,
      "regulator": "FDA",
      "filename": "Ch8OrganizationAndPersonnel.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblecgmp/Ch9BuildingsAndFacilities.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblecgmp/Ch9BuildingsAndFacilities.pdf",
      "sha256": "e62c72e207c1cf63f8f10c8ce18d482483471ae7be81d1625a789dccde5b69c5",
      "size": 326745,
      "pages": null,
      "regulator": "FDA",
      "filename": "Ch9BuildingsAndFacilities.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblecgmp/cgmppreamblesummary.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblecgmp/cgmppreamblesummary.pdf",
      "sha256": "26b79f0383a563be8f9cb9c0467554e4b3aec89b7808bf5ad1e2802266501eb3",
      "size": 155346,
      "pages": null,
      "regulator": "FDA",
      "filename": "cgmppreamblesummary.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart11/21%20cfr%20part%2011%20preamble%20%201997%20iii%20comments%20on%20the%20proposed%20rule.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart11/21%20cfr%20part%2011%20preamble%20%201997%20iii%20comments%20on%20the%20proposed%20rule.pdf",
      "sha256": "2f36eecea87f1f4afd7dbfc33eaa785ac77ef4f25abf827d83c4bf4b32bed0be",
      "size": 401721,
      "pages": null,
      "regulator": "FDA",
      "filename": "21%20cfr%20part%2011%20preamble%20%201997%20iii%20comments%20on%20the%20proposed%20rule.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart11/21%20cfr%20part%2011%20preamble%20%201997%20iv%20scope.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart11/21%20cfr%20part%2011%20preamble%20%201997%20iv%20scope.pdf",
      "sha256": "e4aa2e38f4034cef938eeb681a3c73ba17a52f4c614698c5528423efb7c8fce0",
      "size": 322356,
      "pages": null,
      "regulator": "FDA",
      "filename": "21%20cfr%20part%2011%20preamble%20%201997%20iv%20scope.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart11/21%20cfr%20part%2011%20preamble%20%201997%20ix%20electronic%20records%20signature%20manifestations.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart11/21%20cfr%20part%2011%20preamble%20%201997%20ix%20electronic%20records%20signature%20manifestations.pdf",
      "sha256": "e66730aa850f7a87fb4b1872c5afcbf87a793298954d53423a0bfcd900dbceb0",
      "size": 189463,
      "pages": null,
      "regulator": "FDA",
      "filename": "21%20cfr%20part%2011%20preamble%20%201997%20ix%20electronic%20records%20signature%20manifestations.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart11/21%20cfr%20part%2011%20preamble%20%201997%20summary%20background%20highlights.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart11/21%20cfr%20part%2011%20preamble%20%201997%20summary%20background%20highlights.pdf",
      "sha256": "d0b91ed3b4ee7b6f03963a1f8b60431e59a02d537f591e503ca10ae2c0419920",
      "size": 188634,
      "pages": null,
      "regulator": "FDA",
      "filename": "21%20cfr%20part%2011%20preamble%20%201997%20summary%20background%20highlights.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart11/21%20cfr%20part%2011%20preamble%20%201997%20v%20implementation.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart11/21%20cfr%20part%2011%20preamble%20%201997%20v%20implementation.pdf",
      "sha256": "7b023183cbbd0dcc1ac22ef675d57e33b0fcdc2a39aa0ef3885f19c730b928bb",
      "size": 120286,
      "pages": null,
      "regulator": "FDA",
      "filename": "21%20cfr%20part%2011%20preamble%20%201997%20v%20implementation.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart11/21%20cfr%20part%2011%20preamble%20%201997%20vi%20definitions.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart11/21%20cfr%20part%2011%20preamble%20%201997%20vi%20definitions.pdf",
      "sha256": "625678b2d38ebe479acd41fb894f70ebe72ece3ab6f58d19e1823a5d4901ef79",
      "size": 321509,
      "pages": null,
      "regulator": "FDA",
      "filename": "21%20cfr%20part%2011%20preamble%20%201997%20vi%20definitions.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart11/21%20cfr%20part%2011%20preamble%20%201997%20vii%20electronic%20records%20controls%20for%20closed%20systems.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart11/21%20cfr%20part%2011%20preamble%20%201997%20vii%20electronic%20records%20controls%20for%20closed%20systems.pdf",
      "sha256": "e741e985f8847d2f46543992e31b3541445d9b25c985055b3b912f846d054225",
      "size": 624416,
      "pages": null,
      "regulator": "FDA",
      "filename": "21%20cfr%20part%2011%20preamble%20%201997%20vii%20electronic%20records%20controls%20for%20closed%20systems.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart11/21%20cfr%20part%2011%20preamble%20%201997%20viii%20electronic%20records%20controls%20for%20open%20systems.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart11/21%20cfr%20part%2011%20preamble%20%201997%20viii%20electronic%20records%20controls%20for%20open%20systems.pdf",
      "sha256": "dee5fa7e66d0ee2b5e753b98a912947329f587c6394e2a1d5bf29e866e0acb03",
      "size": 149232,
      "pages": null,
      "regulator": "FDA",
      "filename": "21%20cfr%20part%2011%20preamble%20%201997%20viii%20electronic%20records%20controls%20for%20open%20systems.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart11/21%20cfr%20part%2011%20preamble%20%201997%20x%20electronic%20records%20signature%20record%20linking.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart11/21%20cfr%20part%2011%20preamble%20%201997%20x%20electronic%20records%20signature%20record%20linking.pdf",
      "sha256": "43a4db471e0534b6374592285fa2f489c8ded23158209ba1c9d12e0a22d5336b",
      "size": 160515,
      "pages": null,
      "regulator": "FDA",
      "filename": "21%20cfr%20part%2011%20preamble%20%201997%20x%20electronic%20records%20signature%20record%20linking.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart11/21%20cfr%20part%2011%20preamble%20%201997%20xi%20electronic%20signatures%20general%20requirements.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart11/21%20cfr%20part%2011%20preamble%20%201997%20xi%20electronic%20signatures%20general%20requirements.pdf",
      "sha256": "bf8230fe27590c10d016eb7ab41371d6d557b956d8f5e3be58173a2ca52fde5d",
      "size": 242069,
      "pages": null,
      "regulator": "FDA",
      "filename": "21%20cfr%20part%2011%20preamble%20%201997%20xi%20electronic%20signatures%20general%20requirements.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart11/21%20cfr%20part%2011%20preamble%20%201997%20xii%20electronic%20signature%20components%20and%20controls.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart11/21%20cfr%20part%2011%20preamble%20%201997%20xii%20electronic%20signature%20components%20and%20controls.pdf",
      "sha256": "79a7c83ca68e3ffa1752e0eeda41b82435f0fa99a6289e254e8f872d758ba741",
      "size": 243748,
      "pages": null,
      "regulator": "FDA",
      "filename": "21%20cfr%20part%2011%20preamble%20%201997%20xii%20electronic%20signature%20components%20and%20controls.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart11/21%20cfr%20part%2011%20preamble%20%201997%20xiii%20electronic%20signatures%20controls%20for%20id%20codes%20pw.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart11/21%20cfr%20part%2011%20preamble%20%201997%20xiii%20electronic%20signatures%20controls%20for%20id%20codes%20pw.pdf",
      "sha256": "9e1ae7f2df61c09f4fae1b132d0fd893557fc29e7824f49568bf8b1c232a1eff",
      "size": 239603,
      "pages": null,
      "regulator": "FDA",
      "filename": "21%20cfr%20part%2011%20preamble%20%201997%20xiii%20electronic%20signatures%20controls%20for%20id%20codes%20pw.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart820/part820preamblesubpart%20D%20document%20controls.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart820/part820preamblesubpart%20D%20document%20controls.pdf",
      "sha256": "2c600f623c377bc081cc07e0ff05ce9ace87969a8d4cec287e5daccc5d81e303",
      "size": 174380,
      "pages": 7,
      "regulator": "FDA",
      "filename": "part820preamblesubpart%20D%20document%20controls.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart820/part820preamblesubpart%20E%20purchasing%20controls.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart820/part820preamblesubpart%20E%20purchasing%20controls.pdf",
      "sha256": "34cc68a546838c8ebf9cc423198ce8243e3bd39202fc5fb85ef138d957618e7c",
      "size": 315463,
      "pages": 16,
      "regulator": "FDA",
      "filename": "part820preamblesubpart%20E%20purchasing%20controls.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart820/part820preamblesubpart%20F%20identification%20and%20traceability.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart820/part820preamblesubpart%20F%20identification%20and%20traceability.pdf",
      "sha256": "b587a2634fd32a882f0837792cd59786f06b58f78eab124029d511c0c7b2d216",
      "size": 144336,
      "pages": 5,
      "regulator": "FDA",
      "filename": "part820preamblesubpart%20F%20identification%20and%20traceability.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart820/part820preamblesubpart%20G%20Production%20and%20Process%20Controls.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart820/part820preamblesubpart%20G%20Production%20and%20Process%20Controls.pdf",
      "sha256": "27b8b7d9ec8507ec70fc586ac8ba1b485c15cdce6fa790e999156b34639db51f",
      "size": 400660,
      "pages": 22,
      "regulator": "FDA",
      "filename": "part820preamblesubpart%20G%20Production%20and%20Process%20Controls.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart820/part820preamblesubpart%20H%20acceptance%20activities.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart820/part820preamblesubpart%20H%20acceptance%20activities.pdf",
      "sha256": "45b8f27905d10767eee34e7c232bf2dc53234dc25ad94c261be615eba58e56f0",
      "size": 187886,
      "pages": 8,
      "regulator": "FDA",
      "filename": "part820preamblesubpart%20H%20acceptance%20activities.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart820/part820preamblesubpart%20I%20nonconforming%20product.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart820/part820preamblesubpart%20I%20nonconforming%20product.pdf",
      "sha256": "595b395c52b58d08e5bd62a80e67ba55abceba49886b51bf833e6862f20fc0ad",
      "size": 143400,
      "pages": 5,
      "regulator": "FDA",
      "filename": "part820preamblesubpart%20I%20nonconforming%20product.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart820/part820preamblesubpart%20J%20corrective%20and%20preventive%20action.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart820/part820preamblesubpart%20J%20corrective%20and%20preventive%20action.pdf",
      "sha256": "fe3c672d29fe158d76d8639bb90b4fdd7922f1334e3b9d24ccc198ae4db13548",
      "size": 190390,
      "pages": 8,
      "regulator": "FDA",
      "filename": "part820preamblesubpart%20J%20corrective%20and%20preventive%20action.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart820/part820preamblesubpart%20k%20labeling%20and%20packaging.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart820/part820preamblesubpart%20k%20labeling%20and%20packaging.pdf",
      "sha256": "a9977bae07eb6bd9336812eb6c1bb65e7209653d60897216358cc6cb375ea5b6",
      "size": 233163,
      "pages": 11,
      "regulator": "FDA",
      "filename": "part820preamblesubpart%20k%20labeling%20and%20packaging.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart820/part820preamblesubpart%20l%20handling%20storage%20distribution%20and%20installation.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart820/part820preamblesubpart%20l%20handling%20storage%20distribution%20and%20installation.pdf",
      "sha256": "e672756346ee9975e395955efeb3a2da86507628f3fff10a77bc5ad624e2d559",
      "size": 174948,
      "pages": 7,
      "regulator": "FDA",
      "filename": "part820preamblesubpart%20l%20handling%20storage%20distribution%20and%20installation.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart820/part820preamblesubpart%20m%20records.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart820/part820preamblesubpart%20m%20records.pdf",
      "sha256": "da0a33d79f42a11331e640b3d9f8f1078be00881383aef661d2c7de24910cf30",
      "size": 345791,
      "pages": 18,
      "regulator": "FDA",
      "filename": "part820preamblesubpart%20m%20records.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart820/part820preamblesubpart%20n%20servicing.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart820/part820preamblesubpart%20n%20servicing.pdf",
      "sha256": "d2f13fcb97201446c1963bfb9c88be2ad324fd30a36f1de524ce605d523c1855",
      "size": 124845,
      "pages": 4,
      "regulator": "FDA",
      "filename": "part820preamblesubpart%20n%20servicing.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart820/part820preamblesubpartAgeneralprovisions.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart820/part820preamblesubpartAgeneralprovisions.pdf",
      "sha256": "ab968231b808af290746f7182b598d41d724b474cbfc752f90486b12a8474624",
      "size": 706877,
      "pages": 42,
      "regulator": "FDA",
      "filename": "part820preamblesubpartAgeneralprovisions.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart820/part820preamblesubpartBqualitysystemrequirements.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart820/part820preamblesubpartBqualitysystemrequirements.pdf",
      "sha256": "9020826ecc457d6f7c2880bf2c8196c40b82fd5abd7ec485146437925c809c1b",
      "size": 345218,
      "pages": 18,
      "regulator": "FDA",
      "filename": "part820preamblesubpartBqualitysystemrequirements.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart820/part820preamblesubpartC%20design%20controls.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart820/part820preamblesubpartC%20design%20controls.pdf",
      "sha256": "c07e0a83ca690dcf66b52118447cf9593b6fc6ec924b605259e84aa9b798bf93",
      "size": 631294,
      "pages": 37,
      "regulator": "FDA",
      "filename": "part820preamblesubpartC%20design%20controls.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart820/part820preamblesummary.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart820/part820preamblesummary.pdf",
      "sha256": "308027415027dde587da11ae4acb818ec48a71558deefb24e331d4307f696b08",
      "size": 330512,
      "pages": 17,
      "regulator": "FDA",
      "filename": "part820preamblesummary.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/us%20fda%20cgmp%2021%20cfr%20part%20210.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/us%20fda%20cgmp%2021%20cfr%20part%20210.pdf",
      "sha256": "d1c8b71e5ed758a780f786039ae5f0c1175c31d7bed8e0af2f986cfb8e684aad",
      "size": 271152,
      "pages": null,
      "regulator": "FDA",
      "filename": "us%20fda%20cgmp%2021%20cfr%20part%20210.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/us%20fda%20medical%20device%20qsr%2021%20cfr%20part%20820.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/us%20fda%20medical%20device%20qsr%2021%20cfr%20part%20820.pdf",
      "sha256": "fe43d3731d88c78f136b99fdd26822e0f6a25af1a497a885e25ba2004f18b5b9",
      "size": 726903,
      "pages": null,
      "regulator": "FDA",
      "filename": "us%20fda%20medical%20device%20qsr%2021%20cfr%20part%20820.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/usfdacgmp211/us%20fda%20cgmp%2021%20cfr%20part%20211%20subpart%20A.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/usfdacgmp211/us%20fda%20cgmp%2021%20cfr%20part%20211%20subpart%20A.pdf",
      "sha256": "59b5514809426cd7423568e4ddbcf6fbd8f2db48f5606a98301bf8cfe7740bc8",
      "size": 261981,
      "pages": null,
      "regulator": "FDA",
      "filename": "us%20fda%20cgmp%2021%20cfr%20part%20211%20subpart%20A.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/usfdacgmp211/us%20fda%20cgmp%2021%20cfr%20part%20211%20subpart%20B.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/usfdacgmp211/us%20fda%20cgmp%2021%20cfr%20part%20211%20subpart%20B.pdf",
      "sha256": "bf2174a44a8e672b4ede3a06db1ab2cd03e9a8c283acf6e30938df9746f34e12",
      "size": 283799,
      "pages": null,
      "regulator": "FDA",
      "filename": "us%20fda%20cgmp%2021%20cfr%20part%20211%20subpart%20B.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/usfdacgmp211/us%20fda%20cgmp%2021%20cfr%20part%20211%20subpart%20C.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/usfdacgmp211/us%20fda%20cgmp%2021%20cfr%20part%20211%20subpart%20C.pdf",
      "sha256": "6c8b9d986834e7fe9b38b69242fa9328b9beafbc14e5ccf4787a6dd41740815b",
      "size": 315030,
      "pages": null,
      "regulator": "FDA",
      "filename": "us%20fda%20cgmp%2021%20cfr%20part%20211%20subpart%20C.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/usfdacgmp211/us%20fda%20cgmp%2021%20cfr%20part%20211%20subpart%20D.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/usfdacgmp211/us%20fda%20cgmp%2021%20cfr%20part%20211%20subpart%20D.pdf",
      "sha256": "cd30c881f5bdc27b27939af362fad78d9edb0dbac73483e0c3eed53524c965fa",
      "size": 294488,
      "pages": null,
      "regulator": "FDA",
      "filename": "us%20fda%20cgmp%2021%20cfr%20part%20211%20subpart%20D.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/usfdacgmp211/us%20fda%20cgmp%2021%20cfr%20part%20211%20subpart%20E.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/usfdacgmp211/us%20fda%20cgmp%2021%20cfr%20part%20211%20subpart%20E.pdf",
      "sha256": "20b6a7954ee736da502003c031b0fa0a533c07816f63bd8f900cbf5f1b7b9a74",
      "size": 342356,
      "pages": null,
      "regulator": "FDA",
      "filename": "us%20fda%20cgmp%2021%20cfr%20part%20211%20subpart%20E.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/usfdacgmp211/us%20fda%20cgmp%2021%20cfr%20part%20211%20subpart%20F.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/usfdacgmp211/us%20fda%20cgmp%2021%20cfr%20part%20211%20subpart%20F.pdf",
      "sha256": "e91c4307c5cc06b4cc33169135fc7cf5566099613232ad884a1867f258b69c57",
      "size": 316018,
      "pages": null,
      "regulator": "FDA",
      "filename": "us%20fda%20cgmp%2021%20cfr%20part%20211%20subpart%20F.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/usfdacgmp211/us%20fda%20cgmp%2021%20cfr%20part%20211%20subpart%20G.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/usfdacgmp211/us%20fda%20cgmp%2021%20cfr%20part%20211%20subpart%20G.pdf",
      "sha256": "85e65bd565a8a65d8a0a12d80308eaa476881c295a7611eaf1fb3649e5ac1655",
      "size": 381678,
      "pages": null,
      "regulator": "FDA",
      "filename": "us%20fda%20cgmp%2021%20cfr%20part%20211%20subpart%20G.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/usfdacgmp211/us%20fda%20cgmp%2021%20cfr%20part%20211%20subpart%20H.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/usfdacgmp211/us%20fda%20cgmp%2021%20cfr%20part%20211%20subpart%20H.pdf",
      "sha256": "6f8603cbf42c267a318519c461ad8b02c4cad8dbd4e913c7b652b97d9d474521",
      "size": 259087,
      "pages": null,
      "regulator": "FDA",
      "filename": "us%20fda%20cgmp%2021%20cfr%20part%20211%20subpart%20H.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/usfdacgmp211/us%20fda%20cgmp%2021%20cfr%20part%20211%20subpart%20I.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/usfdacgmp211/us%20fda%20cgmp%2021%20cfr%20part%20211%20subpart%20I.pdf",
      "sha256": "013481050703f3115cc1f938fa9cb8d742d3ccc48c01d4ec5bec37636dfa88e4",
      "size": 357595,
      "pages": null,
      "regulator": "FDA",
      "filename": "us%20fda%20cgmp%2021%20cfr%20part%20211%20subpart%20I.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/usfdacgmp211/us%20fda%20cgmp%2021%20cfr%20part%20211%20subpart%20J.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/usfdacgmp211/us%20fda%20cgmp%2021%20cfr%20part%20211%20subpart%20J.pdf",
      "sha256": "149a2a3d8a1400daf3b90efcac9520035a2abd3ade58964f4f20840c2cd2e1bd",
      "size": 389201,
      "pages": null,
      "regulator": "FDA",
      "filename": "us%20fda%20cgmp%2021%20cfr%20part%20211%20subpart%20J.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/usfdacgmp211/us%20fda%20cgmp%2021%20cfr%20part%20211%20subpart%20K.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/usfdacgmp211/us%20fda%20cgmp%2021%20cfr%20part%20211%20subpart%20K.pdf",
      "sha256": "544e16287bfe545c66395443bf50af1182d4d54bebbd2a28c51cae1cefcb1910",
      "size": 271242,
      "pages": null,
      "regulator": "FDA",
      "filename": "us%20fda%20cgmp%2021%20cfr%20part%20211%20subpart%20K.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/biotechnology%20inspection%20guide.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/biotechnology%20inspection%20guide.pdf",
      "sha256": "cffb44dc5847ad60c9665166af3bbef8911bd1e4dd169972d2154f758536cf6f",
      "size": 1127327,
      "pages": null,
      "regulator": "FDA",
      "filename": "biotechnology%20inspection%20guide.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20CGMP%20for%20Phase%201%20investigational%20drugs.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20CGMP%20for%20Phase%201%20investigational%20drugs.pdf",
      "sha256": "9f0742d8086c019ca69fe79b852e882b04425326ac1b7bc8ba46967c6379e293",
      "size": 651273,
      "pages": null,
      "regulator": "FDA",
      "filename": "gfi%20CGMP%20for%20Phase%201%20investigational%20drugs.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20CMC%20vaccines%20and%20related%20products.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20CMC%20vaccines%20and%20related%20products.pdf",
      "sha256": "b9b33f162dc1552f3bc49907b6f98f8da69be384b57193b9fdc3fe7279695005",
      "size": 952405,
      "pages": null,
      "regulator": "FDA",
      "filename": "gfi%20CMC%20vaccines%20and%20related%20products.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20PAT%20framework.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20PAT%20framework.pdf",
      "sha256": "adfc51a0c2e045df4c367d824e0234896872194588bdc5bcfa5f516033552931",
      "size": 638733,
      "pages": null,
      "regulator": "FDA",
      "filename": "gfi%20PAT%20framework.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20advanced%20manufacturing%20technologies%20designation%20program.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20advanced%20manufacturing%20technologies%20designation%20program.pdf",
      "sha256": "989c349bcfc6141e955f6c1a9e3e0a208e0e6c679b89cf18fde52e01849d1dad",
      "size": 626394,
      "pages": null,
      "regulator": "FDA",
      "filename": "gfi%20advanced%20manufacturing%20technologies%20designation%20program.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20allowable%20excess%20volume%20and%20labeled%20vial%20fill%20size%202015%20final.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20allowable%20excess%20volume%20and%20labeled%20vial%20fill%20size%202015%20final.pdf",
      "sha256": "94494a0c558741978399c3cf269e98018df0664bc0ff6d84faa02e656b178d70",
      "size": 311649,
      "pages": null,
      "regulator": "FDA",
      "filename": "gfi%20allowable%20excess%20volume%20and%20labeled%20vial%20fill%20size%202015%20final.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20alternative%20tools%20assessing%20drug%20manufacturing%20facilities.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20alternative%20tools%20assessing%20drug%20manufacturing%20facilities.pdf",
      "sha256": "cb8b071321f7efbc8991cbfb67a9cb093a3857936dc1e1e7a89a8ac9680299b0",
      "size": 550852,
      "pages": null,
      "regulator": "FDA",
      "filename": "gfi%20alternative%20tools%20assessing%20drug%20manufacturing%20facilities.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20analytical%20procedures%20and%20methods%20validation%20for%20drugs%20and%20biologics%202015%20final.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20analytical%20procedures%20and%20methods%20validation%20for%20drugs%20and%20biologics%202015%20final.pdf",
      "sha256": "c875aa6aa9848eadcb93594480e1ae10bf62e645192c2c6169a03fd220da750e",
      "size": 572548,
      "pages": null,
      "regulator": "FDA",
      "filename": "gfi%20analytical%20procedures%20and%20methods%20validation%20for%20drugs%20and%20biologics%202015%20final.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20and%20fda%20staff%20current%20good%20manufacturing%20practice%20requirements%20for%20combination%20products%20final%202017%201.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20and%20fda%20staff%20current%20good%20manufacturing%20practice%20requirements%20for%20combination%20products%20final%202017%201.pdf",
      "sha256": "e6c87c1858d2dfc41751481e32c70d232a8d7778dbc9c3f98840c6ad60673eef",
      "size": 250849,
      "pages": null,
      "regulator": "FDA",
      "filename": "gfi%20and%20fda%20staff%20current%20good%20manufacturing%20practice%20requirements%20for%20combination%20products%20final%202017%201.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20andas%20impurities%20in%20drug%20products.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20andas%20impurities%20in%20drug%20products.pdf",
      "sha256": "87cfbc2cfff130f242d828a4711c7e0230ab50cbf56bb4588c527dd25e4b9e85",
      "size": 391618,
      "pages": null,
      "regulator": "FDA",
      "filename": "gfi%20andas%20impurities%20in%20drug%20products.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20andas%20impurities%20in%20drug%20substances.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20andas%20impurities%20in%20drug%20substances.pdf",
      "sha256": "15c49ccda56d96ffdbffdc47ff7455ea90788f762e76e87c701f13a06b1bac51",
      "size": 404235,
      "pages": null,
      "regulator": "FDA",
      "filename": "gfi%20andas%20impurities%20in%20drug%20substances.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20andas%20stability%20testing%20of%20drug%20substances%20and%20products%20q%20and%20a.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20andas%20stability%20testing%20of%20drug%20substances%20and%20products%20q%20and%20a.pdf",
      "sha256": "02d6b0fe4f4e6557f88fbab54cd01594a78ace105751a6aa78924a49f8d4df05",
      "size": 600208,
      "pages": null,
      "regulator": "FDA",
      "filename": "gfi%20andas%20stability%20testing%20of%20drug%20substances%20and%20products%20q%20and%20a.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20andas%20stability%20testing%20of%20drug%20substances%20and%20products.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20andas%20stability%20testing%20of%20drug%20substances%20and%20products.pdf",
      "sha256": "961fd07326f72bc98c3b81220b277f557950d4543a3819e2094244349a69c640",
      "size": 213277,
      "pages": null,
      "regulator": "FDA",
      "filename": "gfi%20andas%20stability%20testing%20of%20drug%20substances%20and%20products.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20application%20of%20human%20factors%20engineering%20principles%20for%20combination%20products.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20application%20of%20human%20factors%20engineering%20principles%20for%20combination%20products.pdf",
      "sha256": "1287f33b666531e124a7b1f1caf7a014b65a34c98d257c978c00de414fb4465f",
      "size": 715813,
      "pages": null,
      "regulator": "FDA",
      "filename": "gfi%20application%20of%20human%20factors%20engineering%20principles%20for%20combination%20products.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20blood%20establishment%20computer%20system%20validation%20in%20the%20user%20facility.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20blood%20establishment%20computer%20system%20validation%20in%20the%20user%20facility.pdf",
      "sha256": "ae717431dc3a226179850bacfb742fc448624b46d3ec330446c0d068b29f2368",
      "size": 422076,
      "pages": null,
      "regulator": "FDA",
      "filename": "gfi%20blood%20establishment%20computer%20system%20validation%20in%20the%20user%20facility.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20changes%20to%20disposable%20manufacturing%20materials%20questions%20and%20answers.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20changes%20to%20disposable%20manufacturing%20materials%20questions%20and%20answers.pdf",
      "sha256": "84a5067916b099e1536c1e3a1c488dfa8bf081d419bdac5eecf029cd8bce9c82",
      "size": 454449,
      "pages": null,
      "regulator": "FDA",
      "filename": "gfi%20changes%20to%20disposable%20manufacturing%20materials%20questions%20and%20answers.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20circumstances%20that%20constitute%20delaying%20denying%20limiting%20or%20refusing%20a%20drug%20or%20device%20inspection%20rev%201%202024%206.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20circumstances%20that%20constitute%20delaying%20denying%20limiting%20or%20refusing%20a%20drug%20or%20device%20inspection%20rev%201%202024%206.pdf",
      "sha256": "431d1231e9ce0bc818a0cffb250badd58ae2963b041a6a065937e064b545dfe5",
      "size": 556558,
      "pages": null,
      "regulator": "FDA",
      "filename": "gfi%20circumstances%20that%20constitute%20delaying%20denying%20limiting%20or%20refusing%20a%20drug%20or%20device%20inspection%20rev%201%202024%206.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20cmc%20changes%20to%20an%20approved%20application%20certain%20biological%20products.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20cmc%20changes%20to%20an%20approved%20application%20certain%20biological%20products.pdf",
      "sha256": "11c0f3fd4bed4d121f75977756abb63428685b6268a9408e99b6ede91ad324b5",
      "size": 248454,
      "pages": null,
      "regulator": "FDA",
      "filename": "gfi%20cmc%20changes%20to%20an%20approved%20application%20certain%20biological%20products.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20cmc%20nasal%20spray.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20cmc%20nasal%20spray.pdf",
      "sha256": "f62d287493a1373dbb42186deeb8baaefe5dec8a3f46c771e973d7ed07b3c147",
      "size": 1313896,
      "pages": null,
      "regulator": "FDA",
      "filename": "gfi%20cmc%20nasal%20spray.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20cmc%20postapproval%20manufacturing%20changes%20in%20annual%20reports.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20cmc%20postapproval%20manufacturing%20changes%20in%20annual%20reports.pdf",
      "sha256": "7fd7ecc4093ce8046fa7aacab30d41969001951b3357462f71f72bde188d7877",
      "size": 455614,
      "pages": null,
      "regulator": "FDA",
      "filename": "gfi%20cmc%20postapproval%20manufacturing%20changes%20in%20annual%20reports.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20cmc%20rdna%20mab.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20cmc%20rdna%20mab.pdf",
      "sha256": "fb77768e27274884d3ff50bd88d6dc7d6a99b7f05f06cfb71ea537cb1991cece",
      "size": 545327,
      "pages": null,
      "regulator": "FDA",
      "filename": "gfi%20cmc%20rdna%20mab.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20comparability%20protocols%20for%20postapproval%20changes%20to%20the%20CMC%20information%202022%2010.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20comparability%20protocols%20for%20postapproval%20changes%20to%20the%20CMC%20information%202022%2010.pdf",
      "sha256": "9ead2c4b9e4c1f43cf6b54e3351bea59df51a0078fd606faa6f1f340bfa4a2e1",
      "size": 1127348,
      "pages": null,
      "regulator": "FDA",
      "filename": "gfi%20comparability%20protocols%20for%20postapproval%20changes%20to%20the%20CMC%20information%202022%2010.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20computerized%20systems%20in%20clinical%20investigations.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20computerized%20systems%20in%20clinical%20investigations.pdf",
      "sha256": "f3316222289643779b491e8763537c30b42e4becb42435bf7dd9ff0bd4c8c808",
      "size": 452571,
      "pages": null,
      "regulator": "FDA",
      "filename": "gfi%20computerized%20systems%20in%20clinical%20investigations.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20conducting%20remote%20regulatory%20assessments%20questions%20and%20answers%20draft%202024%201.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20conducting%20remote%20regulatory%20assessments%20questions%20and%20answers%20draft%202024%201.pdf",
      "sha256": "833cb99c0d3b9de57f68149c52c42fdb8a75ebcf51a727fe576eca4ed75739d5",
      "size": 687274,
      "pages": null,
      "regulator": "FDA",
      "filename": "gfi%20conducting%20remote%20regulatory%20assessments%20questions%20and%20answers%20draft%202024%201.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20considerations%20for%20complying%20with%2021%20cfr%20211%20110%20draft.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20considerations%20for%20complying%20with%2021%20cfr%20211%20110%20draft.pdf",
      "sha256": "19a934594a45374ca3b1a4e016e5e18473d534fbfa6c4a3a67e223fab9e32ee3",
      "size": 461913,
      "pages": null,
      "regulator": "FDA",
      "filename": "gfi%20considerations%20for%20complying%20with%2021%20cfr%20211%20110%20draft.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20container%20closure%20integrity.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20container%20closure%20integrity.pdf",
      "sha256": "eda44506cd191e65e7df07acaddfa0d638cdacb67f1e61f57bf170d07ecde261",
      "size": 369484,
      "pages": null,
      "regulator": "FDA",
      "filename": "gfi%20container%20closure%20integrity.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20container%20closure%20systems%20for%20packaging%20human%20drugs%20and%20biologics%20questions%20and%20answers.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20container%20closure%20systems%20for%20packaging%20human%20drugs%20and%20biologics%20questions%20and%20answers.pdf",
      "sha256": "ce87efda00748330c92d8326200ab39d9d499af7a7522f1b512e2061542ca1ef",
      "size": 201498,
      "pages": null,
      "regulator": "FDA",
      "filename": "gfi%20container%20closure%20systems%20for%20packaging%20human%20drugs%20and%20biologics%20questions%20and%20answers.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20container%20closure%20systems.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20container%20closure%20systems.pdf",
      "sha256": "5f95e632c784d2b1f435fce05dc59eff89f6a2b84810095ab6718fdc4322cb1f",
      "size": 1369742,
      "pages": null,
      "regulator": "FDA",
      "filename": "gfi%20container%20closure%20systems.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20contract%20manufactruing%20arrangements%20for%20drugs%20quality%20agreements%20final%202016%2011.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20contract%20manufactruing%20arrangements%20for%20drugs%20quality%20agreements%20final%202016%2011.pdf",
      "sha256": "fbeb564aa40487e7fd510f31e4d2acebac49bd874954e26e6ea17a73f2a9e4a2",
      "size": 566697,
      "pages": null,
      "regulator": "FDA",
      "filename": "gfi%20contract%20manufactruing%20arrangements%20for%20drugs%20quality%20agreements%20final%202016%2011.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20data%20integrity%20and%20compliance%20with%20drug%20cgmp%20final%202018%2012.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20data%20integrity%20and%20compliance%20with%20drug%20cgmp%20final%202018%2012.pdf",
      "sha256": "9e99e62b5459938ac4c356008c7b6145a408cf336e0cfed98fd21a22c04907c7",
      "size": 616967,
      "pages": null,
      "regulator": "FDA",
      "filename": "gfi%20data%20integrity%20and%20compliance%20with%20drug%20cgmp%20final%202018%2012.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20development%20and%20submission%20of%20NIR%20analytical%20procedures%202021%20august.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20development%20and%20submission%20of%20NIR%20analytical%20procedures%202021%20august.pdf",
      "sha256": "669e3ab4d0a75041df4088f4fbc7cd7da65bed8236d43d51aa1c158bef06fa77",
      "size": 190501,
      "pages": null,
      "regulator": "FDA",
      "filename": "gfi%20development%20and%20submission%20of%20NIR%20analytical%20procedures%202021%20august.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20dmf%20bulk%20antibiotic%20drug%20substances.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20dmf%20bulk%20antibiotic%20drug%20substances.pdf",
      "sha256": "2e3105564734dfb2c47de16e906abd601fa887183e14ba3c24a2f14981d9e633",
      "size": 269283,
      "pages": null,
      "regulator": "FDA",
      "filename": "gfi%20dmf%20bulk%20antibiotic%20drug%20substances.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20evaluation%20of%20internal%20standard%20responses%20questions%20and%20answers.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20evaluation%20of%20internal%20standard%20responses%20questions%20and%20answers.pdf",
      "sha256": "6dfe21987776386252501d3feb89413f0eb28a0ba93e62a0cc46de18e06688d5",
      "size": 437075,
      "pages": null,
      "regulator": "FDA",
      "filename": "gfi%20evaluation%20of%20internal%20standard%20responses%20questions%20and%20answers.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20expiration%20dating%20of%20unit%20dose%20repackaged%20solid%20oral%20dosage%20form%20drug%20products.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20expiration%20dating%20of%20unit%20dose%20repackaged%20solid%20oral%20dosage%20form%20drug%20products.pdf",
      "sha256": "62fad591a2637c81247701ec251f6f6e6a1f93cc6bb7aae90065e4613eb0f183",
      "size": 282875,
      "pages": null,
      "regulator": "FDA",
      "filename": "gfi%20expiration%20dating%20of%20unit%20dose%20repackaged%20solid%20oral%20dosage%20form%20drug%20products.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20field%20alert%20report%20submission%20questions%20and%20answers.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20field%20alert%20report%20submission%20questions%20and%20answers.pdf",
      "sha256": "6720e9ad9aac35b3c5c57b100249426e14fa94f86c2e1a62d22689247400a2cc",
      "size": 446998,
      "pages": null,
      "regulator": "FDA",
      "filename": "gfi%20field%20alert%20report%20submission%20questions%20and%20answers.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20format%20and%20content%20for%20cmc%20section%20of%20annual%20report.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20format%20and%20content%20for%20cmc%20section%20of%20annual%20report.pdf",
      "sha256": "5e313fafc16d7d005f30f60eaca8926a44c465c74277f46b9d26b16bcf220f18",
      "size": 299235,
      "pages": null,
      "regulator": "FDA",
      "filename": "gfi%20format%20and%20content%20for%20cmc%20section%20of%20annual%20report.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20heparin%20for%20drug%20and%20medical%20device%20use%20monitoring%20crude%20heparin%20for%20quality.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20heparin%20for%20drug%20and%20medical%20device%20use%20monitoring%20crude%20heparin%20for%20quality.pdf",
      "sha256": "0ae02024527928774286ecbfd6717e142b23a363780d1eb39080cba126df631e",
      "size": 338852,
      "pages": null,
      "regulator": "FDA",
      "filename": "gfi%20heparin%20for%20drug%20and%20medical%20device%20use%20monitoring%20crude%20heparin%20for%20quality.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20ich%20q12%20implementation%20considerations%20for%20fda%20regulated%20products.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20ich%20q12%20implementation%20considerations%20for%20fda%20regulated%20products.pdf",
      "sha256": "bfb40867ef1c574d677e3cb854dac5e29ba447cd13d5d084d608f17b2924a41b",
      "size": 672163,
      "pages": null,
      "regulator": "FDA",
      "filename": "gfi%20ich%20q12%20implementation%20considerations%20for%20fda%20regulated%20products.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20inspection%20of%20injectable%20products%20for%20visible%20particulates%20draft%202021%2012.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20inspection%20of%20injectable%20products%20for%20visible%20particulates%20draft%202021%2012.pdf",
      "sha256": "4e2cf946be01c5684afdcf87087d911904ebe24472d4f1198c983bc7e395725e",
      "size": 539650,
      "pages": null,
      "regulator": "FDA",
      "filename": "gfi%20inspection%20of%20injectable%20products%20for%20visible%20particulates%20draft%202021%2012.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20investigating%20oos%20rev%201%202022%205.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20investigating%20oos%20rev%201%202022%205.pdf",
      "sha256": "dab5b46c0cabdf3cb03065f2ef5aa581568b060c2022e109239be83abcd26749",
      "size": 592259,
      "pages": null,
      "regulator": "FDA",
      "filename": "gfi%20investigating%20oos%20rev%201%202022%205.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20manufacturing%20changes%20and%20comparability%20for%20human%20cellular%20and%20gene%20therapy%20products%20draft.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20manufacturing%20changes%20and%20comparability%20for%20human%20cellular%20and%20gene%20therapy%20products%20draft.pdf",
      "sha256": "b85e3dfa07bb660e251ba1690f22a6ba8c7037560dedec264b560691129ea2c3",
      "size": 869914,
      "pages": null,
      "regulator": "FDA",
      "filename": "gfi%20manufacturing%20changes%20and%20comparability%20for%20human%20cellular%20and%20gene%20therapy%20products%20draft.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20manufacturing%20considerations%20for%20cellular%20and%20gene%20therapy%20products.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20manufacturing%20considerations%20for%20cellular%20and%20gene%20therapy%20products.pdf",
      "sha256": "26d642d0f64f516732639e10b3abf731db478f55afe5bddb0341f6a4816a0845",
      "size": 287162,
      "pages": null,
      "regulator": "FDA",
      "filename": "gfi%20manufacturing%20considerations%20for%20cellular%20and%20gene%20therapy%20products.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20micro%20quality%20considerations%20in%20non%20sterile%20drug%20manufacturing.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20micro%20quality%20considerations%20in%20non%20sterile%20drug%20manufacturing.pdf",
      "sha256": "888cb84c2a70f05b2c300897e1168e0f5dc860a3ecf272d40d7081423e9ff1da",
      "size": 821213,
      "pages": null,
      "regulator": "FDA",
      "filename": "gfi%20micro%20quality%20considerations%20in%20non%20sterile%20drug%20manufacturing.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20monoclonal%20antibody%20reagents.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20monoclonal%20antibody%20reagents.pdf",
      "sha256": "e59f92cddbcdf6083f4566099f76df46cf142325f0e4ec30c7711af4b8e9e312",
      "size": 347493,
      "pages": null,
      "regulator": "FDA",
      "filename": "gfi%20monoclonal%20antibody%20reagents.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20part%2011%20electronic%20records%20electronic%20signature.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20part%2011%20electronic%20records%20electronic%20signature.pdf",
      "sha256": "b57188b0b525f32ade5b7c493e7c4230b64585da18561cba0f82e0da5a9a00d2",
      "size": 407417,
      "pages": null,
      "regulator": "FDA",
      "filename": "gfi%20part%2011%20electronic%20records%20electronic%20signature.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20postapproval%20manufacturing%20changes%20to%20biosimilar%20and%20interchangeable%20biosimilar%20products%20draft.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20postapproval%20manufacturing%20changes%20to%20biosimilar%20and%20interchangeable%20biosimilar%20products%20draft.pdf",
      "sha256": "dc8137f180ce454625b6d053ae06d34b0bba1ba06d6b8e7cb4400e7b5e4780e2",
      "size": 578439,
      "pages": null,
      "regulator": "FDA",
      "filename": "gfi%20postapproval%20manufacturing%20changes%20to%20biosimilar%20and%20interchangeable%20biosimilar%20products%20draft.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20potency%20assay%20considerations%20for%20monoclonal%20antibodies%20and%20other%20therapeutic%20proteins.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20potency%20assay%20considerations%20for%20monoclonal%20antibodies%20and%20other%20therapeutic%20proteins.pdf",
      "sha256": "97173894c34dca6555afbb8a31f9bff2c9f2f7cab4e1fb54a1b4acca546f9b2c",
      "size": 572380,
      "pages": null,
      "regulator": "FDA",
      "filename": "gfi%20potency%20assay%20considerations%20for%20monoclonal%20antibodies%20and%20other%20therapeutic%20proteins.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20process%20validation%20final.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20process%20validation%20final.pdf",
      "sha256": "fe9bf43dafe2d3fd01e9d251605f91d3f2192a0239a4a4a3089a4dc00c0bd4fa",
      "size": 738849,
      "pages": null,
      "regulator": "FDA",
      "filename": "gfi%20process%20validation%20final.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20pyrogen%20and%20endotoxins%20testing%20questions%20and%20answers.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20pyrogen%20and%20endotoxins%20testing%20questions%20and%20answers.pdf",
      "sha256": "00cf90cc06b111c72e9ac6152b27de339ef0552631b0d57f3bb47e0d551ea297",
      "size": 495848,
      "pages": null,
      "regulator": "FDA",
      "filename": "gfi%20pyrogen%20and%20endotoxins%20testing%20questions%20and%20answers.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20quality%20considerations%20for%20topical%20ophthalmic%20drug%20products%20draft%202023%2012.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20quality%20considerations%20for%20topical%20ophthalmic%20drug%20products%20draft%202023%2012.pdf",
      "sha256": "ab7987c7ada1a8bd157a98f9d356f54e9eae94ea3ee98b4cf93fee8f53139ef1",
      "size": 642023,
      "pages": null,
      "regulator": "FDA",
      "filename": "gfi%20quality%20considerations%20for%20topical%20ophthalmic%20drug%20products%20draft%202023%2012.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20quality%20considerations%20in%20demonstrating%20biosimilarity%20of%20a%20therapeutic%20protein%20product.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20quality%20considerations%20in%20demonstrating%20biosimilarity%20of%20a%20therapeutic%20protein%20product.pdf",
      "sha256": "aa1395418433695c843168645c091c350f291f1d35ff693b44f8283d89c1731e",
      "size": 227049,
      "pages": null,
      "regulator": "FDA",
      "filename": "gfi%20quality%20considerations%20in%20demonstrating%20biosimilarity%20of%20a%20therapeutic%20protein%20product.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20quality%20metrics%20technical%20conformance%20guide%20draft.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20quality%20metrics%20technical%20conformance%20guide%20draft.pdf",
      "sha256": "4a6fa1fd3af0baacb5a92a51d6447817eb0106b0557552e2925aed9e6c4f72d3",
      "size": 348324,
      "pages": null,
      "regulator": "FDA",
      "filename": "gfi%20quality%20metrics%20technical%20conformance%20guide%20draft.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20quality%20systems%20approach.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20quality%20systems%20approach.pdf",
      "sha256": "7dd8a0f22895f2e35efc8ec17a81a48202e81fecb27ec724325ec616765ff779",
      "size": 1242144,
      "pages": null,
      "regulator": "FDA",
      "filename": "gfi%20quality%20systems%20approach.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20questions%20and%20answers%20on%20quality%20related%20controlled%20correspondence.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20questions%20and%20answers%20on%20quality%20related%20controlled%20correspondence.pdf",
      "sha256": "54952063aca4c6aada2f022632cf69f308572a0c34ea1f8f791a91705aaaf36f",
      "size": 450300,
      "pages": null,
      "regulator": "FDA",
      "filename": "gfi%20questions%20and%20answers%20on%20quality%20related%20controlled%20correspondence.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20remote%20interactive%20evaluations%20of%20drug%20manufacturing%20and%20bioresearch%20monitoring%20facilities.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20remote%20interactive%20evaluations%20of%20drug%20manufacturing%20and%20bioresearch%20monitoring%20facilities.pdf",
      "sha256": "743ae7cd2992e19b06b0f77a84e1977f43ea6e9492e2a40633b6f43830b8c771",
      "size": 504744,
      "pages": null,
      "regulator": "FDA",
      "filename": "gfi%20remote%20interactive%20evaluations%20of%20drug%20manufacturing%20and%20bioresearch%20monitoring%20facilities.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20residual%20solvents%20in%20drug%20products.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20residual%20solvents%20in%20drug%20products.pdf",
      "sha256": "af24ea573614f291b3d69e78d48c6e449edef4eb6f5882271cbaf39c515e98ab",
      "size": 254919,
      "pages": null,
      "regulator": "FDA",
      "filename": "gfi%20residual%20solvents%20in%20drug%20products.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20scientific%20considerations%20in%20demonstrating%20biosimilarity%20to%20a%20reference%20product.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20scientific%20considerations%20in%20demonstrating%20biosimilarity%20to%20a%20reference%20product.pdf",
      "sha256": "2441f8673e220ec15b56dd6d9c1aedb9248cf2211a2212aa2e5d3fafb6553d02",
      "size": 227071,
      "pages": null,
      "regulator": "FDA",
      "filename": "gfi%20scientific%20considerations%20in%20demonstrating%20biosimilarity%20to%20a%20reference%20product.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20setting%20endotoxin%20limits%20investigational%20oncology%20drugs%20and%20biological%20products%20draft.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20setting%20endotoxin%20limits%20investigational%20oncology%20drugs%20and%20biological%20products%20draft.pdf",
      "sha256": "c40fbf88b305bb33ecb53a5c2e1cf31a87a1e670997e84a425e77eeb7ccba4e5",
      "size": 353265,
      "pages": null,
      "regulator": "FDA",
      "filename": "gfi%20setting%20endotoxin%20limits%20investigational%20oncology%20drugs%20and%20biological%20products%20draft.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20size%20shape%20other%20physical%20attributes%20of%20generic%20tablets%20and%20capsules%202022%2010%20revision%201.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20size%20shape%20other%20physical%20attributes%20of%20generic%20tablets%20and%20capsules%202022%2010%20revision%201.pdf",
      "sha256": "bf19f98eead6d57affe58d83fc30a105fdb8357dd2bb7db80da6c2d80dc8c907",
      "size": 403400,
      "pages": null,
      "regulator": "FDA",
      "filename": "gfi%20size%20shape%20other%20physical%20attributes%20of%20generic%20tablets%20and%20capsules%202022%2010%20revision%201.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20sterile%20drug%20products%20by%20aseptic%20processing%20CGMP.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20sterile%20drug%20products%20by%20aseptic%20processing%20CGMP.pdf",
      "sha256": "f9a1865e2edc182ac1b6262770b351120887f7b238d15e67ec9216922b19c1cf",
      "size": 248051,
      "pages": null,
      "regulator": "FDA",
      "filename": "gfi%20sterile%20drug%20products%20by%20aseptic%20processing%20CGMP.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20sterilization%20process%20validation%20documentation.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20sterilization%20process%20validation%20documentation.pdf",
      "sha256": "a568f00f3f65c37df9078ec7e693e75797a861e0e1440fd52b217a5390199aa5",
      "size": 556952,
      "pages": null,
      "regulator": "FDA",
      "filename": "gfi%20sterilization%20process%20validation%20documentation.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20submission%20of%20documentation%20in%20applications%20for%20parametric%20release.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20submission%20of%20documentation%20in%20applications%20for%20parametric%20release.pdf",
      "sha256": "aa6d5ecdb69394a28ede26ab46c3d43c834399f9b6394cd60b4c7d1f9695ff3d",
      "size": 382832,
      "pages": null,
      "regulator": "FDA",
      "filename": "gfi%20submission%20of%20documentation%20in%20applications%20for%20parametric%20release.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20submission%20of%20quality%20metrics%20data%202016%2011%20draft.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20submission%20of%20quality%20metrics%20data%202016%2011%20draft.pdf",
      "sha256": "3220c09032a95b826b70d2efef9e8355fcd04651e1bc0572c4f17487fbc9c198",
      "size": 813780,
      "pages": null,
      "regulator": "FDA",
      "filename": "gfi%20submission%20of%20quality%20metrics%20data%202016%2011%20draft.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20testing%20for%20diethylene%20glycol%20and%20ethylene%20glycol.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20testing%20for%20diethylene%20glycol%20and%20ethylene%20glycol.pdf",
      "sha256": "99c68b05969b1e7c179f53766dfa6d726545b81fa797a1e4583d301a64f14ea2",
      "size": 471945,
      "pages": null,
      "regulator": "FDA",
      "filename": "gfi%20testing%20for%20diethylene%20glycol%20and%20ethylene%20glycol.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfivaccinesCMC.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfivaccinesCMC.pdf",
      "sha256": "99d962c4a8ef01f20735536f5727a52f944c27bda6f88b3fefb94449b30dc488",
      "size": 969577,
      "pages": 65,
      "regulator": "FDA",
      "filename": "gfivaccinesCMC.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gti%20computerized%20systems%20in%20drug%20establishments.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gti%20computerized%20systems%20in%20drug%20establishments.pdf",
      "sha256": "1c3b6bbb5bbb885260ab1f8fd75fc3d14700fd03533d728f10eeae30a044b18d",
      "size": 856943,
      "pages": null,
      "regulator": "FDA",
      "filename": "gti%20computerized%20systems%20in%20drug%20establishments.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gti%20dosage%20form%20drug%20manufacturers.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gti%20dosage%20form%20drug%20manufacturers.pdf",
      "sha256": "866b21d9a4e60c36f7b3be55e769c87ccdcf2fe7ceda5064d6773c630af62f67",
      "size": 655828,
      "pages": null,
      "regulator": "FDA",
      "filename": "gti%20dosage%20form%20drug%20manufacturers.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gti%20foreign%20medical%20device%20manufacturers.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gti%20foreign%20medical%20device%20manufacturers.pdf",
      "sha256": "81808a9d7f9eee8aaf1467bd992fac4058e0e7285284b0508423a91ba5cc4f8d",
      "size": 311684,
      "pages": null,
      "regulator": "FDA",
      "filename": "gti%20foreign%20medical%20device%20manufacturers.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gti%20foreign%20pharm%20manufacturers.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gti%20foreign%20pharm%20manufacturers.pdf",
      "sha256": "9249f11a696713015713bc4447e5d3776583717d41ccf462e23216b299818edd",
      "size": 459542,
      "pages": null,
      "regulator": "FDA",
      "filename": "gti%20foreign%20pharm%20manufacturers.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gti%20high%20purity%20water%20systems.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gti%20high%20purity%20water%20systems.pdf",
      "sha256": "9cf53cbfba9ce70110995b594d08fc99e94bf6c31466b28799adb387e9c73d85",
      "size": 606947,
      "pages": null,
      "regulator": "FDA",
      "filename": "gti%20high%20purity%20water%20systems.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gti%20lyophilization%20of%20parenterals.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gti%20lyophilization%20of%20parenterals.pdf",
      "sha256": "0d3474cd7c2e30439898e679b38b099f4bab61606acc046bcb350929722d3658",
      "size": 603474,
      "pages": null,
      "regulator": "FDA",
      "filename": "gti%20lyophilization%20of%20parenterals.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gti%20microbiological%20pharm%20qc.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gti%20microbiological%20pharm%20qc.pdf",
      "sha256": "2ba1ccb3807d44b413a3b912fc24187e30b050fb512a04435780f0e0726f3c65",
      "size": 358915,
      "pages": null,
      "regulator": "FDA",
      "filename": "gti%20microbiological%20pharm%20qc.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gti%20oral%20solids.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gti%20oral%20solids.pdf",
      "sha256": "ab01bcddc249108fce3faf8ade7ff685646ca6abddc493f5586ab11aec79eecc",
      "size": 687648,
      "pages": null,
      "regulator": "FDA",
      "filename": "gti%20oral%20solids.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gti%20oral%20solutions%20and%20suspensions.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gti%20oral%20solutions%20and%20suspensions.pdf",
      "sha256": "e0f4fe84623810def4af39162ef9f122272c6e28aa8e9ab0f901945c92259d2e",
      "size": 336348,
      "pages": null,
      "regulator": "FDA",
      "filename": "gti%20oral%20solutions%20and%20suspensions.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gti%20pharmaceutical%20qc%20lab.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gti%20pharmaceutical%20qc%20lab.pdf",
      "sha256": "19b9f750795a68792ff3bbdf2d55df5fdeeb57cd0f703a2ec5fa9feb6682d3f8",
      "size": 567537,
      "pages": null,
      "regulator": "FDA",
      "filename": "gti%20pharmaceutical%20qc%20lab.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gti%20sterile%20drug%20substance.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gti%20sterile%20drug%20substance.pdf",
      "sha256": "96f4bfd03cb0d6437ffbcf877da5a352dcbff7de41dc7196e336d935f8d35673",
      "size": 426442,
      "pages": null,
      "regulator": "FDA",
      "filename": "gti%20sterile%20drug%20substance.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gti%20topical%20drug%20products.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gti%20topical%20drug%20products.pdf",
      "sha256": "9fc710a3d7e11ad660f915411374045bdfc1562ac0f38d4e1be1e7cff9853b77",
      "size": 381083,
      "pages": null,
      "regulator": "FDA",
      "filename": "gti%20topical%20drug%20products.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gti%20validation%20of%20cleaning%20processes.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gti%20validation%20of%20cleaning%20processes.pdf",
      "sha256": "04c408aee32a74f492ab3e1e06c424f026d503903c8bd99406761aa571a46445",
      "size": 381925,
      "pages": null,
      "regulator": "FDA",
      "filename": "gti%20validation%20of%20cleaning%20processes.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/guideline%20for%20drug%20master%20file.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/guideline%20for%20drug%20master%20file.pdf",
      "sha256": "222a16858f9ab895b26d2d7a54300ca3ce35100d1a54acfeecc941b07d290ed0",
      "size": 378368,
      "pages": null,
      "regulator": "FDA",
      "filename": "guideline%20for%20drug%20master%20file.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/guideline%20on%20preparation%20of%20IND%20products.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/guideline%20on%20preparation%20of%20IND%20products.pdf",
      "sha256": "ffa62613f18c56302d3f19fd9e894adb055c8569b7f59899525564d037757d09",
      "size": 337608,
      "pages": null,
      "regulator": "FDA",
      "filename": "guideline%20on%20preparation%20of%20IND%20products.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/non%20penicillin%20beta%20lactam%20CGMP%20framework.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/non%20penicillin%20beta%20lactam%20CGMP%20framework.pdf",
      "sha256": "08815baa22698a1a4614154b220e267835973dfb4cb7c4cb88de7061a3e27025",
      "size": 363021,
      "pages": null,
      "regulator": "FDA",
      "filename": "non%20penicillin%20beta%20lactam%20CGMP%20framework.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/software%20validation.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/software%20validation.pdf",
      "sha256": "598ee7f93ad370fcc6bf5fe49ebee29880a0e45990acff94671f4a853c801f3b",
      "size": 277627,
      "pages": null,
      "regulator": "FDA",
      "filename": "software%20validation.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/who/gmp/who%20gmp%202014%20trs%20986%20ch%201%20pharmaceutical%20quality%20system.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/who/gmp/who%20gmp%202014%20trs%20986%20ch%201%20pharmaceutical%20quality%20system.pdf",
      "sha256": "241d047dbb3be9605bb85acc631ec73fc144a37a9246e37f95792aa464624206",
      "size": 177314,
      "pages": null,
      "regulator": "WHO",
      "filename": "who%20gmp%202014%20trs%20986%20ch%201%20pharmaceutical%20quality%20system.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/who/gmp/who%20gmp%202014%20trs%20986%20ch%2010%20training.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/who/gmp/who%20gmp%202014%20trs%20986%20ch%2010%20training.pdf",
      "sha256": "5ad07915555b5d88d95f5a3ec2a04aef5f4c6c370e645fe6ae8ab5347d81c07a",
      "size": 80159,
      "pages": null,
      "regulator": "WHO",
      "filename": "who%20gmp%202014%20trs%20986%20ch%2010%20training.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/who/gmp/who%20gmp%202014%20trs%20986%20ch%2011%20personal%20hygiene.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/who/gmp/who%20gmp%202014%20trs%20986%20ch%2011%20personal%20hygiene.pdf",
      "sha256": "30d394236a69292c75510144f5b0929b0c3c0288096bea1f9aa07e4b786e1f56",
      "size": 84596,
      "pages": null,
      "regulator": "WHO",
      "filename": "who%20gmp%202014%20trs%20986%20ch%2011%20personal%20hygiene.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/who/gmp/who%20gmp%202014%20trs%20986%20ch%2012%20premises.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/who/gmp/who%20gmp%202014%20trs%20986%20ch%2012%20premises.pdf",
      "sha256": "baccad43de399f2072e5d258b9978d140551236d0448a7a7eb2ca0d568746e38",
      "size": 161258,
      "pages": null,
      "regulator": "WHO",
      "filename": "who%20gmp%202014%20trs%20986%20ch%2012%20premises.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/who/gmp/who%20gmp%202014%20trs%20986%20ch%2013%20equipment.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/who/gmp/who%20gmp%202014%20trs%20986%20ch%2013%20equipment.pdf",
      "sha256": "4a39abfba10aa62f729ee52d6f74160fc0c8f915c433f37b2a287200871c8608",
      "size": 91622,
      "pages": null,
      "regulator": "WHO",
      "filename": "who%20gmp%202014%20trs%20986%20ch%2013%20equipment.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/who/gmp/who%20gmp%202014%20trs%20986%20ch%2014%20materials.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/who/gmp/who%20gmp%202014%20trs%20986%20ch%2014%20materials.pdf",
      "sha256": "c0edb56c577899a853246bffd53aab9e182d77279d55122ac92592db5c1e8f17",
      "size": 192453,
      "pages": null,
      "regulator": "WHO",
      "filename": "who%20gmp%202014%20trs%20986%20ch%2014%20materials.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/who/gmp/who%20gmp%202014%20trs%20986%20ch%2015%20documentation.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/who/gmp/who%20gmp%202014%20trs%20986%20ch%2015%20documentation.pdf",
      "sha256": "0947a224cd0800433f7613086b79daf6d746c7842424066bb6c37148e01afbfe",
      "size": 286337,
      "pages": null,
      "regulator": "WHO",
      "filename": "who%20gmp%202014%20trs%20986%20ch%2015%20documentation.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/who/gmp/who%20gmp%202014%20trs%20986%20ch%2016%20good%20practices%20in%20production.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/who/gmp/who%20gmp%202014%20trs%20986%20ch%2016%20good%20practices%20in%20production.pdf",
      "sha256": "f23521ffc76de715eecafc4761b6a4a3fcb8bbc0251573a3370d01ac6dfb4ceb",
      "size": 184863,
      "pages": null,
      "regulator": "WHO",
      "filename": "who%20gmp%202014%20trs%20986%20ch%2016%20good%20practices%20in%20production.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/who/gmp/who%20gmp%202014%20trs%20986%20ch%2017%20good%20practices%20in%20quality%20control.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/who/gmp/who%20gmp%202014%20trs%20986%20ch%2017%20good%20practices%20in%20quality%20control.pdf",
      "sha256": "bc666a50c47437fa60eb2732b390e02b2909eeb3a909ce04c2349947a459f1c6",
      "size": 183627,
      "pages": null,
      "regulator": "WHO",
      "filename": "who%20gmp%202014%20trs%20986%20ch%2017%20good%20practices%20in%20quality%20control.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/who/gmp/who%20gmp%202014%20trs%20986%20ch%202%20good%20manufacturing%20practices.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/who/gmp/who%20gmp%202014%20trs%20986%20ch%202%20good%20manufacturing%20practices.pdf",
      "sha256": "423cb898afef90faeecb691c9b4127eefe0706f06b1b354c9c9b3e2d88f985f6",
      "size": 93494,
      "pages": null,
      "regulator": "WHO",
      "filename": "who%20gmp%202014%20trs%20986%20ch%202%20good%20manufacturing%20practices.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/who/gmp/who%20gmp%202014%20trs%20986%20ch%203%20sanitation%20and%20hygiene.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/who/gmp/who%20gmp%202014%20trs%20986%20ch%203%20sanitation%20and%20hygiene.pdf",
      "sha256": "9fb489d9b599c7e3059a74a90a4f7bbdd905e5c4ac2118f660e8862d9baf9271",
      "size": 57837,
      "pages": null,
      "regulator": "WHO",
      "filename": "who%20gmp%202014%20trs%20986%20ch%203%20sanitation%20and%20hygiene.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/who/gmp/who%20gmp%202014%20trs%20986%20ch%204%20qualification%20and%20validation.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/who/gmp/who%20gmp%202014%20trs%20986%20ch%204%20qualification%20and%20validation.pdf",
      "sha256": "0eeead8b310937c847c61059859aecfdeff7acaa52b14023a94bbc830c77415e",
      "size": 94279,
      "pages": null,
      "regulator": "WHO",
      "filename": "who%20gmp%202014%20trs%20986%20ch%204%20qualification%20and%20validation.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/who/gmp/who%20gmp%202014%20trs%20986%20ch%205%20complaints.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/who/gmp/who%20gmp%202014%20trs%20986%20ch%205%20complaints.pdf",
      "sha256": "f89915af92e9708019b836bd9728fce9b856fa19b2121bae805d92f9a5f9d740",
      "size": 76960,
      "pages": null,
      "regulator": "WHO",
      "filename": "who%20gmp%202014%20trs%20986%20ch%205%20complaints.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/who/gmp/who%20gmp%202014%20trs%20986%20ch%206%20product%20recalls.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/who/gmp/who%20gmp%202014%20trs%20986%20ch%206%20product%20recalls.pdf",
      "sha256": "5122a9953c596912c06b77e79442c1e42e63351ef59bc1495dfccfb86cad5650",
      "size": 77587,
      "pages": null,
      "regulator": "WHO",
      "filename": "who%20gmp%202014%20trs%20986%20ch%206%20product%20recalls.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/who/gmp/who%20gmp%202014%20trs%20986%20ch%207%20contract%20production%20analysis%20and%20other%20activities.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/who/gmp/who%20gmp%202014%20trs%20986%20ch%207%20contract%20production%20analysis%20and%20other%20activities.pdf",
      "sha256": "636db469f608d1ca426787606efe1221928398d441c898212a13d5a5e2c875e6",
      "size": 121055,
      "pages": null,
      "regulator": "WHO",
      "filename": "who%20gmp%202014%20trs%20986%20ch%207%20contract%20production%20analysis%20and%20other%20activities.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/who/gmp/who%20gmp%202014%20trs%20986%20ch%208%20self%20inspection%20quality%20audits%20and%20supplier%20audits%20and%20approval.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/who/gmp/who%20gmp%202014%20trs%20986%20ch%208%20self%20inspection%20quality%20audits%20and%20supplier%20audits%20and%20approval.pdf",
      "sha256": "f824738d0763726670a377cee97d8ad948672fff11066dbbbab07157250729eb",
      "size": 105288,
      "pages": null,
      "regulator": "WHO",
      "filename": "who%20gmp%202014%20trs%20986%20ch%208%20self%20inspection%20quality%20audits%20and%20supplier%20audits%20and%20approval.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/who/gmp/who%20gmp%202014%20trs%20986%20ch%209%20personnel.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/who/gmp/who%20gmp%202014%20trs%20986%20ch%209%20personnel.pdf",
      "sha256": "23ac52fd3907c88f3eafc9679e09cec4869c163bcb6b5580087a5e28bef06043",
      "size": 156945,
      "pages": null,
      "regulator": "WHO",
      "filename": "who%20gmp%202014%20trs%20986%20ch%209%20personnel.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/who/gmp/who%20gmp%202014%20trs%20986%20glossary.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/who/gmp/who%20gmp%202014%20trs%20986%20glossary.pdf",
      "sha256": "e08047e294b7f18cdaa93889f6a88b441dc47a8c9a8ababebaf06fa82ff3d795",
      "size": 175448,
      "pages": null,
      "regulator": "WHO",
      "filename": "who%20gmp%202014%20trs%20986%20glossary.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/who/gmp/who%20gmp%202014%20trs%20986%20introduction.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/who/gmp/who%20gmp%202014%20trs%20986%20introduction.pdf",
      "sha256": "a06b4f28bf7cd5cba426eb798221389f7feb0c1a23c7c32ceed1fcdec9ec0727",
      "size": 189239,
      "pages": null,
      "regulator": "WHO",
      "filename": "who%20gmp%202014%20trs%20986%20introduction.pdf"
    },
    "http://www.gmpeye.co.kr/gmpguidesandguidelines/who/gmp/who%20gmp%202014%20trs%20986%20references.pdf": {
      "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/who/gmp/who%20gmp%202014%20trs%20986%20references.pdf",
      "sha256": "70f635359de92d6c2ad8a8675835eff6ab4a352dd98e9e1bab191cdab61a5e91",
      "size": 56537,
      "pages": null,
      "regulator": "WHO",
      "filename": "who%20gmp%202014%20trs%20986%20references.pdf"
    },
    "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20483%202020%202021%20sample%20pages.pdf": {
      "url": "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20483%202020%202021%20sample%20pages.pdf",
      "sha256": "c4ec26222c6a8ee5494aa5026ab19cc09b2fb2a1b4d845c11da2ce9ad42d6511",
      "size": 331943,
      "pages": null,
      "regulator": "OTHER",
      "filename": "us%20fda%20483%202020%202021%20sample%20pages.pdf"
    },
    "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20483%202022%201st%20half%20sample%20pages.pdf": {
      "url": "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20483%202022%201st%20half%20sample%20pages.pdf",
      "sha256": "60b0fd8631e918e0d17d0011a2495835c4d5215ff0286c60d0b0e2db5a41c628",
      "size": 284552,
      "pages": null,
      "regulator": "OTHER",
      "filename": "us%20fda%20483%202022%201st%20half%20sample%20pages.pdf"
    },
    "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20483%202022%202nd%20half%20sample%20pages.pdf": {
      "url": "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20483%202022%202nd%20half%20sample%20pages.pdf",
      "sha256": "6409863c531b2455cc091d8d5271981fdedb84c8702a8e76ba6bbd0fe6c404b4",
      "size": 300442,
      "pages": null,
      "regulator": "OTHER",
      "filename": "us%20fda%20483%202022%202nd%20half%20sample%20pages.pdf"
    },
    "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20483%202023%201st%20half%20sample%20pages.pdf": {
      "url": "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20483%202023%201st%20half%20sample%20pages.pdf",
      "sha256": "3338aac26555dccd0a42ff339a625a8ad687b3f2cb3038ecd4a5a70b74e426ad",
      "size": 282935,
      "pages": null,
      "regulator": "OTHER",
      "filename": "us%20fda%20483%202023%201st%20half%20sample%20pages.pdf"
    },
    "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20483%202023%202nd%20half%20sample%20pages.pdf": {
      "url": "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20483%202023%202nd%20half%20sample%20pages.pdf",
      "sha256": "62cf5abe9803e55566cee2872eda3d2b9a71b0b78f6438e9d3955f10d4c94354",
      "size": 296746,
      "pages": null,
      "regulator": "OTHER",
      "filename": "us%20fda%20483%202023%202nd%20half%20sample%20pages.pdf"
    },
    "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20483%202024%201st%20half%20sample%20pages.pdf": {
      "url": "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20483%202024%201st%20half%20sample%20pages.pdf",
      "sha256": "f5c017f5ea457bdb888d68a52af79355e1eddc53bb5786e29dd527ad24e61593",
      "size": 289419,
      "pages": null,
      "regulator": "OTHER",
      "filename": "us%20fda%20483%202024%201st%20half%20sample%20pages.pdf"
    },
    "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20483%202024%202nd%20half%20sample%20pages.pdf": {
      "url": "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20483%202024%202nd%20half%20sample%20pages.pdf",
      "sha256": "30402a404d6197dd40403227f464fc8f84182145f956dcd3f75594697ccff16e",
      "size": 268930,
      "pages": null,
      "regulator": "OTHER",
      "filename": "us%20fda%20483%202024%202nd%20half%20sample%20pages.pdf"
    },
    "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20wl%202016%20sample%20pages.pdf": {
      "url": "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20wl%202016%20sample%20pages.pdf",
      "sha256": "16162af2d4067a6886169e9f094b0d54c558480206d7cebb29c68ed004a09087",
      "size": 198106,
      "pages": null,
      "regulator": "OTHER",
      "filename": "us%20fda%20wl%202016%20sample%20pages.pdf"
    },
    "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20wl%202017%20sample%20pages.pdf": {
      "url": "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20wl%202017%20sample%20pages.pdf",
      "sha256": "6aea03546454ec8a78750a5ea8fa5b6760da5418939ca7181912800958eb1455",
      "size": 178157,
      "pages": null,
      "regulator": "OTHER",
      "filename": "us%20fda%20wl%202017%20sample%20pages.pdf"
    },
    "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20wl%202018%20sample%20pages.pdf": {
      "url": "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20wl%202018%20sample%20pages.pdf",
      "sha256": "0eae29f6664b583f2d48aa09196e851f69805556ee0da551ba68d1435d20b4fe",
      "size": 196119,
      "pages": null,
      "regulator": "OTHER",
      "filename": "us%20fda%20wl%202018%20sample%20pages.pdf"
    },
    "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20wl%202019%20sample%20pages.pdf": {
      "url": "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20wl%202019%20sample%20pages.pdf",
      "sha256": "d034a751804cc7d479a7bd588bde274abbcccd99ff16ef97812ae0eaa2a2b17a",
      "size": 174547,
      "pages": null,
      "regulator": "OTHER",
      "filename": "us%20fda%20wl%202019%20sample%20pages.pdf"
    },
    "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20wl%202020%20sample%20pages.pdf": {
      "url": "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20wl%202020%20sample%20pages.pdf",
      "sha256": "5a961ef3b1e615862dba19184d9d4507f43d288c4e81b4998900baa41ab283ed",
      "size": 199357,
      "pages": null,
      "regulator": "OTHER",
      "filename": "us%20fda%20wl%202020%20sample%20pages.pdf"
    },
    "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20wl%202021%20sample%20pages.pdf": {
      "url": "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20wl%202021%20sample%20pages.pdf",
      "sha256": "f69ba2dc3f54f453b1ec075267f91714eccd84e591bef37b6e2ce157101c93b1",
      "size": 191934,
      "pages": null,
      "regulator": "OTHER",
      "filename": "us%20fda%20wl%202021%20sample%20pages.pdf"
    },
    "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20wl%202022%20sample%20pages.pdf": {
      "url": "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20wl%202022%20sample%20pages.pdf",
      "sha256": "4e86757735402563b8fbb932738577ed6d3836ea82908452dcace01c6b96d895",
      "size": 289531,
      "pages": null,
      "regulator": "OTHER",
      "filename": "us%20fda%20wl%202022%20sample%20pages.pdf"
    },
    "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20wl%202023%20sample%20pages.pdf": {
      "url": "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20wl%202023%20sample%20pages.pdf",
      "sha256": "b102690234708251c891fe8025ad4e8266743bc6a6d38e86b0cc33380c79d382",
      "size": 297554,
      "pages": null,
      "regulator": "OTHER",
      "filename": "us%20fda%20wl%202023%20sample%20pages.pdf"
    },
    "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20wl%202024%201st%20half%20sample%20pages.pdf": {
      "url": "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20wl%202024%201st%20half%20sample%20pages.pdf",
      "sha256": "5beaa43b8b2af5445ddd10006e94f9b235285e615539f490864702c09031d9ea",
      "size": 311583,
      "pages": 8,
      "regulator": "OTHER",
      "filename": "us%20fda%20wl%202024%201st%20half%20sample%20pages.pdf"
    },
    "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20wl%202024%202nd%20half%20sample%20pages.pdf": {
      "url": "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20wl%202024%202nd%20half%20sample%20pages.pdf",
      "sha256": "d257da80314626555696df96db94107615ced05d1d747e0feca8e2574fa2068f",
      "size": 305676,
      "pages": null,
      "regulator": "OTHER",
      "filename": "us%20fda%20wl%202024%202nd%20half%20sample%20pages.pdf"
    },
    "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20wl%202025%201st%20half%20sample%20pages.pdf": {
      "url": "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20wl%202025%201st%20half%20sample%20pages.pdf",
      "sha256": "6b579a488ee11ebcb34ac6572e09771aed27418bbc335463b2ff63d31c2b4a2e",
      "size": 315992,
      "pages": null,
      "regulator": "OTHER",
      "filename": "us%20fda%20wl%202025%201st%20half%20sample%20pages.pdf"
    },
    "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20wl%20483%20vol%201%20sample%20pages.pdf": {
      "url": "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20wl%20483%20vol%201%20sample%20pages.pdf",
      "sha256": "50d0fa9bd214d3c551fce0bf0b9020bc8f958bab8987346e19ee526b49230717",
      "size": 136479,
      "pages": null,
      "regulator": "OTHER",
      "filename": "us%20fda%20wl%20483%20vol%201%20sample%20pages.pdf"
    },
    "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20wl%20483%20vol%202%20sample%20pages.pdf": {
      "url": "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20wl%20483%20vol%202%20sample%20pages.pdf",
      "sha256": "e6d0828a9c083b9dbe21dcbc81108c3484471f96d40c6ce65bde1a10e6425b6c",
      "size": 131506,
      "pages": null,
      "regulator": "OTHER",
      "filename": "us%20fda%20wl%20483%20vol%202%20sample%20pages.pdf"
    },
    "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20wl%20483%20vol%203%20sample%20pages.pdf": {
      "url": "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20wl%20483%20vol%203%20sample%20pages.pdf",
      "sha256": "ddda7a51c78ee7c20995c2cc2925c071ddf913c91c515f36b94ac983049b63a2",
      "size": 141301,
      "pages": null,
      "regulator": "OTHER",
      "filename": "us%20fda%20wl%20483%20vol%203%20sample%20pages.pdf"
    },
    "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20wl%20483%20vol%204%20sample%20pages.pdf": {
      "url": "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20wl%20483%20vol%204%20sample%20pages.pdf",
      "sha256": "7fa1b5426e67909656666b02bd793f9b6e37e695f7954b7a0d813c821ff31c2a",
      "size": 126515,
      "pages": null,
      "regulator": "OTHER",
      "filename": "us%20fda%20wl%20483%20vol%204%20sample%20pages.pdf"
    },
    "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20wl%20483%20vol%205%20sample%20pages.pdf": {
      "url": "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20wl%20483%20vol%205%20sample%20pages.pdf",
      "sha256": "2155749b02b6f3f785a0c1197da967ebdf773adf3cd92fd5e648381e0fc8eb33",
      "size": 133027,
      "pages": null,
      "regulator": "OTHER",
      "filename": "us%20fda%20wl%20483%20vol%205%20sample%20pages.pdf"
    },
    "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20wl%20483%20vol%206%20sample%20pages.pdf": {
      "url": "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20wl%20483%20vol%206%20sample%20pages.pdf",
      "sha256": "8b7a6db9766395ab1d05e465b9ea5c4de5920cb033cc5df1ad92897939cc9a48",
      "size": 132598,
      "pages": null,
      "regulator": "OTHER",
      "filename": "us%20fda%20wl%20483%20vol%206%20sample%20pages.pdf"
    },
    "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20wl%20483%20vol%207%20sample%20pages.pdf": {
      "url": "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20wl%20483%20vol%207%20sample%20pages.pdf",
      "sha256": "7c9b5fbba500914e280f592376a08d688fff45c9ff181beeaa14f5a344b5cfbb",
      "size": 147846,
      "pages": null,
      "regulator": "OTHER",
      "filename": "us%20fda%20wl%20483%20vol%207%20sample%20pages.pdf"
    }
  },
  "last_run": "2025-09-23T07:58:43.480470+00:00",
  "last_snapshot_dir": "C:\\Users\\MASTER\\Desktop\\crawler\\2025-09-13"
}